<!DOCTYPE html>
<html><head><meta charset="UTF-8">
<title>Earnings Call ë²ˆì—­</title>
<style>
    body { font-family: Arial; margin: 40px; background-color: #fdfdfd; }
    h1 { text-align: center; }
    h2 { margin-top: 50px; color: #003366; }
    h3 { color: #333; }
    table { border: 1px solid #ddd; width: 100%; border-collapse: collapse; }
    th { background: #f0f0f0; padding: 10px; border-bottom: 2px solid #ccc; }
    td { padding: 10px; border-bottom: 1px dotted #ccc; vertical-align: top; }
    p { line-height: 1.6; }
    hr { margin: 50px 0; border: none; border-top: 1px solid #ccc; }
    .back-button {
        display: inline-block;
        background-color: #5f5f5f;
        color: white;
        padding: 10px 16px;
        border-radius: 6px;
        text-decoration: none;
        font-weight: 500;
        box-shadow: 0 2px 6px rgba(0,0,0,0.1);
        margin-bottom: 30px;
    }
</style>
</head><body>
<a href="../../index.html" class="back-button">â†</a>
<h1>ğŸ“„ Earnings Call Transcript ë²ˆì—­ ê²°ê³¼</h1>

    <h2>ğŸ“Š Presentation</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>AbbVie Inc.</td><td># AbbVie Inc. ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ<br><br>## íšŒì‚¬ ì°¸ì„ì<br>- ë¦¬ì¦ˆ ì‰¬ì–´(Liz Shea) - íˆ¬ìì ê´€ê³„ ë¶€ë¬¸ ë¶€ì‚¬ì¥<br>- ë¦­ ê³¤ì˜ë ˆìŠ¤(Rick Gonzalez) - íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ì<br>- ë¡œë²„íŠ¸ ë§ˆì´í´(Robert Michael) - ìµœê³ ì¬ë¬´ì±…ì„ì<br>- ë§ˆì´í´ ì„¸ë²„ë¦¬ë…¸(Michael Severino) - ë¶€íšŒì¥ ê²¸ ì‚¬ì¥<br><br>## ì• ë„ë¦¬ìŠ¤íŠ¸ ì°¸ì„ì<br>- í¬ë¦¬ìŠ¤ ìŠˆíŠ¸(Chris Schott) - JPëª¨ê±´<br>- í…Œë ŒìŠ¤ í”Œë¦°(Terence Flynn) - ê³¨ë“œë§Œì‚­ìŠ¤<br>- ìŠ¤í‹°ë¸Œ ìŠ¤ì¹¼ë¼(Steve Scala) - ì½”ì›¬<br>- ì œí”„ ë¯¸ì²¼(Geoff Meacham) - ë±…í¬ì˜¤ë¸Œì•„ë©”ë¦¬ì¹´ ë©”ë¦´ë¦°ì¹˜<br>- ë¹ˆìŠ¤ ëª°ë¦¬ë‚˜ë¡œ(Vince Molinaro) - ë ˆì´ë¨¼ë“œ ì œì„ìŠ¤<br><br>---<br><br>**ì˜¤í¼ë ˆì´í„°**<br><br>ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. AbbVie 2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. í˜„ì¬ ëª¨ë“  ì°¸ì„ìëŠ” ì²­ì·¨ ì „ìš© ëª¨ë“œì…ë‹ˆë‹¤. ë°œí‘œ í›„ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì´ ìˆì„ ì˜ˆì •ì…ë‹ˆë‹¤.<br><br>ì´ì œ íšŒì˜ë¥¼ AbbVie íˆ¬ìì ê´€ê³„ ë¶€ë¬¸ ë¶€ì‚¬ì¥ ë¦¬ì¦ˆ ì‰¬ì–´ê»˜ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. ì‹œì‘í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.<br><br>---<br><br>**ë¦¬ì¦ˆ ì‰¬ì–´**<br><br>ê°ì‚¬í•©ë‹ˆë‹¤. ì—¬ëŸ¬ë¶„, ì•ˆë…•í•˜ì‹­ë‹ˆê¹Œ. AbbVie 2024ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ íšŒì¥ ê²¸ CEOì¸ ë¦­ ê³¤ì˜ë ˆìŠ¤, CFOì¸ ë¡œë²„íŠ¸ ë§ˆì´í´, ê·¸ë¦¬ê³  ë¶€íšŒì¥ ê²¸ ì‚¬ì¥ì¸ ë§ˆì´í´ ì„¸ë²„ë¦¬ë…¸ê°€ í•¨ê»˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ì˜¤ëŠ˜ ë°œí‘œ ì „ì— ëª‡ ê°€ì§€ ì£¼ì˜ì‚¬í•­ì„ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¼ë¶€ ë°œì–¸ì€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì— í•´ë‹¹í•˜ë©° ì‹¤ì œ ê²°ê³¼ì™€ ë‹¤ë¥¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. AbbVieëŠ” ì´ëŸ¬í•œ ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ê°€ ì—†ìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ë°œí‘œì—ì„œëŠ” ë¹„GAAP ì¬ë¬´ì§€í‘œë¥¼ ì‚¬ìš©í•  ì˜ˆì •ì´ë©°, ì´ëŠ” íŠ¹ì • ë¹„í˜„ê¸ˆ ë° ì¼íšŒì„± í•­ëª©ì„ ì œì™¸í•œ ê²ƒì…ë‹ˆë‹¤.<br><br>ê·¸ëŸ¼ ë¦­ì—ê²Œ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>---<br><br>**ë¦­ ê³¤ì˜ë ˆìŠ¤**<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ë¦¬ì¦ˆ. ê·¸ë¦¬ê³  ì˜¤ëŠ˜ ì°¸ì„í•´ ì£¼ì‹  ëª¨ë“  ë¶„ë“¤ê»˜ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.<br><br>2024ë…„ì€ AbbVieì—ê²Œ ë§¤ìš° ì„±ê³µì ì¸ í•œ í•´ì˜€ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê°•ë ¥í•œ ì¬ë¬´ ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ë§¤ì¶œì€ ì „ë…„ ëŒ€ë¹„ 4% ì¦ê°€í•œ 560ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 11.29ë‹¬ëŸ¬ë¡œ 7% ì„±ì¥í–ˆìŠµë‹ˆë‹¤.<br><br>íŠ¹íˆ ìš°ë¦¬ì˜ ë©´ì—­í•™ í¬íŠ¸í´ë¦¬ì˜¤ê°€ íƒì›”í•œ ì„±ê³¼ë¥¼</td></tr>
<tr><td>(ABBV) Q4 2025 Earnings Call February 4, 2026 9:00 AM EST<br><br>Company Participants<br><br>Elizabeth Shea - Senior Vice President of Investor Relations<br>Robert Michael - CEO & Chairman of the Board<br>Jeffrey Stewart - Executive VP & Chief Commercial Officer<br>Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer<br>Scott Reents - Executive VP & CFO<br><br>Conference Call Participants<br><br>David Risinger - Leerink Partners LLC, Research Division<br>Christopher Schott - JPMorgan Chase & Co, Research Division<br>Terence Flynn - Morgan Stanley, Research Division<br>Asad Haider - Goldman Sachs Group, Inc., Research Division<br>Vamil Divan - Guggenheim Securities, LLC, Research Division<br>Steve Scala - TD Cowen, Research Division<br>Mohit Bansal - Wells Fargo Securities, LLC, Research Division<br>David Amsellem - Piper Sandler & Co., Research Division<br>Luisa Hector - Joh.</td><td># (ABBV) 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ì»¨í¼ëŸ°ìŠ¤ ì½œ 2026ë…„ 2ì›” 4ì¼ ì˜¤ì „ 9ì‹œ (ë¯¸êµ­ ë™ë¶€ í‘œì¤€ì‹œ)<br><br>## íšŒì‚¬ ì°¸ì„ì<br><br>Elizabeth Shea - íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br>Robert Michael - CEO ê²¸ ì´ì‚¬íšŒ ì˜ì¥<br>Jeffrey Stewart - ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³  ìƒì—… ì±…ì„ì<br>Roopal Thakkar - ì—°êµ¬ê°œë°œ ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³  ê³¼í•™ ì±…ì„ì<br>Scott Reents - ì „ë¬´ì´ì‚¬ ê²¸ CFO<br><br>## ì»¨í¼ëŸ°ìŠ¤ ì½œ ì°¸ì„ ì• ë„ë¦¬ìŠ¤íŠ¸<br><br>David Risinger - Leerink Partners LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Christopher Schott - JPMorgan Chase & Co, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Terence Flynn - Morgan Stanley, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Asad Haider - Goldman Sachs Group, Inc., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Vamil Divan - Guggenheim Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Steve Scala - TD Cowen, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Mohit Bansal - Wells Fargo Securities, LLC, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>David Amsellem - Piper Sandler & Co., ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>Luisa Hector - Joh.</td></tr>
<tr><td>Berenberg, Gossler & Co. KG, Research Division<br>Michael Yee - UBS Investment Bank, Research Division<br>Malcolm Hoffman - BMO Capital Markets Equity Research<br><br>Presentation<br><br>Operator<br><br>Good morning, and thank you for standing by. Welcome to the AbbVie Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations. Elizabeth Shea<br>Senior Vice President of Investor Relations<br><br>Good morning, and thanks for joining us.</td><td># ë² ë Œë² ë¥´í¬, ê³ ìŠ¬ëŸ¬ ì•¤ ì»´í¼ë‹ˆ KG, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ˆì´í´ ì´ - UBS ì¸ë² ìŠ¤íŠ¸ë¨¼íŠ¸ ë±…í¬, ë¦¬ì„œì¹˜ ë¶€ë¬¸<br>ë§ì½¤ í˜¸í”„ë§Œ - BMO ìºí”¼íƒˆ ë§ˆì¼“ì¸  ì£¼ì‹ ë¦¬ì„œì¹˜<br><br>ë°œí‘œ<br><br>ì‚¬íšŒì<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ê¸°ë‹¤ë ¤ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì• ë¸Œë¹„ 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. [ì‚¬íšŒì ì•ˆë‚´ì‚¬í•­] ì˜¤ëŠ˜ ì½œì€ ë…¹ìŒë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì˜ê°€ ìˆìœ¼ì‹œë©´ ì§€ê¸ˆ ì—°ê²°ì„ ëŠìœ¼ì…”ë„ ë©ë‹ˆë‹¤. ì´ì œ ë¦¬ì¦ˆ ì‰¬ íˆ¬ììê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥ì„ ì†Œê°œí•˜ê² ìŠµë‹ˆë‹¤.<br><br>ì—˜ë¦¬ìë² ìŠ¤ ì‰¬<br>íˆ¬ììê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer; Jeff Stewart, Executive Vice President, Chief Commercial Officer; Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer; and Scott Reents, Executive Vice President, Chief Financial Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements.</td><td>ì˜¤ëŠ˜ ì €ì™€ í•¨ê»˜ í†µí™”ì— ì°¸ì—¬í•˜ì‹  ë¶„ë“¤ì€ Rob Michael íšŒì¥ ê²¸ ìµœê³ ê²½ì˜ì, Jeff Stewart ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ìƒì—…ì±…ì„ì, Roopal Thakkar ì „ë¬´ì´ì‚¬ ê²¸ ì—°êµ¬ê°œë°œ ìµœê³ ê³¼í•™ì±…ì„ì, ê·¸ë¦¬ê³  Scott Reents ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ì¬ë¬´ì±…ì„ìì…ë‹ˆë‹¤. ë³¸ë¡ ìœ¼ë¡œ ë“¤ì–´ê°€ê¸° ì „ì—, ì˜¤ëŠ˜ ìš°ë¦¬ê°€ í•˜ëŠ” ì¼ë¶€ ë°œì–¸ë“¤ì€ í˜„ì¬ì˜ ê¸°ëŒ€ì— ê¸°ë°˜í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ë¡œ ê°„ì£¼ë  ìˆ˜ ìˆìŒì„ ë§ì”€ë“œë¦½ë‹ˆë‹¤. AbbVieëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì´ ë¦¬ìŠ¤í¬ì™€ ë¶ˆí™•ì‹¤ì„±ì˜ ì˜í–¥ì„ ë°›ìœ¼ë©°, ì´ë¡œ ì¸í•´ ì‹¤ì œ ê²°ê³¼ê°€ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì—ì„œ ì œì‹œëœ ë‚´ìš©ê³¼ ì¤‘ëŒ€í•˜ê²Œ ë‹¤ë¥¼ ìˆ˜ ìˆìŒì„ ìœ ì˜í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements, except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance. These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we will take your questions. So with that, I'll turn the call over to Rob. Robert Michael<br>CEO & Chairman of the Board<br><br>Thank you, Liz.</td><td>ì´ëŸ¬í•œ ìœ„í—˜ê³¼ ë¶ˆí™•ì‹¤ì„±ì— ëŒ€í•œ ì¶”ê°€ ì •ë³´ëŠ” ë‹¹ì‚¬ì˜ SEC ì œì¶œ ì„œë¥˜ì— í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. AbbVieëŠ” ë²•ë¥ ì—ì„œ ìš”êµ¬í•˜ëŠ” ê²½ìš°ë¥¼ ì œì™¸í•˜ê³ ëŠ” ì´ëŸ¬í•œ ë¯¸ë˜ì˜ˆì¸¡ì§„ìˆ ì„ ì—…ë°ì´íŠ¸í•  ì˜ë¬´ë¥¼ ì§€ì§€ ì•ŠìŠµë‹ˆë‹¤. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì—ì„œëŠ” íˆ¬ììë“¤ì´ AbbVieì˜ ì‚¬ì—… ì‹¤ì ì„ ì´í•´í•˜ëŠ” ë° ë„ì›€ì´ ë˜ë„ë¡ ë¹„-GAAP ì¬ë¬´ì§€í‘œê°€ ì‚¬ìš©ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ë¹„-GAAP ì¬ë¬´ì§€í‘œëŠ” ì˜¤ëŠ˜ ë°œí‘œëœ ì‹¤ì  ë³´ê³ ì„œ ë° ê·œì œ ì œì¶œ ì„œë¥˜ì—ì„œ ë¹„êµ ê°€ëŠ¥í•œ GAAP ì¬ë¬´ì§€í‘œì™€ ì¡°ì •ë˜ì–´ ìˆìœ¼ë©°, ë‹¹ì‚¬ ì›¹ì‚¬ì´íŠ¸ì—ì„œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì¤€ë¹„ëœ ë°œì–¸ì— ì´ì–´ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ê°–ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤. ê·¸ëŸ¼ Robì—ê²Œ ë°œì–¸ê¶Œì„ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>Robert Michael<br>CEO ê²¸ ì´ì‚¬íšŒ ì˜ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Liz.</td></tr>
<tr><td>Good morning, everyone, and thank you for joining us. Our fourth quarter performance closes out another excellent year for AbbVie. I am very pleased with the significant progress we made in 2025. We delivered record net sales and exceeded our financial commitments, advanced our pipeline across all stages of development and acquired new sources of growth through strategic transactions. We are entering 2026 with substantial momentum and remain well positioned to deliver another year of strong growth. Turning to our results. We delivered full year adjusted earnings per share of $10, which is $0.54 above our initial guidance midpoint, excluding the impact of IPR&D expense.</td><td>ì¢‹ì€ ì•„ì¹¨ì…ë‹ˆë‹¤. ì°¸ì„í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. 4ë¶„ê¸° ì‹¤ì ìœ¼ë¡œ AbbVieì˜ ë˜ ë‹¤ë¥¸ í›Œë¥­í•œ í•œ í•´ë¥¼ ë§ˆë¬´ë¦¬í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. 2025ë…„ì— ì´ë£¬ ì˜ë¯¸ ìˆëŠ” ì§„ì „ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±ìŠ¤ëŸ½ê²Œ ìƒê°í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ê¸°ë¡ì ì¸ ë§¤ì¶œì„ ë‹¬ì„±í•˜ê³  ì¬ë¬´ ëª©í‘œë¥¼ ì´ˆê³¼ ë‹¬ì„±í–ˆìœ¼ë©°, ëª¨ë“  ê°œë°œ ë‹¨ê³„ì— ê±¸ì³ íŒŒì´í”„ë¼ì¸ì„ ë°œì „ì‹œì¼°ê³ , ì „ëµì  ê±°ë˜ë¥¼ í†µí•´ ìƒˆë¡œìš´ ì„±ì¥ ë™ë ¥ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ìƒë‹¹í•œ ëª¨ë©˜í…€ì„ ê°€ì§€ê³  2026ë…„ì„ ë§ì´í•˜ê³  ìˆìœ¼ë©°, ë˜ í•œ í•´ ê°•ë ¥í•œ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì‹¤ì ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì—°ê°„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ 10ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” IPR&D ë¹„ìš©ì˜ ì˜í–¥ì„ ì œì™¸í•˜ê³  ì´ˆê¸° ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ì„ 0.54ë‹¬ëŸ¬ ìƒíšŒí•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Total net revenues were $61.2 billion, beating our initial guidance by more than $2 billion. Our sales growth of 8.6% led to a new all-time high for AbbVie, exceeding our previous peak revenue by more than $3 billion despite nearly $16 billion of U.S. Humira erosion since the LOE. Our excellent performance puts us in a strong position to advance our innovative medicines. In 2025, we increased adjusted R&D expense by nearly $1 billion, fully funding the 90 clinical programs currently in development. We also obtained several new product and indication approvals, including Rinvoq for GCA, EMRELIS for non-squamous non-small cell lung cancer and EPKINLY for second-line follicular lymphoma.</td><td>ì´ ìˆœë§¤ì¶œì€ 612ì–µ ë‹¬ëŸ¬ë¡œ ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ë¥¼ 20ì–µ ë‹¬ëŸ¬ ì´ìƒ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. 8.6%ì˜ ë§¤ì¶œ ì„±ì¥ìœ¼ë¡œ AbbVieì˜ ì—­ëŒ€ ìµœê³  ì‹¤ì ì„ ë‹¬ì„±í–ˆìœ¼ë©°, ë¯¸êµ­ Humiraì˜ íŠ¹í—ˆë§Œë£Œ(LOE) ì´í›„ ì•½ 160ì–µ ë‹¬ëŸ¬ì˜ ë§¤ì¶œ ê°ì†Œì—ë„ ë¶ˆêµ¬í•˜ê³  ì´ì „ ìµœê³  ë§¤ì¶œì„ 30ì–µ ë‹¬ëŸ¬ ì´ìƒ ì´ˆê³¼í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ìš°ìˆ˜í•œ ì‹¤ì ìœ¼ë¡œ ìš°ë¦¬ëŠ” í˜ì‹  ì˜ì•½í’ˆì„ ë°œì „ì‹œí‚¬ ìˆ˜ ìˆëŠ” ê°•ë ¥í•œ ì…ì§€ë¥¼ í™•ë³´í–ˆìŠµë‹ˆë‹¤. 2025ë…„ì—ëŠ” ì¡°ì • ì—°êµ¬ê°œë°œë¹„ë¥¼ ì•½ 10ì–µ ë‹¬ëŸ¬ ì¦ì•¡í•˜ì—¬ í˜„ì¬ ê°œë°œ ì¤‘ì¸ 90ê°œ ì„ìƒ í”„ë¡œê·¸ë¨ì— ì „ì•¡ íˆ¬ìí–ˆìŠµë‹ˆë‹¤. ë˜í•œ ê±°ëŒ€ì„¸í¬ë™ë§¥ì—¼(GCA) ì ì‘ì¦ Rinvoq, ë¹„í¸í‰ ë¹„ì†Œì„¸í¬íì•” ì¹˜ë£Œì œ EMRELIS, 2ì°¨ ì¹˜ë£Œ ì—¬í¬ì„± ë¦¼í”„ì¢… ì¹˜ë£Œì œ EPKINLYë¥¼ í¬í•¨í•œ ì—¬ëŸ¬ ì‹ ì œí’ˆ ë° ì ì‘ì¦ ìŠ¹ì¸ì„ íšë“í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we bolstered our pipeline by investing more than $5 billion in new business development, including several promising mechanisms and technologies. These include an in vivo CAR-T platform in immunology from Capstan Therapeutics, bretisilocin, a next-generation psychedelic with promising data in depression; ISB-2001, a novel trispecific antibody for multiple myeloma; 295, a long-acting amylin analog for obesity and a next-generation siRNA platform from ARx that has applicability in immunology, neuroscience and oncology.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” 50ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ì‹ ê·œ ì‚¬ì—… ê°œë°œì— íˆ¬ìí•˜ì—¬ íŒŒì´í”„ë¼ì¸ì„ ê°•í™”í–ˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì—¬ëŸ¬ ìœ ë§í•œ ë©”ì»¤ë‹ˆì¦˜ê³¼ ê¸°ìˆ ë“¤ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê¸°ìˆ ë“¤ë¡œëŠ” Capstan Therapeuticsì˜ ë©´ì—­í•™ ë¶„ì•¼ ìƒì²´ ë‚´(in vivo) CAR-T í”Œë«í¼, ìš°ìš¸ì¦ì—ì„œ ìœ ë§í•œ ë°ì´í„°ë¥¼ ë³´ì¸ ì°¨ì„¸ëŒ€ ì‚¬ì´í‚¤ë¸ë¦­ ë¬¼ì§ˆì¸ ë¸Œë ˆí‹°ì‹¤ë¡œì‹ (bretisilocin), ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ì¹˜ë£Œë¥¼ ìœ„í•œ ì‹ ê·œ ì‚¼ì¤‘íŠ¹ì´í•­ì²´(trispecific antibody) ISB-2001, ë¹„ë§Œ ì¹˜ë£Œë¥¼ ìœ„í•œ ì¥ì‹œê°„ ì‘ìš© ì•„ë°€ë¦° ìœ ì‚¬ì²´(long-acting amylin analog) 295, ê·¸ë¦¬ê³  ë©´ì—­í•™, ì‹ ê²½ê³¼í•™, ì¢…ì–‘í•™ì— ì ìš© ê°€ëŠ¥í•œ ARxì˜ ì°¨ì„¸ëŒ€ siRNA í”Œë«í¼ì´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We also recently announced a transaction with RemeGen, adding a novel PD-1 VEGF bispecific antibody to combine with our ADCs across multiple solid tumors, further strengthening AbbVie's oncology portfolio. Turning to 2026. We expect AbbVie to once again deliver top-tier performance. We anticipate total sales growth of 9.5%, reflecting another year of robust sales results despite headwinds from continued Humira erosion and Imbruvica IRA pricing. The main drivers of this growth include Skyrizi and Rinvoq with combined sales of more than $31 billion, already surpassing our 2027 long-term guidance by $0.5 billion.</td><td>ë˜í•œ ìµœê·¼ RemeGenê³¼ì˜ ê±°ë˜ë¥¼ ë°œí‘œí–ˆëŠ”ë°, ì´ëŠ” ì‹ ê·œ PD-1 VEGF ì´ì¤‘íŠ¹ì´í•­ì²´ë¥¼ ì¶”ê°€í•˜ì—¬ ì—¬ëŸ¬ ê³ í˜•ì•”ì— ê±¸ì³ ë‹¹ì‚¬ì˜ ADCë“¤ê³¼ ë³‘ìš©í•  ìˆ˜ ìˆê²Œ í•¨ìœ¼ë¡œì¨ AbbVieì˜ ì¢…ì–‘í•™ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë”ìš± ê°•í™”í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. 2026ë…„ìœ¼ë¡œ ë„˜ì–´ê°€ì„œ, ìš°ë¦¬ëŠ” AbbVieê°€ ë‹¤ì‹œ í•œë²ˆ ìµœìƒìœ„ê¶Œ ì‹¤ì ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì§€ì†ì ì¸ Humira ì¹¨ì‹ê³¼ Imbruvica IRA ê°€ê²© ì±…ì •ìœ¼ë¡œ ì¸í•œ ì—­í’ì—ë„ ë¶ˆêµ¬í•˜ê³ , ë˜ í•œ í•´ ê²¬ê³ í•œ ë§¤ì¶œ ì‹¤ì ì„ ë°˜ì˜í•˜ì—¬ ì´ ë§¤ì¶œ ì„±ì¥ë¥  9.5%ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì„±ì¥ì˜ ì£¼ìš” ë™ë ¥ì€ Skyriziì™€ Rinvoqë¡œ, í•©ì‚° ë§¤ì¶œì´ 310ì–µ ë‹¬ëŸ¬ë¥¼ ì´ˆê³¼í•˜ì—¬ ì´ë¯¸ 2027ë…„ ì¥ê¸° ê°€ì´ë˜ìŠ¤ë¥¼ 5ì–µ ë‹¬ëŸ¬ ìƒíšŒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We are also forecasting a substantial sales ramp for Vyalev, achieving blockbuster status this year as a transformational treatment for Parkinson's. And we expect continued double-digit revenue growth from our leading migraine products, which are also trending significantly above our long-term expectations. Given the strong outlook of our diverse portfolio, we are well positioned to deliver high single-digit revenue growth through 2029. Turning now to R&D. We anticipate a number of key catalysts across our core therapeutic areas over the next 24 months.</td><td>ë˜í•œ ìš°ë¦¬ëŠ” Vyalevì˜ íŒë§¤ê°€ í¬ê²Œ ì¦ê°€í•˜ì—¬ íŒŒí‚¨ìŠ¨ë³‘ì˜ í˜ì‹ ì ì¸ ì¹˜ë£Œì œë¡œì„œ ì˜¬í•´ ë¸”ë¡ë²„ìŠ¤í„° ì§€ìœ„ë¥¼ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ì˜ ì„ ë„ì ì¸ í¸ë‘í†µ ì œí’ˆë“¤ë¡œë¶€í„° ì§€ì†ì ì¸ ë‘ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ì„ ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ë“¤ ì œí’ˆì€ ë˜í•œ ìš°ë¦¬ì˜ ì¥ê¸° ì „ë§ì„ í¬ê²Œ ìƒíšŒí•˜ëŠ” ì¶”ì„¸ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ì˜ ë‹¤ì–‘í•œ í¬íŠ¸í´ë¦¬ì˜¤ì˜ ê°•ë ¥í•œ ì „ë§ì„ ê³ ë ¤í•  ë•Œ, ìš°ë¦¬ëŠ” 2029ë…„ê¹Œì§€ ë†’ì€ í•œ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ R&Dë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” í–¥í›„ 24ê°œì›” ë™ì•ˆ í•µì‹¬ ì¹˜ë£Œ ì˜ì—­ ì „ë°˜ì— ê±¸ì³ ì—¬ëŸ¬ ì£¼ìš” ì´‰ë§¤ì œë“¤ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In immunology, this includes pivotal data for 3 additional Rinvoq indications as well as initial data for our Crohn's combination platform with Skyrizi. In neuroscience, we anticipate key readouts for next-generation assets, 932, bretisilocin and emraclidine. And in oncology, we expect registrational data for etentamig as well as mid- to late-stage readouts for Temab-A in several solid tumors. These are all very exciting opportunities that have the potential to drive sustained long-term growth. Lastly, we recently announced a voluntary agreement with the U.S.</td><td>ë©´ì—­í•™ ë¶„ì•¼ì—ì„œëŠ” Rinvoqì˜ 3ê°€ì§€ ì¶”ê°€ ì ì‘ì¦ì— ëŒ€í•œ í”¼ë²—(pivotal) ë°ì´í„°ì™€ Skyrizië¥¼ í™œìš©í•œ í¬ë¡ ë³‘ ë³‘ìš©ìš”ë²• í”Œë«í¼ì˜ ì´ˆê¸° ë°ì´í„°ê°€ í¬í•¨ë©ë‹ˆë‹¤. ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì—ì„œëŠ” ì°¨ì„¸ëŒ€ ìì‚°ì¸ 932, ë¸Œë ˆí‹°ì‹¤ë¡œì‹ (bretisilocin), ì— ë¼í´ë¦¬ë”˜(emraclidine)ì— ëŒ€í•œ ì£¼ìš” ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œëŠ” ì—í…íƒ€ë°‰(etentamig)ì˜ ë“±ë¡ìš© ë°ì´í„°ì™€ ì—¬ëŸ¬ ê³ í˜•ì•”ì—ì„œ Temab-Aì˜ ì¤‘í›„ê¸° ë‹¨ê³„ ê²°ê³¼ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ëª¨ë“  ê²ƒë“¤ì€ ì§€ì†ì ì¸ ì¥ê¸° ì„±ì¥ì„ ê²¬ì¸í•  ì ì¬ë ¥ì„ ê°€ì§„ ë§¤ìš° í¥ë¯¸ë¡œìš´ ê¸°íšŒë“¤ì…ë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ìµœê·¼ ë¯¸êµ­ê³¼ì˜ ìë°œì  í•©ì˜ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>government that reinforces our commitment to patient access and affordability while also protecting our ability to invest in innovation. Key elements of this 3-year agreement include offering low prices in Medicaid, expanding direct-to-patient cash pay options for select products and committing $100 billion in U.S. R&D and capital investments over the next decade. In summary, we are delivering outstanding execution and the outlook of our business remains very strong. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights. Jeff? Jeffrey Stewart<br>Executive VP & Chief Commercial Officer<br><br>Thank you, Rob.</td><td>ì •ë¶€ì™€ì˜ í˜‘ë ¥ì„ ê°•í™”í•˜ì—¬ í™˜ì ì ‘ê·¼ì„±ê³¼ ê²½ì œì„±ì— ëŒ€í•œ ìš°ë¦¬ì˜ ì•½ì†ì„ ì¬í™•ì¸í•˜ëŠ” ë™ì‹œì— í˜ì‹ ì— ëŒ€í•œ íˆ¬ì ëŠ¥ë ¥ë„ ë³´í˜¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ 3ê°œë…„ í˜‘ì•½ì˜ í•µì‹¬ ìš”ì†Œë¡œëŠ” ë©”ë””ì¼€ì´ë“œì—ì„œ ì €ë ´í•œ ê°€ê²© ì œê³µ, ì¼ë¶€ ì œí’ˆì— ëŒ€í•œ í™˜ì ì§ì ‘ í˜„ê¸ˆ ì§€ë¶ˆ ì˜µì…˜ í™•ëŒ€, í–¥í›„ 10ë…„ê°„ ë¯¸êµ­ ë‚´ R&D ë° ìë³¸ íˆ¬ìì— 1,000ì–µ ë‹¬ëŸ¬ íˆ¬ì… ì•½ì† ë“±ì´ í¬í•¨ë©ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ìš°ë¦¬ëŠ” íƒì›”í•œ ì‹¤í–‰ë ¥ì„ ë³´ì—¬ì£¼ê³  ìˆìœ¼ë©° ì‚¬ì—… ì „ë§ë„ ë§¤ìš° ê²¬ê³ í•©ë‹ˆë‹¤. ì´ì œ ì œí”„ì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê²¨ ìƒì—…ì  ì„±ê³¼ì— ëŒ€í•œ ì¶”ê°€ ì½”ë©˜íŠ¸ë¥¼ ë“£ê² ìŠµë‹ˆë‹¤. ì œí”„?<br><br>ì œí”„ë¦¬ ìŠ¤íŠœì–´íŠ¸<br>ì „ë¬´ì´ì‚¬ ê²¸ ìµœê³ ìƒì—…ì±…ì„ì<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ë¡­.</td></tr>
<tr><td>I'll start with the quarterly results for immunology, which delivered total revenues of approximately $8.6 billion. Skyrizi total sales were $5 billion, reflecting operational growth of 31.9%. Rinvoq total sales were nearly $2.4 billion, reflecting operational growth of 28.6%. On a full year basis, Skyrizi and Rinvoq delivered approximately $25.9 billion in total combined revenue, an impressive increase of more than $8 billion year-over-year, well exceeding our initial guidance expectations. These results reflect exceptional performance across their respective indications, and I'll highlight a few examples.</td><td>ë©´ì—­í•™ ë¶€ë¬¸ì˜ ë¶„ê¸° ì‹¤ì ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì´ ë§¤ì¶œì€ ì•½ 86ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ìŠ¤ì¹´ì´ë¦¬ì§€(Skyrizi)ì˜ ì´ ë§¤ì¶œì€ 50ì–µ ë‹¬ëŸ¬ë¡œ ìš´ì˜ìƒ 31.9% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ë¦°ë³µ(Rinvoq)ì˜ ì´ ë§¤ì¶œì€ ì•½ 24ì–µ ë‹¬ëŸ¬ë¡œ ìš´ì˜ìƒ 28.6% ì„±ì¥í–ˆìŠµë‹ˆë‹¤. ì—°ê°„ ê¸°ì¤€ìœ¼ë¡œ ìŠ¤ì¹´ì´ë¦¬ì§€ì™€ ë¦°ë³µì€ í•©ì‚° ì´ ë§¤ì¶œ ì•½ 259ì–µ ë‹¬ëŸ¬ë¥¼ ë‹¬ì„±í–ˆìœ¼ë©°, ì´ëŠ” ì „ë…„ ëŒ€ë¹„ 80ì–µ ë‹¬ëŸ¬ ì´ìƒ ì¦ê°€í•œ ì¸ìƒì ì¸ ì‹¤ì ìœ¼ë¡œ, ë‹¹ì´ˆ ê°€ì´ë˜ìŠ¤ ì „ë§ì„ í¬ê²Œ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²°ê³¼ëŠ” ê° ì ì‘ì¦ì—ì„œì˜ íƒì›”í•œ ì„±ê³¼ë¥¼ ë°˜ì˜í•˜ê³  ìˆìœ¼ë©°, ëª‡ ê°€ì§€ ì‚¬ë¡€ë¥¼ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Starting with psoriatic disease, a market that is growing high single digits with modest biologic penetration where our portfolio has clear leadership. Skyrizi total prescription share in the U.S. biologic psoriasis market is now more than 45% and accelerating in the fourth quarter. Our in-play capture rates of new and switching patients has exceeded 55% across all lines of therapy, 4x higher than the next closest competitor.</td><td>ê±´ì„  ì§ˆí™˜ë¶€í„° ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì´ëŠ” ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ë¥ ì„ ë³´ì´ê³  ìˆìœ¼ë©° ìƒë¬¼í•™ì  ì œì œ ì¹¨íˆ¬ìœ¨ì´ ì™„ë§Œí•œ ì‹œì¥ìœ¼ë¡œ, ë‹¹ì‚¬ì˜ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ëª…í™•í•œ ì„ ë„ì  ì§€ìœ„ë¥¼ ì°¨ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ ìƒë¬¼í•™ì  ì œì œ ê±´ì„  ì‹œì¥ì—ì„œ Skyriziì˜ ì´ ì²˜ë°© ì ìœ ìœ¨ì€ í˜„ì¬ 45%ë¥¼ ë„˜ì–´ì„°ìœ¼ë©° 4ë¶„ê¸°ì— ê°€ì†í™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹ ê·œ í™˜ìì™€ ì „í™˜ í™˜ìì— ëŒ€í•œ ë‹¹ì‚¬ì˜ ì¸í”Œë ˆì´ í¬ì°©ë¥ ì€ ëª¨ë“  ì¹˜ë£Œ ë‹¨ê³„ì—ì„œ 55%ë¥¼ ì´ˆê³¼í–ˆìœ¼ë©°, ì´ëŠ” ì°¨ìˆœìœ„ ê²½ìŸì‚¬ë³´ë‹¤ 4ë°° ë†’ì€ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>And when you consider Skyrizi's very high and durable skin clearance, including new and statistically significant data across the board for hard-to-treat areas like scalp, genitals, palmer, planter, also widely demonstrated superior efficacy to both biologic and 2 oral agents, along with that simple quarterly dosing, we do not expect a material impact to our robust outlook in psoriasis from any existing or new therapies this year and beyond. Moving to PSA derm, where nearly 30% of patients visiting dermatologists have both skin and joint involvement.</td><td>ê·¸ë¦¬ê³  Skyriziì˜ ë§¤ìš° ë†’ê³  ì§€ì†ì ì¸ í”¼ë¶€ ì²­ê²°ë„, ë‘í”¼, ìƒì‹ê¸°, ì†ë°”ë‹¥, ë°œë°”ë‹¥ê³¼ ê°™ì€ ì¹˜ë£Œí•˜ê¸° ì–´ë ¤ìš´ ë¶€ìœ„ì—ì„œ ì „ë°˜ì ìœ¼ë¡œ ìƒˆë¡­ê³  í†µê³„ì ìœ¼ë¡œ ìœ ì˜ë¯¸í•œ ë°ì´í„°ë¥¼ í¬í•¨í•˜ì—¬, ìƒë¬¼í•™ì  ì œì œì™€ 2ê°€ì§€ ê²½êµ¬ ì•½ë¬¼ ëª¨ë‘ì— ëŒ€í•´ ê´‘ë²”ìœ„í•˜ê²Œ ì…ì¦ëœ ìš°ìˆ˜í•œ íš¨ëŠ¥, ê·¸ë¦¬ê³  ê°„í¸í•œ ë¶„ê¸°ë³„ íˆ¬ì—¬ë¥¼ ê³ ë ¤í•  ë•Œ, ì˜¬í•´ì™€ ê·¸ ì´í›„ ê¸°ì¡´ ë˜ëŠ” ì‹ ê·œ ì¹˜ë£Œì œë¡œë¶€í„° ê±´ì„  ë¶„ì•¼ì˜ ê²¬ê³ í•œ ì „ë§ì— ì¤‘ëŒ€í•œ ì˜í–¥ì„ ë°›ì„ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤. í”¼ë¶€ê³¼ë¥¼ ë°©ë¬¸í•˜ëŠ” í™˜ìì˜ ê±°ì˜ 30%ê°€ í”¼ë¶€ì™€ ê´€ì ˆ ì¦ìƒì„ ëª¨ë‘ ê°€ì§€ê³  ìˆëŠ” PSA í”¼ë¶€ê³¼ ë¶„ì•¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Skyrizi is now capturing roughly 1 out of every 4 in-play patients on biologics across all lines of therapy in the U.S., further supporting Skyrizi's strong momentum. The PSA indication represents a critical differentiator in the psoriasis market, especially relative to emerging options where PSA efficacy is still unproven. Importantly, Skyrizi has achieved PSA frontline in-play patient share leadership for biologics in both the derm and the room segments. Turning more broadly to room. Rinvoq continues to achieve a leading mid-teen in-play patient share for RA across all lines of therapy in the U.S.</td><td>ìŠ¤ì¹´ì´ë¦¬ì§€ëŠ” í˜„ì¬ ë¯¸êµ­ ë‚´ ëª¨ë“  ì¹˜ë£Œ ë¼ì¸ì—ì„œ ìƒë¬¼í•™ì ì œì œë¥¼ ì‚¬ìš©í•˜ëŠ” ì¸í”Œë ˆì´ í™˜ìì˜ ì•½ 4ëª… ì¤‘ 1ëª…ì„ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ìŠ¤ì¹´ì´ë¦¬ì§€ì˜ ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë”ìš± ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê±´ì„ ì„± ê´€ì ˆì—¼(PSA) ì ì‘ì¦ì€ ê±´ì„  ì‹œì¥ì—ì„œ ì¤‘ìš”í•œ ì°¨ë³„í™” ìš”ì†Œë¡œ ì‘ìš©í•˜ê³  ìˆìœ¼ë©°, íŠ¹íˆ PSA íš¨ëŠ¥ì´ ì•„ì§ ì…ì¦ë˜ì§€ ì•Šì€ ì‹ ê·œ ì˜µì…˜ë“¤ê³¼ ë¹„êµí•  ë•Œ ë”ìš± ê·¸ëŸ¬í•©ë‹ˆë‹¤. ì¤‘ìš”í•œ ì ì€ ìŠ¤ì¹´ì´ë¦¬ì§€ê°€ í”¼ë¶€ê³¼ì™€ ë¥˜ë§ˆí‹°ìŠ¤ê³¼ ë¶€ë¬¸ ëª¨ë‘ì—ì„œ ìƒë¬¼í•™ì ì œì œ ì¤‘ PSA 1ì°¨ ì¹˜ë£Œ ì¸í”Œë ˆì´ í™˜ì ì ìœ ìœ¨ ì„ ë‘ë¥¼ ë‹¬ì„±í–ˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¥˜ë§ˆí‹°ìŠ¤ ë¶„ì•¼ë¡œ ë” í­ë„“ê²Œ ì‚´í´ë³´ë©´, ë¦°ë³µì€ ë¯¸êµ­ ë‚´ ëª¨ë“  ì¹˜ë£Œ ë¼ì¸ì—ì„œ ë¥˜ë§ˆí‹°ìŠ¤ ê´€ì ˆì—¼(RA) ì¸í”Œë ˆì´ í™˜ì ì ìœ ìœ¨ 10%ëŒ€ ì¤‘ë°˜ì˜ ì„ ë„ì  ìœ„ì¹˜ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This is roughly double our total TRx share, highlighting a nice setup for incremental share capture in RA over the next several years, driven by our active communication of the SELECT-SWITCH trial with data demonstrating Rinvoq's doubling of remission rates versus treatment with a second TNF inhibitor. And lastly, in IBD, where we continue to deliver strong performance and remained very well positioned. The IBD market is very robust with high single-digit growth driven by increasing biologic penetration and rapidly expanding lines of therapy as patients cycle to newer high-efficacy agents like Skyrizi and Rinvoq. We are very pleased with Skyrizi's strong growth in IBD.</td><td>ì´ëŠ” ìš°ë¦¬ì˜ ì „ì²´ TRx ì ìœ ìœ¨ì˜ ì•½ ë‘ ë°°ì— í•´ë‹¹í•˜ë©°, í–¥í›„ ëª‡ ë…„ê°„ RAì—ì„œ ì ì§„ì ì¸ ì ìœ ìœ¨ í™•ëŒ€ë¥¼ ìœ„í•œ ì¢‹ì€ ê¸°ë°˜ì„ ë§ˆë ¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” SELECT-SWITCH ì„ìƒì‹œí—˜ì— ëŒ€í•œ ì ê·¹ì ì¸ ì»¤ë®¤ë‹ˆì¼€ì´ì…˜ì„ í†µí•´ ì¶”ì§„ë  ê²ƒì´ë©°, í•´ë‹¹ ë°ì´í„°ëŠ” Rinvoqê°€ ë‘ ë²ˆì§¸ TNF ì–µì œì œ ì¹˜ë£Œ ëŒ€ë¹„ ê´€í•´ìœ¨ì„ ë‘ ë°°ë¡œ ë†’ì¸ë‹¤ëŠ” ê²ƒì„ ì…ì¦í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ IBDì—ì„œëŠ” ê°•ë ¥í•œ ì‹¤ì ì„ ì§€ì†ì ìœ¼ë¡œ ë‹¬ì„±í•˜ê³  ìˆìœ¼ë©° ë§¤ìš° ìœ ë¦¬í•œ ìœ„ì¹˜ë¥¼ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. IBD ì‹œì¥ì€ ìƒë¬¼í•™ì ì œì œ ì¹¨íˆ¬ìœ¨ ì¦ê°€ì™€ í™˜ìë“¤ì´ Skyrizi ë° Rinvoqì™€ ê°™ì€ ìƒˆë¡œìš´ ê³ íš¨ëŠ¥ ì•½ë¬¼ë¡œ ì „í™˜í•¨ì— ë”°ë¼ ì¹˜ë£Œ ë¼ì¸ì´ ë¹ ë¥´ê²Œ í™•ëŒ€ë˜ë©´ì„œ ë†’ì€ í•œ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë³´ì´ë©° ë§¤ìš° ê²¬ê³ í•œ ìƒíƒœì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” IBDì—ì„œ Skyriziì˜ ê°•ë ¥í•œ ì„±ì¥ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Global sales for this indication were approximately $6.4 billion in 2025, more than double our prior year performance in IBD. We remain very confident in Skyrizi's profile in IBD, including its demonstrated strong impact on clinical remission as well as extremely strong endoscopic data with best-in-class placebo-adjusted rates, particularly in the bio-naive patients. And you can see this clinical profile playing out well when you consider our current market shares by line of therapy.</td><td>ì´ ì ì‘ì¦ì— ëŒ€í•œ ê¸€ë¡œë²Œ ë§¤ì¶œì€ 2025ë…„ ì•½ 64ì–µ ë‹¬ëŸ¬ë¡œ, IBD ë¶€ë¬¸ì—ì„œ ì „ë…„ ëŒ€ë¹„ ë‘ ë°° ì´ìƒì˜ ì„±ê³¼ë¥¼ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” Skyriziì˜ IBD í”„ë¡œíŒŒì¼ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì„ìƒì  ê´€í•´(clinical remission)ì— ëŒ€í•œ ì…ì¦ëœ ê°•ë ¥í•œ íš¨ê³¼ì™€ í•¨ê»˜ íŠ¹íˆ ë°”ì´ì˜¤ ë¯¸ê²½í—˜(bio-naive) í™˜ìë“¤ì—ì„œ ë™ì¢… ìµœê³  ìˆ˜ì¤€ì˜ ìœ„ì•½ ëŒ€ë¹„ ì¡°ì • ë¹„ìœ¨(placebo-adjusted rates)ì„ ë³´ì´ëŠ” ë§¤ìš° ìš°ìˆ˜í•œ ë‚´ì‹œê²½ ë°ì´í„°ê°€ í¬í•¨ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì„ìƒ í”„ë¡œíŒŒì¼ì´ ì¹˜ë£Œ ë¼ì¸ë³„ í˜„ì¬ ì‹œì¥ ì ìœ ìœ¨ì„ ê³ ë ¤í•  ë•Œ ì˜ ë‚˜íƒ€ë‚˜ê³  ìˆìŒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Importantly, and despite in-class competition for most of 2025, Skyrizi's capture rates remain exceptionally impressive, especially in that frontline treatment of IBD, which is the strongest signal of overall physician preference and Skyrizi remains the clear leader. Skyrizi retains a very high IL-23 category patient share with an in-play capture rate of approximately 75% in the frontline setting overall for IBD. This is driven by an even higher frontline capture rate for Skyrizi in Crohn's disease, which is roughly 2/3 of the total IBD market. And these capture rates have been strong and consistent even as the IL-23 category expands rapidly.</td><td>ì¤‘ìš”í•œ ì ì€, 2025ë…„ ëŒ€ë¶€ë¶„ì˜ ê¸°ê°„ ë™ì•ˆ ë™ì¼ ê³„ì—´ ë‚´ ê²½ìŸì´ ìˆì—ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³ , Skyriziì˜ ì ìœ ìœ¨ì€ ì—¬ì „íˆ ë§¤ìš° ì¸ìƒì ì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤. íŠ¹íˆ IBDì˜ 1ì°¨ ì¹˜ë£Œì—ì„œ ê·¸ëŸ¬í•œë°, ì´ëŠ” ì „ë°˜ì ì¸ ì˜ì‚¬ ì„ í˜¸ë„ë¥¼ ë³´ì—¬ì£¼ëŠ” ê°€ì¥ ê°•ë ¥í•œ ì‹ í˜¸ì´ë©° SkyriziëŠ” ëª…í™•í•œ ì„ ë‘ì£¼ìë¡œ ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. SkyriziëŠ” IL-23 ê³„ì—´ì—ì„œ ë§¤ìš° ë†’ì€ í™˜ì ì ìœ ìœ¨ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, IBD ì „ì²´ 1ì°¨ ì¹˜ë£Œ í™˜ê²½ì—ì„œ ì•½ 75%ì˜ ì¸í”Œë ˆì´ ì ìœ ìœ¨ì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì „ì²´ IBD ì‹œì¥ì˜ ì•½ 2/3ë¥¼ ì°¨ì§€í•˜ëŠ” í¬ë¡ ë³‘ì—ì„œ Skyriziì˜ ë”ìš± ë†’ì€ 1ì°¨ ì¹˜ë£Œ ì ìœ ìœ¨ì— ì˜í•´ ì£¼ë„ë˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì ìœ ìœ¨ì€ IL-23 ê³„ì—´ì´ ë¹ ë¥´ê²Œ í™•ëŒ€ë˜ê³  ìˆëŠ” ê°€ìš´ë°ì—ë„ ê°•ë ¥í•˜ê³  ì¼ê´€ë˜ê²Œ ìœ ì§€ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Skyrizi's dosing convenience is also favored with less frequent maintenance treatment to the most effective dose for other IL-23s, which is very important as patients tend to be on therapy for many years. So Skyrizi continues to perform very well and will continue to do so in 2026 and beyond. Equally importantly, and unlike any other competitor, we have a second compelling treatment in IBD, Rinvoq, which is also capturing robust mid-teens in-play share across all lines of therapy in Crohn's disease and ulcerative colitis.</td><td>ìŠ¤ì¹´ì´ë¦¬ì§€ì˜ íˆ¬ì•½ í¸ì˜ì„±ë„ ì„ í˜¸ë˜ê³  ìˆëŠ”ë°, ë‹¤ë¥¸ IL-23 ì œì œë“¤ì˜ ê°€ì¥ íš¨ê³¼ì ì¸ ìš©ëŸ‰ ëŒ€ë¹„ ìœ ì§€ ì¹˜ë£Œ ë¹ˆë„ê°€ ë‚®ë‹¤ëŠ” ì ì´ íŠ¹ì§•ì…ë‹ˆë‹¤. í™˜ìë“¤ì´ ìˆ˜ë…„ê°„ ì¹˜ë£Œë¥¼ ë°›ëŠ” ê²½í–¥ì´ ìˆë‹¤ëŠ” ì ì—ì„œ ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ìŠ¤ì¹´ì´ë¦¬ì§€ëŠ” ê³„ì†í•´ì„œ ìš°ìˆ˜í•œ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìœ¼ë©°, 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ì´ëŸ¬í•œ ì„±ê³¼ë¥¼ ì§€ì†í•  ê²ƒì…ë‹ˆë‹¤. ë§ˆì°¬ê°€ì§€ë¡œ ì¤‘ìš”í•œ ì ì€, ë‹¤ë¥¸ ê²½ìŸì‚¬ì™€ ë‹¬ë¦¬ ìš°ë¦¬ëŠ” IBD(ì—¼ì¦ì„± ì¥ì§ˆí™˜) ë¶„ì•¼ì—ì„œ ë‘ ë²ˆì§¸ë¡œ ê°•ë ¥í•œ ì¹˜ë£Œì œì¸ ë¦°ë³µì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ë¦°ë³µ ì—­ì‹œ í¬ë¡ ë³‘ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ì˜ ëª¨ë“  ì¹˜ë£Œ ë‹¨ê³„ì—ì„œ ê²¬ê³ í•œ 10%ëŒ€ ì¤‘ë°˜ì˜ ì¸í”Œë ˆì´ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Rinvoq has demonstrated some of the strongest response rates to date in IBD including rapidity of action, which is important for patients who need rapid control and durable remission. And with Rinvoq's recently expanded label in IBD, patients will now have access to Rinvoq earlier in the treatment paradigm when anti-TNF treatment is clinically and advisable. Skyrizi and Rinvoq are a great payer in IBD. Skyrizi is well positioned in frontline, and we see more opportunity than ever before for Rinvoq in the second-line plus setting.</td><td>ë¦°ë³µì€ IBDì—ì„œ í˜„ì¬ê¹Œì§€ ê°€ì¥ ê°•ë ¥í•œ ë°˜ì‘ë¥ ì„ ì…ì¦í–ˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ì‹ ì†í•œ ì‘ìš© íš¨ê³¼ë„ í¬í•¨ë©ë‹ˆë‹¤. ì´ëŠ” ë¹ ë¥¸ ì¦ìƒ ì¡°ì ˆê³¼ ì§€ì†ì ì¸ ê´€í•´ê°€ í•„ìš”í•œ í™˜ìë“¤ì—ê²Œ ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìµœê·¼ IBDì—ì„œ ë¦°ë³µì˜ ì ì‘ì¦ì´ í™•ëŒ€ë¨ì— ë”°ë¼, í™˜ìë“¤ì€ ì´ì œ í•­-TNF ì¹˜ë£Œê°€ ì„ìƒì ìœ¼ë¡œ ê¶Œê³ ë˜ëŠ” ì¹˜ë£Œ íŒ¨ëŸ¬ë‹¤ì„ì˜ ë” ì´ë¥¸ ë‹¨ê³„ì—ì„œ ë¦°ë³µì— ì ‘ê·¼í•  ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ìŠ¤ì¹´ì´ë¦¬ì§€ì™€ ë¦°ë³µì€ IBDì—ì„œ í›Œë¥­í•œ ë³´í—˜ê¸‰ì—¬ ëŒ€ìƒì…ë‹ˆë‹¤. ìŠ¤ì¹´ì´ë¦¬ì§€ëŠ” 1ì°¨ ì¹˜ë£Œì—ì„œ ì¢‹ì€ ìœ„ì¹˜ë¥¼ ì°¨ì§€í•˜ê³  ìˆìœ¼ë©°, ë¦°ë³µì€ 2ì°¨ ì¹˜ë£Œ ì´ìƒì˜ ì˜ì—­ì—ì„œ ê·¸ ì–´ëŠ ë•Œë³´ë‹¤ ë§ì€ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>So together, our 2 brands have already exceeded peak Humira sales by more than $4.5 billion and are on pace to deliver more than 20% growth in 2026, remarkable considering this year will be their eighth year on the market. Turning now to Humira, which delivered global sales of more than $1.2 billion, down 26.1% on an operational basis, primarily due to biosimilar competition and in line with our expectations. We anticipate Humira access will decrease further throughout 2026 as more plans move to exclusive biosimilar contracts. Moving to neuroscience, where full year revenues were more than $10.7 billion, reflecting impressive absolute sales growth of nearly $1.8 billion.</td><td>ì´ë ‡ê²Œ ë‘ ë¸Œëœë“œë¥¼ í•©ì¹˜ë©´ ì´ë¯¸ íœ´ë¯¸ë¼ì˜ ìµœê³  ë§¤ì¶œì„ 45ì–µ ë‹¬ëŸ¬ ì´ìƒ ì´ˆê³¼í–ˆìœ¼ë©°, 2026ë…„ì—ëŠ” 20% ì´ìƒì˜ ì„±ì¥ì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì˜¬í•´ê°€ ì‹œì¥ ì¶œì‹œ 8ë…„ì°¨ë¼ëŠ” ì ì„ ê³ ë ¤í•˜ë©´ ë†€ë¼ìš´ ì„±ê³¼ì…ë‹ˆë‹¤. ì´ì œ íœ´ë¯¸ë¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. íœ´ë¯¸ë¼ëŠ” ì „ ì„¸ê³„ì ìœ¼ë¡œ 12ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ë§¤ì¶œì„ ê¸°ë¡í–ˆìœ¼ë©°, ì£¼ë¡œ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ê²½ìŸìœ¼ë¡œ ì¸í•´ ì‹¤ì§ˆ ê¸°ì¤€ìœ¼ë¡œ 26.1% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ì˜ˆìƒê³¼ ì¼ì¹˜í•˜ëŠ” ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë” ë§ì€ ë³´í—˜ì‚¬ë“¤ì´ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ë…ì  ê³„ì•½ìœ¼ë¡œ ì „í™˜í•¨ì— ë”°ë¼ 2026ë…„ ë‚´ë‚´ íœ´ë¯¸ë¼ì˜ ì ‘ê·¼ì„±ì´ ë”ìš± ê°ì†Œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì‹ ê²½ê³¼í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ë©´, ì—°ê°„ ë§¤ì¶œì´ 107ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„°ìœ¼ë©°, ì´ëŠ” ì•½ 18ì–µ ë‹¬ëŸ¬ì˜ ì¸ìƒì ì¸ ì ˆëŒ€ ë§¤ì¶œ ì„±ì¥ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>In the quarter, total revenues were more than $2.9 billion, up 17.3% on an operational basis. This robust performance is driven by continued double-digit growth of Vraylar with global sales of $1 billion, Botox Therapeutic with global revenues of $990 million, Ubrelvy with global sales of $339 million and Qulipta with global revenues of $288 million. Beyond these leading therapies for psychiatry and migraine, we are very excited for our emerging portfolio in Parkinson's disease, which we believe remains underappreciated. Vyalev's launch continues to be outstanding. Total sales were $183 million in the quarter, up approximately 33% on a sequential basis.</td><td>ì´ë²ˆ ë¶„ê¸° ì´ ë§¤ì¶œì€ 29ì–µ ë‹¬ëŸ¬ë¥¼ ìƒíšŒí•˜ë©°, ì˜ì—… ê¸°ì¤€ìœ¼ë¡œ 17.3% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ê²¬ì¡°í•œ ì‹¤ì ì€ ì „ ì„¸ê³„ ë§¤ì¶œ 10ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•œ Vraylarì˜ ì§€ì†ì ì¸ ë‘ ìë¦¿ìˆ˜ ì„±ì¥, ì „ ì„¸ê³„ ë§¤ì¶œ 9ì–µ 9ì²œë§Œ ë‹¬ëŸ¬ì˜ Botox Therapeutic, ì „ ì„¸ê³„ ë§¤ì¶œ 3ì–µ 3,900ë§Œ ë‹¬ëŸ¬ì˜ Ubrelvy, ê·¸ë¦¬ê³  ì „ ì„¸ê³„ ë§¤ì¶œ 2ì–µ 8,800ë§Œ ë‹¬ëŸ¬ì˜ Quliptaì— í˜ì…ì€ ê²ƒì…ë‹ˆë‹¤. ì •ì‹ ì˜í•™ ë° í¸ë‘í†µ ë¶„ì•¼ì˜ ì´ëŸ¬í•œ ì£¼ë ¥ ì¹˜ë£Œì œë“¤ì„ ë„˜ì–´, ìš°ë¦¬ëŠ” íŒŒí‚¨ìŠ¨ë³‘ ë¶„ì•¼ì˜ ì‹ ê·œ í¬íŠ¸í´ë¦¬ì˜¤ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìœ¼ë©°, ì´ ë¶„ì•¼ê°€ ì—¬ì „íˆ ì €í‰ê°€ë˜ì–´ ìˆë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. Vyalevì˜ ì¶œì‹œëŠ” ê³„ì†í•´ì„œ íƒì›”í•œ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë¶„ê¸° ì´ ë§¤ì¶œì€ 1ì–µ 8,300ë§Œ ë‹¬ëŸ¬ë¡œ, ì „ ë¶„ê¸° ëŒ€ë¹„ ì•½ 33% ì¦ê°€í–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The uptake is exceptionally strong across international markets, and we expect sales to ramp in the U.S. where Vyalev recently received full coverage. Feedback from prescribers and patient communities remain very encouraging, highlighting meaningful improvements in on-time and off time as a result of Vyalev's continuous 24-hour delivery and the control of symptoms morning, day and night. Given these insights and the robust early launch trends globally, we now expect Vyalev to achieve blockbuster revenue in 2026.</td><td>í•´ì™¸ ì‹œì¥ì—ì„œì˜ ìˆ˜ìš©ë„ê°€ ë§¤ìš° ê°•ë ¥í•˜ë©°, ìµœê·¼ ì „ë©´ ë³´í—˜ ì ìš©ì„ ë°›ì€ Vyalevì˜ ë¯¸êµ­ ë‚´ ë§¤ì¶œì´ ì¦ê°€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë©ë‹ˆë‹¤. ì²˜ë°© ì˜ì‚¬ë“¤ê³¼ í™˜ì ì»¤ë®¤ë‹ˆí‹°ë¡œë¶€í„°ì˜ í”¼ë“œë°±ì€ ë§¤ìš° ê³ ë¬´ì ì´ë©°, Vyalevì˜ 24ì‹œê°„ ì§€ì†ì  ì „ë‹¬ê³¼ ì•„ì¹¨, ë‚®, ë°¤ì˜ ì¦ìƒ ì¡°ì ˆë¡œ ì¸í•œ ì˜¨íƒ€ì„(on-time)ê³¼ ì˜¤í”„íƒ€ì„(off time)ì˜ ì˜ë¯¸ ìˆëŠ” ê°œì„ ì„ ê°•ì¡°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¸ì‚¬ì´íŠ¸ì™€ ì „ ì„¸ê³„ì ìœ¼ë¡œ ê²¬ê³ í•œ ì´ˆê¸° ì¶œì‹œ ì¶”ì„¸ë¥¼ ê°ì•ˆí•  ë•Œ, ìš°ë¦¬ëŠ” ì´ì œ Vyalevê°€ 2026ë…„ì— ë¸”ë¡ë²„ìŠ¤í„° ë§¤ì¶œì„ ë‹¬ì„±í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>And when you add tavapadon for potential use as a monotherapy for early Parkinson's disease as well as an adjunct to optimize oral therapy for more advanced patients, we believe we have the potential multibillion-dollar emerging PD franchise over the long term. And we remain on track for commercial approval of tavapadon in the U.S. later this year. Moving now to oncology, where total revenues were nearly $1.7 billion in the quarter, down 2.5% on an operational basis.</td><td>ê·¸ë¦¬ê³  ì´ˆê¸° íŒŒí‚¨ìŠ¨ë³‘ ë‹¨ë…ìš”ë²• ë° ì§„í–‰ëœ í™˜ìì˜ ê²½êµ¬ ì¹˜ë£Œ ìµœì í™”ë¥¼ ìœ„í•œ ë³´ì¡°ìš”ë²•ìœ¼ë¡œì„œ tavapadonì˜ ì ì¬ì  ì‚¬ìš©ì„ ì¶”ê°€í•˜ë©´, ìš°ë¦¬ëŠ” ì¥ê¸°ì ìœ¼ë¡œ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ì‹ í¥ íŒŒí‚¨ìŠ¨ë³‘ í”„ëœì°¨ì´ì¦ˆë¥¼ ë³´ìœ í•  ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë¯¿ìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” ì˜¬í•´ ë§ ë¯¸êµ­ì—ì„œ tavapadonì˜ ìƒì—…ì  ìŠ¹ì¸ì„ ë°›ì„ ìˆ˜ ìˆë„ë¡ ìˆœì¡°ë¡­ê²Œ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ì¢…ì–‘í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì˜ ë¶„ê¸° ì´ ë§¤ì¶œì€ ì•½ 17ì–µ ë‹¬ëŸ¬ë¡œ ìš´ì˜ ê¸°ì¤€ 2.5% ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Venclexta global sales were $710 million, up 6.4% on an operational basis, reflecting continued strong demand in CLL with combination use of Venclexta plus BTK inhibitors emerging as a preferred all-oral fixed duration treatment. In 2026, we anticipate another major commercial catalyst with the global approvals of Venclexta plus Calquence in combination, 2 leading brands in CLL, offering patients the potential for time off treatment, addressing an important need. Double-digit sales growth from Elahere, Epkinly and EMRELIS also helped to partially offset the expected sales decline for Imbruvica, which was down 20.8%, primarily due to continued competitive dynamics.</td><td>ë²¤í´ë ‰ìŠ¤íƒ€ì˜ ê¸€ë¡œë²Œ ë§¤ì¶œì€ 7ì–µ 1ì²œë§Œ ë‹¬ëŸ¬ë¡œ ìš´ì˜ ê¸°ì¤€ 6.4% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ì´ëŠ” CLLì—ì„œì˜ ì§€ì†ì ì¸ ê°•ë ¥í•œ ìˆ˜ìš”ë¥¼ ë°˜ì˜í•œ ê²ƒìœ¼ë¡œ, ë²¤í´ë ‰ìŠ¤íƒ€ì™€ BTK ì–µì œì œì˜ ë³‘ìš©ìš”ë²•ì´ ì„ í˜¸ë˜ëŠ” ì „ì²´ ê²½êµ¬ ê³ ì • ê¸°ê°„ ì¹˜ë£Œë²•ìœ¼ë¡œ ë¶€ìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. 2026ë…„ì—ëŠ” CLL ë¶„ì•¼ì˜ ì–‘ëŒ€ ì„ ë„ ë¸Œëœë“œì¸ ë²¤í´ë ‰ìŠ¤íƒ€ì™€ ì¹¼ì¼„ìŠ¤ì˜ ë³‘ìš©ìš”ë²•ì´ ì „ ì„¸ê³„ì ìœ¼ë¡œ ìŠ¹ì¸ë˜ë©´ì„œ ë˜ ë‹¤ë¥¸ ì£¼ìš” ìƒì—…ì  ì´‰ë§¤ì œê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” í™˜ìë“¤ì—ê²Œ ì¹˜ë£Œ ì¤‘ë‹¨ ê¸°ê°„ì„ ì œê³µí•  ìˆ˜ ìˆëŠ” ê°€ëŠ¥ì„±ì„ ì œì‹œí•˜ì—¬ ì¤‘ìš”í•œ ë¯¸ì¶©ì¡± ìˆ˜ìš”ë¥¼ í•´ê²°í•  ê²ƒì…ë‹ˆë‹¤. ì—˜ë¼íˆì–´, ì—¡í‚¨ë¦¬, ì— ë ë¦¬ìŠ¤ì˜ ë‘ ìë¦¿ìˆ˜ ë§¤ì¶œ ì„±ì¥ì´ ì„ë¸Œë£¨ë¹„ì¹´ì˜ ì˜ˆìƒëœ ë§¤ì¶œ ê°ì†Œë¥¼ ë¶€ë¶„ì ìœ¼ë¡œ ìƒì‡„í•˜ëŠ” ë° ê¸°ì—¬í–ˆìŠµë‹ˆë‹¤. ì„ë¸Œë£¨ë¹„ì¹´ëŠ” ì§€ì†ì ì¸ ê²½ìŸ ì—­í•™ìœ¼ë¡œ ì¸í•´ ì£¼ë¡œ 20.8% ê°ì†Œí–ˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>And we do anticipate Imbruvica IRA pricing will unfavorably impact our oncology portfolio growth in 2026. Turning now to aesthetics, which delivered global sales of nearly $1.3 billion in the quarter, down 1.2% on an operational basis. Botox Cosmetic global revenues were $717 million, up 3.8% on an operational basis. Juvederm global sales were $249 million, down 10.8% on an operational basis. As we've seen over the last several quarters, economic headwinds have continued to impact market conditions globally, and we anticipate category growth will remain challenged in 2026.</td><td>ê·¸ë¦¬ê³  ìš°ë¦¬ëŠ” Imbruvica IRA ê°€ê²© ì •ì±…ì´ 2026ë…„ ìš°ë¦¬ì˜ ì¢…ì–‘í•™ í¬íŠ¸í´ë¦¬ì˜¤ ì„±ì¥ì— ë¶€ì •ì ì¸ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ ë¯¸ìš©ì˜í•™ ë¶€ë¬¸ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì´ ë¶€ë¬¸ì€ ì´ë²ˆ ë¶„ê¸°ì— ì•½ 13ì–µ ë‹¬ëŸ¬ì˜ ê¸€ë¡œë²Œ ë§¤ì¶œì„ ê¸°ë¡í–ˆìœ¼ë©°, ìš´ì˜ ê¸°ì¤€ìœ¼ë¡œ 1.2% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. Botox Cosmetic ê¸€ë¡œë²Œ ë§¤ì¶œì€ 7ì–µ 1,700ë§Œ ë‹¬ëŸ¬ë¡œ ìš´ì˜ ê¸°ì¤€ 3.8% ì¦ê°€í–ˆìŠµë‹ˆë‹¤. Juvederm ê¸€ë¡œë²Œ ë§¤ì¶œì€ 2ì–µ 4,900ë§Œ ë‹¬ëŸ¬ë¡œ ìš´ì˜ ê¸°ì¤€ 10.8% ê°ì†Œí–ˆìŠµë‹ˆë‹¤. ì§€ë‚œ ëª‡ ë¶„ê¸° ë™ì•ˆ ì§€ì†ì ìœ¼ë¡œ í™•ì¸í–ˆë“¯ì´, ê²½ì œì  ì—­í’ì´ ì „ ì„¸ê³„ì ìœ¼ë¡œ ì‹œì¥ ìƒí™©ì— ê³„ì† ì˜í–¥ì„ ë¯¸ì¹˜ê³  ìˆìœ¼ë©°, ìš°ë¦¬ëŠ” 2026ë…„ì—ë„ ì¹´í…Œê³ ë¦¬ ì„±ì¥ì´ ì–´ë ¤ìš´ ìƒí™©ì´ ì§€ì†ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>With our leading market shares relatively stable for both toxins and fillers, we are focused on investing to stimulate the market, which remains highly underpenetrated. We expect to further catalyze growth with new promotional programs for Botox, including the Only You campaign that was launched over the last several months with encouraging early results, an unbranded program to educate practices and consumers about the benefit of HA fillers with a focus on driving natural outcomes as well as additional injector training, which will be supported by our 3 new AMI training centers in the U.S. as well as training programs in key international geographies.</td><td>ë…ì†Œì™€ í•„ëŸ¬ ëª¨ë‘ì—ì„œ ìš°ë¦¬ì˜ ì„ ë„ì ì¸ ì‹œì¥ ì ìœ ìœ¨ì´ ìƒëŒ€ì ìœ¼ë¡œ ì•ˆì •ì ì¸ ê°€ìš´ë°, ìš°ë¦¬ëŠ” ì—¬ì „íˆ ì¹¨íˆ¬ìœ¨ì´ ë§¤ìš° ë‚®ì€ ì‹œì¥ì„ í™œì„±í™”í•˜ê¸° ìœ„í•œ íˆ¬ìì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë³´í†¡ìŠ¤ì— ëŒ€í•œ ìƒˆë¡œìš´ í”„ë¡œëª¨ì…˜ í”„ë¡œê·¸ë¨ë“¤ì„ í†µí•´ ì„±ì¥ì„ ë”ìš± ì´‰ì§„í•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì§€ë‚œ ëª‡ ê°œì›”ê°„ ì¶œì‹œë˜ì–´ ê³ ë¬´ì ì¸ ì´ˆê¸° ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆëŠ” Only You ìº í˜ì¸, ìì—°ìŠ¤ëŸ¬ìš´ ê²°ê³¼ ë„ì¶œì— ì´ˆì ì„ ë§ì¶° HA í•„ëŸ¬ì˜ ì´ì ì— ëŒ€í•´ ì˜ë£Œê¸°ê´€ê³¼ ì†Œë¹„ìë¥¼ êµìœ¡í•˜ëŠ” ë¹„ë¸Œëœë“œ í”„ë¡œê·¸ë¨, ê·¸ë¦¬ê³  ë¯¸êµ­ ë‚´ 3ê°œì˜ ìƒˆë¡œìš´ AMI êµìœ¡ì„¼í„°ì™€ ì£¼ìš” í•´ì™¸ ì§€ì—­ì˜ êµìœ¡ í”„ë¡œê·¸ë¨ì„ í†µí•´ ì§€ì›ë  ì¶”ê°€ì ì¸ ì‹œìˆ ì êµìœ¡ì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>Bringing innovation to the aesthetics market with our pipeline is also a clear priority. We look forward to commercializing TrenibotE, a fast-acting short-duration toxin, which is expected to be approved in the U.S. later this year. So overall, I'm extremely pleased with the execution across our commercial portfolio, which is demonstrating very, very strong momentum as we head into 2026. And with that, I will turn the call over to Roopal for comments on our R&D highlights. Roopal? Scott Reents<br>Executive VP & CFO<br><br>Thank you, Roopal. Starting with our fourth quarter results. We reported adjusted earnings per share of $2.71, which is $0.08 above our guidance midpoint.</td><td>ë¯¸ìš© ì‹œì¥ì— í˜ì‹ ì„ ê°€ì ¸ì˜¤ëŠ” ê²ƒë„ ìš°ë¦¬ íŒŒì´í”„ë¼ì¸ì˜ ëª…í™•í•œ ìš°ì„ ìˆœìœ„ì…ë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ ë¯¸êµ­ì—ì„œ ìŠ¹ì¸ì´ ì˜ˆìƒë˜ëŠ” ë¹ ë¥´ê²Œ ì‘ìš©í•˜ëŠ” ë‹¨ê¸° ì§€ì†í˜• ë³´í†¡ìŠ¤ì¸ TrenibotEì˜ ìƒìš©í™”ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ ì €ëŠ” 2026ë…„ì„ í–¥í•´ ë‚˜ì•„ê°€ëŠ” ìš°ë¦¬ ìƒì—… í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì˜ ì‹¤í–‰ì— ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ë§¤ìš° ê°•ë ¥í•œ ëª¨ë©˜í…€ì„ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ì´ì œ R&D í•˜ì´ë¼ì´íŠ¸ì— ëŒ€í•œ ë…¼í‰ì„ ìœ„í•´ Roopalì—ê²Œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤. Roopal?<br><br>Scott Reents<br>ìµœê³ ì¬ë¬´ì±…ì„ì(CFO) ê²¸ ì „ë¬´ì´ì‚¬<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, Roopal. 4ë¶„ê¸° ì‹¤ì ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 2.71ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í–ˆìœ¼ë©°, ì´ëŠ” ê°€ì´ë˜ìŠ¤ ì¤‘ê°„ê°’ë³´ë‹¤ 0.08ë‹¬ëŸ¬ ë†’ì€ ìˆ˜ì¹˜ì…ë‹ˆë‹¤.</td></tr>
<tr><td>These results include a $0.71 unfavorable impact from acquired IPR&D expense. Total net revenues were $16.6 billion, reflecting robust growth of 10%, including a 0.5% favorable impact from foreign exchange. Our ex-Humira growth platform delivered reported growth of 14.5%, once again exceeding our expectations. Adjusted gross margin was 83.6% of sales. Adjusted R&D expense was 15.4% of sales, and adjusted SG&A expense was 22.3% of sales. The adjusted operating margin was 38.3% of sales, which included a 7.6% unfavorable impact from acquired IPR&D expense. Net interest expense was $655 million.</td><td>ì´ëŸ¬í•œ ì‹¤ì ì—ëŠ” ì¸ìˆ˜í•œ IPR&D ë¹„ìš©ìœ¼ë¡œ ì¸í•œ 0.71ë‹¬ëŸ¬ì˜ ë¶€ì •ì  ì˜í–¥ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì´ ìˆœë§¤ì¶œì€ 166ì–µ ë‹¬ëŸ¬ë¡œ, ì™¸í™˜ì˜ 0.5% ê¸ì •ì  ì˜í–¥ì„ í¬í•¨í•˜ì—¬ 10%ì˜ ê²¬ì¡°í•œ ì„±ì¥ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. íœ´ë¯¸ë¼ë¥¼ ì œì™¸í•œ ì„±ì¥ í”Œë«í¼ì€ ë³´ê³  ê¸°ì¤€ 14.5%ì˜ ì„±ì¥ì„ ë‹¬ì„±í•˜ì—¬ ë‹¤ì‹œ í•œë²ˆ ìš°ë¦¬ì˜ ê¸°ëŒ€ì¹˜ë¥¼ ìƒíšŒí–ˆìŠµë‹ˆë‹¤. ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ë§¤ì¶œì˜ 83.6%ì˜€ìŠµë‹ˆë‹¤. ì¡°ì • R&D ë¹„ìš©ì€ ë§¤ì¶œì˜ 15.4%ì˜€ìœ¼ë©°, ì¡°ì • íŒë§¤ê´€ë¦¬ë¹„ëŠ” ë§¤ì¶œì˜ 22.3%ì˜€ìŠµë‹ˆë‹¤. ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ ë§¤ì¶œì˜ 38.3%ë¡œ, ì—¬ê¸°ì—ëŠ” ì¸ìˆ˜í•œ IPR&D ë¹„ìš©ìœ¼ë¡œ ì¸í•œ 7.6%ì˜ ë¶€ì •ì  ì˜í–¥ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ìˆœì´ìë¹„ìš©ì€ 6ì–µ 5,500ë§Œ ë‹¬ëŸ¬ì˜€ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>The adjusted tax rate was 18.3%, reflecting the lower deductibility of the acquired IPR&D expense this quarter. Turning to our financial outlook for 2026. Our full year adjusted earnings per share guidance is between $14.37 and $14.57. Please note that this guidance does not include an estimate for acquired IPR&D expense that may be incurred throughout the year. We expect total net revenues of approximately $67 billion, reflecting growth of 9.5%. At current rates, we expect foreign exchange to have a roughly 0.8% favorable impact on full year sales growth. This revenue forecast contemplates the following approximate assumptions for select key products and therapeutic areas.</td><td>ì¡°ì • ì„¸ìœ¨ì€ 18.3%ë¡œ, ì´ë²ˆ ë¶„ê¸° ì·¨ë“í•œ IPR&D ë¹„ìš©ì˜ ë‚®ì€ ì„¸ê¸ˆê³µì œìœ¨ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. 2026ë…„ ì¬ë¬´ ì „ë§ìœ¼ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—°ê°„ ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ ê°€ì´ë˜ìŠ¤ëŠ” 14.37ë‹¬ëŸ¬ì—ì„œ 14.57ë‹¬ëŸ¬ ì‚¬ì´ì…ë‹ˆë‹¤. ì´ ê°€ì´ë˜ìŠ¤ì—ëŠ” ì—°ì¤‘ ë°œìƒí•  ìˆ˜ ìˆëŠ” ì·¨ë“ IPR&D ë¹„ìš©ì— ëŒ€í•œ ì¶”ì •ì¹˜ê°€ í¬í•¨ë˜ì–´ ìˆì§€ ì•Šë‹¤ëŠ” ì ì„ ìœ ì˜í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ì´ ìˆœë§¤ì¶œì€ ì•½ 670ì–µ ë‹¬ëŸ¬ë¡œ 9.5% ì„±ì¥ì„ ë°˜ì˜í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ, ì™¸í™˜ì´ ì—°ê°„ ë§¤ì¶œ ì„±ì¥ì— ì•½ 0.8%ì˜ ê¸ì •ì  ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ ë§¤ì¶œ ì „ë§ì€ ì£¼ìš” ì œí’ˆ ë° ì¹˜ë£Œ ì˜ì—­ì— ëŒ€í•œ ë‹¤ìŒê³¼ ê°™ì€ ëŒ€ëµì ì¸ ê°€ì •ì„ í¬í•¨í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>We expect global immunology sales of $34.5 billion, including Skyrizi revenue of $21.5 billion, driven by market growth and share gains across the psoriatic and IBD indications. Rinvoq revenue of $10.1 billion with growth across room, derm and gastro indications and Humira total revenue of $2.9 billion, reflecting continued biosimilar impact. For neuroscience, we expect global sales of $12.5 billion, reflecting robust double-digit growth.</td><td>ê¸€ë¡œë²Œ ë©´ì—­í•™ ë¶€ë¬¸ ë§¤ì¶œì€ 345ì–µ ë‹¬ëŸ¬ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” Skyrizi ë§¤ì¶œ 215ì–µ ë‹¬ëŸ¬ë¥¼ í¬í•¨í•˜ëŠ” ìˆ˜ì¹˜ë¡œ, ê±´ì„  ë° ì—¼ì¦ì„± ì¥ì§ˆí™˜(IBD) ì ì‘ì¦ ì „ë°˜ì— ê±¸ì¹œ ì‹œì¥ ì„±ì¥ê³¼ ì ìœ ìœ¨ í™•ëŒ€ì— ê¸°ì¸í•©ë‹ˆë‹¤. Rinvoq ë§¤ì¶œì€ 101ì–µ ë‹¬ëŸ¬ë¡œ ë¥˜ë§ˆí‹°ìŠ¤, í”¼ë¶€ê³¼, ìœ„ì¥ê´€ ì ì‘ì¦ ì „ë°˜ì— ê±¸ì³ ì„±ì¥í•  ê²ƒì´ë©°, Humira ì´ ë§¤ì¶œì€ 29ì–µ ë‹¬ëŸ¬ë¡œ ì§€ì†ì ì¸ ë°”ì´ì˜¤ì‹œë°€ëŸ¬ ì˜í–¥ì„ ë°˜ì˜í•œ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì‹ ê²½ê³¼í•™ ë¶€ë¬¸ì˜ ê²½ìš°, ê²¬ì¡°í•œ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ì„ ë°˜ì˜í•˜ì—¬ ê¸€ë¡œë²Œ ë§¤ì¶œ 125ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•©ë‹ˆë‹¤.</td></tr>
<tr><td>This includes Vraylar revenue of $4 billion, driven by continued strong prescription demand, Botox Therapeutic sales of $4.1 billion with strong performance across indications, total oral CGRP revenue of $2.9 billion, supported by market growth and share gains and Vyalev sales of $1 billion, demonstrating the brand's impressive launch and multibillion-dollar potential. In oncology, we expect global sales of $6.5 billion, including Imbruvica revenue of $2.2 billion, reflecting competitive headwinds and the impact of lower IRA-related pricing. Venclexta sales of $3 billion, which reflects continued strong demand and Elahere revenue of $850 million.</td><td>ì—¬ê¸°ì—ëŠ” ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ì²˜ë°© ìˆ˜ìš”ì— í˜ì…ì€ Vraylarì˜ 40ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ, ëª¨ë“  ì ì‘ì¦ì—ì„œ ê°•ë ¥í•œ ì‹¤ì ì„ ë³´ì¸ Botox Therapeuticì˜ 41ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ, ì‹œì¥ ì„±ì¥ê³¼ ì ìœ ìœ¨ í™•ëŒ€ì— í˜ì…ì€ ê²½êµ¬ìš© CGRP ì œì œ ì´ 29ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ, ê·¸ë¦¬ê³  ë¸Œëœë“œì˜ ì¸ìƒì ì¸ ì¶œì‹œì™€ ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ì ì¬ë ¥ì„ ì…ì¦í•˜ëŠ” Vyalevì˜ 10ì–µ ë‹¬ëŸ¬ ë§¤ì¶œì´ í¬í•¨ë©ë‹ˆë‹¤. ì¢…ì–‘í•™ ë¶€ë¬¸ì—ì„œëŠ” 65ì–µ ë‹¬ëŸ¬ì˜ ê¸€ë¡œë²Œ ë§¤ì¶œì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì—¬ê¸°ì—ëŠ” ê²½ìŸ ì—­í’ê³¼ IRA ê´€ë ¨ ê°€ê²© ì¸í•˜ ì˜í–¥ì„ ë°˜ì˜í•œ Imbruvicaì˜ 22ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ, ì§€ì†ì ìœ¼ë¡œ ê°•ë ¥í•œ ìˆ˜ìš”ë¥¼ ë°˜ì˜í•œ Venclextaì˜ 30ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ, ê·¸ë¦¬ê³  Elahereì˜ 8ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ ë§¤ì¶œì´ í¬í•¨ë©ë‹ˆë‹¤.</td></tr>
<tr><td>For aesthetics, we expect global sales of $5 billion. This includes Botox Cosmetic revenue of $2.7 billion, reflecting modest market growth and relatively stable market share and Juvederm sales of $950 million, reflecting continued headwinds in key dermal filler markets. Moving to the P&L for 2026. We are forecasting full year adjusted gross margin above 84% of sales, adjusted R&D expense of approximately $9.7 billion and adjusted SG&A expense of approximately $14.2 billion. We also expect an adjusted operating margin ratio of approximately 48.5%, reflecting meaningful expansion compared to 2025.</td><td>ë¯¸ìš© ë¶€ë¬¸ì—ì„œëŠ” ê¸€ë¡œë²Œ ë§¤ì¶œ 50ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ë³´í†¡ìŠ¤ ì½”ìŠ¤ë©”í‹± ë§¤ì¶œ 27ì–µ ë‹¬ëŸ¬ê°€ í¬í•¨ë˜ëŠ”ë°, ì´ëŠ” ì™„ë§Œí•œ ì‹œì¥ ì„±ì¥ê³¼ ìƒëŒ€ì ìœ¼ë¡œ ì•ˆì •ì ì¸ ì‹œì¥ ì ìœ ìœ¨ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì¥¬ë¹„ë¤ ë§¤ì¶œì€ 9ì–µ 5ì²œë§Œ ë‹¬ëŸ¬ë¡œ, ì£¼ìš” í”¼ë¶€ í•„ëŸ¬ ì‹œì¥ì—ì„œì˜ ì§€ì†ì ì¸ ì—­í’ì„ ë°˜ì˜í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>2026ë…„ ì†ìµê³„ì‚°ì„œë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ì—°ê°„ ì¡°ì • ë§¤ì¶œì´ì´ìµë¥ ì€ ë§¤ì¶œì˜ 84% ì´ìƒ, ì¡°ì • ì—°êµ¬ê°œë°œë¹„ëŠ” ì•½ 97ì–µ ë‹¬ëŸ¬, ì¡°ì • íŒë§¤ê´€ë¦¬ë¹„ëŠ” ì•½ 142ì–µ ë‹¬ëŸ¬ë¥¼ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ ì•½ 48.5%ë¡œ ì˜ˆìƒí•˜ë©°, ì´ëŠ” 2025ë…„ ëŒ€ë¹„ ì˜ë¯¸ ìˆëŠ” í™•ëŒ€ë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We expect adjusted net interest expense of approximately $2.8 billion, which includes anticipated refinancing. We forecast our non-GAAP tax rate to be approximately 14%, reflecting a modest underlying improvement compared to 2025 due to recent tax law changes. Keep in mind that last year's non-GAAP tax rate of 18% included a 3% impact from acquired IPR&D expense. Finally, we expect our share count to be roughly in line with 2025. Turning to the first quarter. We anticipate net revenues of approximately $14.7 billion. At current rates, we expect foreign exchange to have a roughly 2% favorable impact on sales growth.</td><td>ì¡°ì • ìˆœì´ìë¹„ìš©ì€ ì˜ˆìƒ ë¦¬íŒŒì´ë‚¸ì‹±ì„ í¬í•¨í•˜ì—¬ ì•½ 28ì–µ ë‹¬ëŸ¬ê°€ ë  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤. ë¹„GAAP ì„¸ìœ¨ì€ ìµœê·¼ ì„¸ë²• ê°œì •ìœ¼ë¡œ ì¸í•´ 2025ë…„ ëŒ€ë¹„ ì†Œí­ ê°œì„ ëœ ì•½ 14%ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. ì°¸ê³ ë¡œ ì‘ë…„ ë¹„GAAP ì„¸ìœ¨ 18%ì—ëŠ” ì·¨ë“í•œ IPR&D ë¹„ìš©ìœ¼ë¡œ ì¸í•œ 3%ì˜ ì˜í–¥ì´ í¬í•¨ë˜ì–´ ìˆì—ˆìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ ì£¼ì‹ìˆ˜ëŠ” 2025ë…„ê³¼ ëŒ€ì²´ë¡œ ë¹„ìŠ·í•œ ìˆ˜ì¤€ì„ ìœ ì§€í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•©ë‹ˆë‹¤. 1ë¶„ê¸°ë¡œ ë„˜ì–´ê°€ê² ìŠµë‹ˆë‹¤. ìˆœë§¤ì¶œì€ ì•½ 147ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ í™˜ìœ¨ ê¸°ì¤€ìœ¼ë¡œ ì™¸í™˜ì´ ë§¤ì¶œ ì„±ì¥ì— ì•½ 2%ì˜ ê¸ì •ì  ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ì „ë§í•©ë‹ˆë‹¤.</td></tr>
<tr><td>This revenue forecast considers the following approximate assumptions for key products and selected therapeutic areas. We expect global immunology sales to approach $7.1 billion, including Skyrizi sales of $4.4 billion and Rinvoq revenue of $2 billion, reflecting typical seasonality as well as an unfavorable price comparison for Rinvoq related to timing of prior year rebates in the first half. We also anticipate neuroscience revenue of $2.8 billion, oncology sales of $1.6 billion, and aesthetics revenue of $1.2 billion, reflecting growth of roughly 9%, including a favorable comparison as we lap onetime price headwinds associated with changes to the [ ALI ] program.</td><td>ì´ ë§¤ì¶œ ì „ë§ì€ ì£¼ìš” ì œí’ˆ ë° ì„ ë³„ëœ ì¹˜ë£Œ ì˜ì—­ì— ëŒ€í•œ ë‹¤ìŒê³¼ ê°™ì€ ëŒ€ëµì ì¸ ê°€ì •ì„ ê³ ë ¤í•œ ê²ƒì…ë‹ˆë‹¤. ê¸€ë¡œë²Œ ë©´ì—­í•™ ë§¤ì¶œì€ ì•½ 71ì–µ ë‹¬ëŸ¬ì— ë‹¬í•  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ë©°, ì´ëŠ” Skyrizi ë§¤ì¶œ 44ì–µ ë‹¬ëŸ¬ì™€ Rinvoq ë§¤ì¶œ 20ì–µ ë‹¬ëŸ¬ë¥¼ í¬í•¨í•˜ëŠ” ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ëŠ” ì¼ë°˜ì ì¸ ê³„ì ˆì„±ê³¼ í•¨ê»˜ ìƒë°˜ê¸° ì „ë…„ë„ ë¦¬ë² ì´íŠ¸ ì‹œê¸°ì™€ ê´€ë ¨ëœ Rinvoqì˜ ë¶ˆë¦¬í•œ ê°€ê²© ë¹„êµë¥¼ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤. ë˜í•œ ì‹ ê²½ê³¼í•™ ë§¤ì¶œ 28ì–µ ë‹¬ëŸ¬, ì¢…ì–‘í•™ ë§¤ì¶œ 16ì–µ ë‹¬ëŸ¬, ê·¸ë¦¬ê³  ë¯¸ìš© ë§¤ì¶œ 12ì–µ ë‹¬ëŸ¬ë¥¼ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” [ALI] í”„ë¡œê·¸ë¨ ë³€ê²½ê³¼ ê´€ë ¨ëœ ì¼íšŒì„± ê°€ê²© ì—­í’ì„ ê¸°ì €íš¨ê³¼ë¡œ í•˜ëŠ” ìœ ë¦¬í•œ ë¹„êµë¥¼ í¬í•¨í•˜ì—¬ ì•½ 9%ì˜ ì„±ì¥ì„ ë°˜ì˜í•œ ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>We are forecasting an adjusted operating margin ratio of roughly 46% and model a non-GAAP tax rate of approximately 13.7%. We expect adjusted earnings per share between $2.97 and $3.01. This guidance does not include acquired IPR&D expense that may be incurred in the quarter. Finally, AbbVie's robust business performance continues to support our capital allocation priorities. Our cash balance at the end of December was approximately $5.2 billion, and we expect to generate free cash flow of approximately $18.5 billion in 2026, which includes roughly $3.5 billion of Skyrizi royalty payments.</td><td>ì¡°ì • ì˜ì—…ì´ìµë¥ ì€ ì•½ 46%ë¥¼ ì „ë§í•˜ê³  ìˆìœ¼ë©°, ë¹„-GAAP ì„¸ìœ¨ì€ ì•½ 13.7%ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì¡°ì • ì£¼ë‹¹ìˆœì´ìµì€ 2.97ë‹¬ëŸ¬ì—ì„œ 3.01ë‹¬ëŸ¬ ì‚¬ì´ë¥¼ ì˜ˆìƒí•©ë‹ˆë‹¤. ì´ ê°€ì´ë˜ìŠ¤ì—ëŠ” í•´ë‹¹ ë¶„ê¸°ì— ë°œìƒí•  ìˆ˜ ìˆëŠ” ì¸ìˆ˜ ê´€ë ¨ IPR&D ë¹„ìš©ì€ í¬í•¨ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë§ˆì§€ë§‰ìœ¼ë¡œ, ì• ë¸Œë¹„ì˜ ê²¬ê³ í•œ ì‚¬ì—… ì‹¤ì ì€ ë‹¹ì‚¬ì˜ ìë³¸ë°°ë¶„ ìš°ì„ ìˆœìœ„ë¥¼ ì§€ì†ì ìœ¼ë¡œ ë’·ë°›ì¹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. 12ì›” ë§ í˜„ê¸ˆ ì”ì•¡ì€ ì•½ 52ì–µ ë‹¬ëŸ¬ì˜€ìœ¼ë©°, 2026ë…„ì—ëŠ” ì•½ 185ì–µ ë‹¬ëŸ¬ì˜ ì‰ì—¬í˜„ê¸ˆíë¦„ì„ ì°½ì¶œí•  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì—¬ê¸°ì—ëŠ” ì•½ 35ì–µ ë‹¬ëŸ¬ì˜ ìŠ¤ì¹´ì´ë¦¬ì§€ ë¡œì—´í‹° ì§€ê¸‰ì•¡ì´ í¬í•¨ë˜ì–´ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>This free cash flow will support a strong and growing quarterly dividend, which we have increased by more than 330% since inception as well as investments in business development to further enhance our portfolio. In closing, we are pleased with AbbVie's results in 2025 and our financial outlook remains very strong. We have significant momentum across our diverse portfolio and are well positioned to deliver strong results in 2026 and beyond. With that, I'll turn the call back over to Liz. Elizabeth Shea<br>Senior Vice President of Investor Relations<br><br>Thanks, Scott. We will now open the call for questions.</td><td>ì´ëŸ¬í•œ ì‰ì—¬í˜„ê¸ˆíë¦„ì€ ê°•ë ¥í•˜ê³  ì„±ì¥í•˜ëŠ” ë¶„ê¸° ë°°ë‹¹ê¸ˆì„ ë’·ë°›ì¹¨í•  ê²ƒì´ë©°, ìš°ë¦¬ëŠ” ì„¤ë¦½ ì´í›„ ë°°ë‹¹ê¸ˆì„ 330% ì´ìƒ ì¦ê°€ì‹œì¼°ìŠµë‹ˆë‹¤. ë˜í•œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë”ìš± ê°•í™”í•˜ê¸° ìœ„í•œ ì‚¬ì—… ê°œë°œ íˆ¬ìì—ë„ í™œìš©ë  ê²ƒì…ë‹ˆë‹¤. ë§ˆë¬´ë¦¬í•˜ë©´ì„œ, ìš°ë¦¬ëŠ” 2025ë…„ ì• ë¸Œë¹„ì˜ ì‹¤ì ì— ë§Œì¡±í•˜ê³  ìˆìœ¼ë©° ì¬ë¬´ ì „ë§ì€ ì—¬ì „íˆ ë§¤ìš° ê²¬ê³ í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë‹¤ê°í™”ëœ í¬íŠ¸í´ë¦¬ì˜¤ ì „ë°˜ì— ê±¸ì³ ìƒë‹¹í•œ ëª¨ë©˜í…€ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, 2026ë…„ê³¼ ê·¸ ì´í›„ì—ë„ ê°•ë ¥í•œ ì‹¤ì ì„ ë‹¬ì„±í•  ìˆ˜ ìˆëŠ” ì¢‹ì€ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ì´ì œ ë¦¬ì¦ˆì—ê²Œ ë‹¤ì‹œ ë§ˆì´í¬ë¥¼ ë„˜ê¸°ê² ìŠµë‹ˆë‹¤.<br><br>ì—˜ë¦¬ìë² ìŠ¤ ì‰ì–´<br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥<br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ìŠ¤ì½§. ì´ì œ ì§ˆì˜ì‘ë‹µ ì‹œê°„ì„ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>In the interest of hearing from as many analysts as possible over the remainder of the call, we ask that you please limit your question to one or two. Operator, we'll take the first question, please.</td><td>ê°€ëŠ¥í•œ í•œ ë§ì€ ì• ë„ë¦¬ìŠ¤íŠ¸ ë¶„ë“¤ì˜ ì§ˆë¬¸ì„ ë“£ê¸° ìœ„í•´, ì§ˆë¬¸ì€ í•œë‘ ê°œë¡œ ì œí•œí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. êµí™˜ì›ë‹˜, ì²« ë²ˆì§¸ ì§ˆë¬¸ ë°›ì•„ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># AbbVie 2025ë…„ 4ë¶„ê¸° ì‹¤ì  ë°œí‘œ ìš”ì•½<br><br>## í•µì‹¬ ë‚´ìš©<br><br>â€¢ **ê°•ë ¥í•œ ì‹¤ì  ë‹¬ì„±**: 2025ë…„ ì´ ë§¤ì¶œ 612ì–µ ë‹¬ëŸ¬(ì „ë…„ ëŒ€ë¹„ 8.6% ì„±ì¥)ë¡œ ì‚¬ìƒ ìµœê³  ê¸°ë¡ ê²½ì‹ . ì¡°ì • ì£¼ë‹¹ìˆœì´ìµ(EPS) 10ë‹¬ëŸ¬ë¡œ ì´ˆê¸° ê°€ì´ë˜ìŠ¤ ëŒ€ë¹„ 0.54ë‹¬ëŸ¬ ì´ˆê³¼ ë‹¬ì„±. Humiraì˜ 160ì–µ ë‹¬ëŸ¬ ë¯¸êµ­ íŠ¹í—ˆë§Œë£Œ ì†ì‹¤ì—ë„ ë¶ˆêµ¬í•˜ê³  ì´ì „ ìµœê³  ë§¤ì¶œì„ 30ì–µ ë‹¬ëŸ¬ ì´ìƒ ì´ˆê³¼.<br><br>â€¢ **2026ë…„ ì „ë§ ë° í•µì‹¬ ì„±ì¥ ë™ë ¥**: 2026ë…„ ë§¤ì¶œ 670ì–µ ë‹¬ëŸ¬(9.5% ì„±ì¥), EPS 14.37~14.57ë‹¬ëŸ¬ ê°€ì´ë˜ìŠ¤ ì œì‹œ. Skyriziì™€ Rinvoq í•©ì‚° ë§¤ì¶œ 310ì–µ ë‹¬ëŸ¬ ì´ìƒ ì˜ˆìƒ(2027ë…„ ì¥ê¸° ëª©í‘œë¥¼ ì´ë¯¸ 5ì–µ ë‹¬ëŸ¬ ì´ˆê³¼). VyalevëŠ” 2026ë…„ ë¸”ë¡ë²„ìŠ¤í„° ì§€ìœ„ ë‹¬ì„± ì „ë§(10ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ), í¸ë‘í†µ ì¹˜ë£Œì œë“¤ë„ ë‘ ìë¦¿ìˆ˜ ì„±ì¥ ì§€ì†.<br><br>â€¢ **íŒŒì´í”„ë¼ì¸ ê°•í™” ë° R&D íˆ¬ì**: 2025ë…„ R&D ë¹„ìš© ì•½ 10ì–µ ë‹¬ëŸ¬ ì¦ê°€í•˜ì—¬ 90ê°œ ì„ìƒ í”„ë¡œê·¸ë¨ ì§€ì›. 50ì–µ ë‹¬ëŸ¬ ì´ìƒì„ ì‹ ê·œ ì‚¬ì—…ê°œë°œì— íˆ¬ì(Capstanì˜ CAR-T í”Œë«í¼, ì°¨ì„¸ëŒ€ ì‚¬ì´í‚¤ë¸ë¦­ bretisilocin, ë¹„ë§Œ ì¹˜ë£Œì œ ë“± í¬í•¨). í–¥í›„ 24ê°œì›”ê°„ ë©´ì—­í•™, ì‹ </p>
    <hr style="margin:50px 0;">
    

    <h2>â“ Q&A</h2>
    <table style="width:100%; border-collapse:collapse; margin-bottom: 40px;">
        <tr>
            <th style="width:50%; border-bottom: 2px solid #333;">Original</th>
            <th style="width:50%; border-bottom: 2px solid #333;">Translation</th>
        </tr>
        <tr><td>Operator: [Operator Instructions] The first question in the queue is from David Risinger with Leerink Partners.</td><td>**Operator:** [êµí™˜ì› ì•ˆë‚´] ì²« ë²ˆì§¸ ì§ˆë¬¸ì€ Leerink Partnersì˜ David Risingerë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Risinger: Leerink Partners LLC, Research Division Congrats on the solid fourth quarter and the momentum of the company. I just have one question, which is you mentioned the psychedelic that's in development. Could you please provide some more details on that, including the opportunity to improve upon the profile of J&J's bravado?</td><td>**David Risinger:** ì¶•í•˜ë“œë¦½ë‹ˆë‹¤. ê²¬ê³ í•œ 4ë¶„ê¸° ì‹¤ì ê³¼ íšŒì‚¬ì˜ ëª¨ë©˜í…€ì— ëŒ€í•´ ë§ì”€ë“œë¦½ë‹ˆë‹¤. í•œ ê°€ì§€ë§Œ ì—¬ì­™ê² ìŠµë‹ˆë‹¤. ê°œë°œ ì¤‘ì´ì‹  ì‚¬ì´í‚¤ë¸ë¦­ ì•½ë¬¼ì— ëŒ€í•´ ì–¸ê¸‰í•˜ì…¨ëŠ”ë°ìš”, J&Jì˜ ë¸Œë¼ë°”ë„(Bravado) í”„ë¡œíŒŒì¼ì„ ê°œì„ í•  ìˆ˜ ìˆëŠ” ê¸°íšŒë¥¼ í¬í•¨í•´ì„œ ì¢€ ë” ìì„¸í•œ ë‚´ìš©ì„ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹ ê°€ìš”?</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer It's Roopal. I'll take that one. We see this one as a potential breakthrough type of therapy in a couple of elements. One is it works through 5-HT2A serotonergic pathway and has a short-acting, I would say, hallucination time period where patients experience the potential hallucinations upfront and then it rapidly goes away. And what we've observed is that you see immediate efficacy and then you see that efficacy held on for quite some time. So that's a benefit. And these patients are then able to stay for a short time in the clinic and then leave. The other notable differences from any other medications in this space are the very high levels of efficacy that were observed. And that almost led to a remission like state in the majority of patients. Now we have 2 more readouts before the Phase III begins. And in those readouts, what we're doing is reducing the dose of the control arm. And recall, the data that we've seen thus far were not against placebo. They were, in fact, against an active control of the drug itself, which that data looked pretty good. But when you looked at the main dose, it looked very impressive. So we're going to look at a comparator with a slightly lower dose of self-control. And then that will read out, I would say, by Q3 or so, and then we'll have a Phase III plan going forward that we'll discuss with regulators. But this has a potential to be highly differentiated.</td><td>**Roopal Thakkar:** ì´ ì¹˜ë£Œë²•ì´ ì ì¬ì  í˜ì‹  ì¹˜ë£Œì œê°€ ë  ìˆ˜ ìˆëŠ” ìš”ì†ŒëŠ” ëª‡ ê°€ì§€ê°€ ìˆìŠµë‹ˆë‹¤. ì²«ì§¸, 5-HT2A ì„¸ë¡œí† ë‹Œì„± ê²½ë¡œ(serotonergic pathway)ë¥¼ í†µí•´ ì‘ìš©í•˜ë©° ë‹¨ê¸° ì‘ìš©í˜•ìœ¼ë¡œ, í™˜ìë“¤ì´ ì´ˆê¸°ì— ì ì¬ì  í™˜ê°ì„ ê²½í—˜í•˜ì§€ë§Œ ë¹ ë¥´ê²Œ ì‚¬ë¼ì§„ë‹¤ëŠ” ì ì…ë‹ˆë‹¤. ì €í¬ê°€ ê´€ì°°í•œ ë°”ë¡œëŠ” ì¦‰ê°ì ì¸ íš¨ëŠ¥ì´ ë‚˜íƒ€ë‚˜ê³ , ê·¸ íš¨ëŠ¥ì´ ìƒë‹¹ ê¸°ê°„ ì§€ì†ë©ë‹ˆë‹¤. ì´ê²ƒì´ ì¥ì ì´ì£ . í™˜ìë“¤ì€ í´ë¦¬ë‹‰ì— ì§§ì€ ì‹œê°„ë§Œ ë¨¸ë¬¼ë‹¤ê°€ í‡´ì›í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ë¶„ì•¼ì˜ ë‹¤ë¥¸ ì•½ë¬¼ë“¤ê³¼ ë¹„êµí–ˆì„ ë•Œ ë˜ ë‹¤ë¥¸ ì£¼ëª©í•  ë§Œí•œ ì°¨ì´ì ì€ ê´€ì°°ëœ íš¨ëŠ¥ ìˆ˜ì¤€ì´ ë§¤ìš° ë†’ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ ê²°ê³¼ ëŒ€ë¶€ë¶„ì˜ í™˜ìì—ì„œ ê´€í•´(remission)ì— ê°€ê¹Œìš´ ìƒíƒœê°€ ë‚˜íƒ€ë‚¬ìŠµë‹ˆë‹¤. ì´ì œ 3ìƒ ì‹œí—˜ ì‹œì‘ ì „ì— 2ê±´ì˜ ë°ì´í„° ë°œí‘œê°€ ë” ë‚¨ì•„ìˆìŠµë‹ˆë‹¤. ì´ë²ˆ ë°œí‘œì—ì„œëŠ” ëŒ€ì¡°êµ°ì˜ ìš©ëŸ‰ì„ ì¤„ì´ê³  ìˆìŠµë‹ˆë‹¤. ì°¸ê³ ë¡œ ì§€ê¸ˆê¹Œì§€ í™•ì¸í•œ ë°ì´í„°ëŠ” ìœ„ì•½ ëŒ€ì¡°ê°€ ì•„ë‹ˆì—ˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œëŠ” ë™ì¼ ì•½ë¬¼ì˜ í™œì„± ëŒ€ì¡°êµ°ì„ ì‚¬ìš©í–ˆëŠ”ë°, ê·¸ ë°ì´í„°ë„ ê½¤ ì¢‹ì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì£¼ìš” ìš©ëŸ‰ì„ ë³´ë©´ ë§¤ìš° ì¸ìƒì ì´ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìì²´ ëŒ€ì¡°êµ°ì˜ ìš©ëŸ‰ì„ ì•½ê°„ ë‚®ì¶°ì„œ ë¹„êµí•  ì˜ˆì •ì…ë‹ˆë‹¤. ì´ ê²°ê³¼ëŠ” 3ë¶„ê¸°ì¯¤ ë‚˜ì˜¬ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, ì´í›„ ê·œì œë‹¹êµ­ê³¼ ë…¼ì˜í•  3ìƒ ê³„íšì„ ìˆ˜ë¦½í•  ê²ƒì…ë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ë†’ì€ ì°¨ë³„í™” ê°€ëŠ¥ì„±ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Yes. The next question is from Chris Schott with JPMorgan.</td><td>**Operator:** ë„¤, ë‹¤ìŒ ì§ˆë¬¸ì€ JPëª¨ê±´ì˜ í¬ë¦¬ìŠ¤ ìˆ ë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Christopher Schott: JPMorgan Chase & Co, Research Division Just a couple of parter on the immunology franchise. I guess just first on Skyrizi in IBD. It sounds like you haven't really seen any change in new start share here with the TREMFYA entry. I guess my question, is that the case in both Crohn's and UC? Or is that just more a holistic kind of IBD comment? And then my bigger picture question is, I've been reading more investors feeling that the Street now better understands the potential for Skyrizi and Rinvoq over time. As a result, there's no longer as much potential upside to numbers. I guess I'd just be interested in your view of consensus growth expectations for these assets over time. Is the market now largely getting this right at this point? Or do you see further potential for growth upside as we think about the breadth of indications, et cetera?</td><td>**Christopher Schott:** IBDì—ì„œì˜ Skyriziì— ëŒ€í•´ ëª‡ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë¨¼ì € IBDì—ì„œ Skyrizi ì‹ ê·œ ì²˜ë°© ì ìœ ìœ¨ì´ TREMFYA ì§„ì… ì´í›„ì—ë„ íŠ¹ë³„í•œ ë³€í™”ê°€ ì—†ëŠ” ê²ƒìœ¼ë¡œ ë“¤ë ¸ëŠ”ë°ìš”. ì´ê²ƒì´ í¬ë¡ ë³‘ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ ëª¨ë‘ì— í•´ë‹¹í•˜ëŠ” ê²ƒì¸ì§€, ì•„ë‹ˆë©´ IBD ì „ì²´ì ì¸ ê´€ì ì—ì„œ ë§ì”€í•˜ì‹  ê±´ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.<br><br>ê·¸ë¦¬ê³  ë” í° ê·¸ë¦¼ì—ì„œ ë³´ë©´, ìµœê·¼ íˆ¬ììë“¤ ì‚¬ì´ì—ì„œ ì‹œì¥ì´ ì´ì œ Skyriziì™€ Rinvoqì˜ ì¥ê¸° ì ì¬ë ¥ì„ ë” ì˜ ì´í•´í•˜ê²Œ ë˜ì—ˆë‹¤ëŠ” ì˜ê²¬ì´ ë§ì•„ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ ê²°ê³¼ ì´ì œëŠ” ì»¨ì„¼ì„œìŠ¤ ëŒ€ë¹„ ìƒìŠ¹ ì—¬ë ¥ì´ ì˜ˆì „ë§Œí¼ í¬ì§€ ì•Šë‹¤ëŠ” ì‹œê°ì´ ìˆëŠ”ë°ìš”. ì´ ë‘ ì œí’ˆì˜ ì¥ê¸° ì„±ì¥ ì „ë§ì— ëŒ€í•œ ì‹œì¥ ì»¨ì„¼ì„œìŠ¤ê°€ í˜„ì¬ ëŒ€ì²´ë¡œ ì ì ˆí•˜ê²Œ í˜•ì„±ë˜ì–´ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ íšŒì‚¬ ì¸¡ ê²¬í•´ê°€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì•„ë‹ˆë©´ ì ì‘ì¦ì˜ í­ ë“±ì„ ê³ ë ¤í•  ë•Œ ì¶”ê°€ì ì¸ ì„±ì¥ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”?</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. Chris, it's Jeff. So we see some slight distinctions between the capture rate for Skyrizi in Crohn's versus UC. And that's really probably largely based on when the launches took place with the competitors. But as I mentioned, and it may not be widely understood, we see definitely a bifurcation in where the capture rate is coming. It's quite clear that our new patient starts are very, very stable, and they're very high in both UC and Crohn's. If you look at where the starts are coming from, and I mentioned in my prepared remarks, we have very, very high capture rates, 75% overall in IBD in frontline setting, which sort of gives you a sense of where the preference of the customers are. And it's 80%. I didn't highlight that in my speech, it's 80% in Crohn's. So it's slightly lower in UC on the frontline setting. So we see the dynamics again as very stable and high new patient starts despite the competitive entrant high capture rates, leading capture rates by far in front line, which is really, really critical, which gives you a sense that competitors coming in and capturing in the second line. And then overall, we see a very substantial overall IL-23 category expansion. So when we look at all of those dynamics, our compete level is extremely high, and we're very, very comfortable with the momentum that we're going to continue to see with Skyrizi even before we get to Rinvoq coming in, in the later line. So that gives you some sense overall on IBD. I'll let maybe Rob address the second question.</td><td>**Jeffrey Stewart:** ë„¤, í¬ë¦¬ìŠ¤. ì œí”„ì…ë‹ˆë‹¤. ìŠ¤ì¹´ì´ë¦¬ì§€ì˜ í¬ë¡ ë³‘ê³¼ ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ì—ì„œì˜ ì ìœ ìœ¨(capture rate)ì—ëŠ” ì•½ê°„ì˜ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì£¼ë¡œ ê²½ìŸì‚¬ë“¤ì˜ ì¶œì‹œ ì‹œì  ì°¨ì´ì— ê¸°ì¸í•œ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì œê°€ ë§ì”€ë“œë ¸ë“¯ì´, ê·¸ë¦¬ê³  ì´ ë¶€ë¶„ì´ ë„ë¦¬ ì•Œë ¤ì§€ì§€ ì•Šì•˜ì„ ìˆ˜ë„ ìˆëŠ”ë°, ì ìœ ìœ¨ì˜ ì¶œì²˜ë¥¼ ë³´ë©´ ëª…í™•í•œ ì–‘ë¶„í™”ê°€ ë‚˜íƒ€ë‚˜ê³  ìˆìŠµë‹ˆë‹¤. ì‹ ê·œ í™˜ì ì‹œì‘(new patient starts)ì€ ë§¤ìš° ì•ˆì •ì ì´ê³ , ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ê³¼ í¬ë¡ ë³‘ ëª¨ë‘ì—ì„œ ë§¤ìš° ë†’ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>í™˜ì ì‹œì‘ì´ ì–´ë””ì„œ ì˜¤ëŠ”ì§€ ì‚´í´ë³´ë©´, ì œê°€ ì¤€ë¹„ëœ ë°œì–¸ì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´, IBD 1ì°¨ ì¹˜ë£Œ(frontline setting)ì—ì„œ ì „ì²´ì ìœ¼ë¡œ 75%ë¼ëŠ” ë§¤ìš° ë†’ì€ ì ìœ ìœ¨ì„ ê¸°ë¡í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ê³ ê°ë“¤ì˜ ì„ í˜¸ë„ê°€ ì–´ë””ì— ìˆëŠ”ì§€ë¥¼ ì˜ ë³´ì—¬ì£¼ëŠ” ì§€í‘œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  80%ì…ë‹ˆë‹¤. ì œ ë°œí‘œì—ì„œ ê°•ì¡°í•˜ì§€ ì•Šì•˜ëŠ”ë°, í¬ë¡ ë³‘ì—ì„œëŠ” 80%ì…ë‹ˆë‹¤. ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼ì˜ 1ì°¨ ì¹˜ë£Œì—ì„œëŠ” ì•½ê°„ ë‚®ìŠµë‹ˆë‹¤. ê²½ìŸ ì œí’ˆì´ ì§„ì…í–ˆìŒì—ë„ ë¶ˆêµ¬í•˜ê³  ì‹ ê·œ í™˜ì ì‹œì‘ë¥ ì´ ë§¤ìš° ì•ˆì •ì ì´ê³  ë†’ì€ ìˆ˜ì¤€ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, 1ì°¨ ì¹˜ë£Œì—ì„œ ì••ë„ì ìœ¼ë¡œ ë†’ì€ ì ìœ ìœ¨ì„ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì •ë§ ì¤‘ìš”í•œ ë¶€ë¶„ì¸ë°, ê²½ìŸì‚¬ë“¤ì´ 2ì°¨ ì¹˜ë£Œì—ì„œ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆë‹¤ëŠ” ê²ƒì„ ë³´ì—¬ì¤ë‹ˆë‹¤. ì „ë°˜ì ìœ¼ë¡œ IL-23 ì¹´í…Œê³ ë¦¬ ì „ì²´ê°€ ìƒë‹¹íˆ í™•ëŒ€ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ëª¨ë“  ì—­í•™ê´€ê³„ë¥¼ ì‚´í´ë³´ë©´, ìš°ë¦¬ì˜ ê²½ìŸë ¥ì€ ë§¤ìš° ë†’ìœ¼ë©°, ë¦°ë³µì´ í›„ì† ì¹˜ë£Œì— ì§„ì…í•˜ê¸° ì „ì—ë„ ìŠ¤ì¹´ì´ë¦¬ì§€ê°€ ê³„ì†í•´ì„œ ë³´ì—¬ì¤„ ëª¨ë©˜í…€ì— ëŒ€í•´ ë§¤ìš° í™•ì‹ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ IBD(ì—¼ì¦ì„± ì¥ì§ˆí™˜) ì „ë°˜ì— ëŒ€í•œ ê°œê´„ì ì¸ ì„¤ëª…ì…ë‹ˆë‹¤. ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ Robì´ ë‹µë³€í•˜ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board Yes. So Chris, this is Rob. Thanks for your question. Look, I see numerous sources of upside across the enterprise. I'll start with your question on Skyrizi and Rinvoq. Obviously, the combined guidance for this year is already $0.5 billion higher than our 2027 estimate. And we do expect both Skyrizi and Rinvoq to grow robustly into the 2030s. And clearly, as we look at models, that longer-term growth is not reflected. And so we do think on a longer-term basis, there's clearly more upside to Skyrizi and Rinvoq. And then when you consider things like the market growth projections, we'll gain share, along with the next wave of Rinvoq indications, we have a lot of confidence in the long-term potential for those 2 assets. But beyond immunology, when you look at AbbVie, I think what's underappreciated is both, I'd say, neuroscience and oncology in particular. I'd say neuroscience clearly overperforming. We delivered nearly 20% growth last year. We expect to deliver mid-teens growth this year. It will put us in the #1 position in the industry. I mean Vyalev has already -- will already achieve our peak sales guidance this year. We had given long-term guidance of greater than $1 billion peak. We're guiding to $1 billion. We think our Parkinson's franchise, including Vyalev, Duopa and tavapadon can achieve peak sales in excess of $5 billion. That's not reflected in models. And given the ramp of our oral CGRPs, we believe our migraine franchise will also exceed $5 billion in peak sales. Recall, we gave peak sales estimates of greater than $3 billion based on this year's guidance. We're almost there. And so clearly, the Street is not modeling that type of upside for our migraine business. In psychiatry, we have several next-generation assets with 932, bretisilocin, as Roopal highlighted, and emraclidine, we're clearly studying the dose that can help replace the $5 billion peak of Vraylar after its LOE in 2030. So we're in a very strong position to lead in neuroscience for the long term with $3, $5 billion-plus franchises. And I haven't even mentioned essential tremor or other therapeutic toxic indications or the opportunity in Alzheimer's. And so we have, I'd say, a profound opportunity to lead in neuroscience for the long term, and that's clearly not reflected in Street models. And then when I look at oncology, we have a very compelling pipeline that doesn't get enough attention. For example, our ADC Temab-A has shown promising data in CRC, lung gastroesophageal and pancreatic cancers. In CRC alone, Temab-A has the potential to be a multibillion-dollar opportunity, not to mention the other solid tumors that it could potentially treat. And we also have exciting opportunities in oncology such as etentamig and the follow-on trispecifics in multiple myeloma, 706 in small cell lung cancer and 969 in prostate cancer. So we have many opportunities to deliver upside to Street long-term estimates. And with no significant LOEs until the next decade, we have plenty of capacity to invest in both internal and external innovation to drive very strong long-term growth.</td><td>**Robert Michael:** ë„¤, Chris, ì €ëŠ” Robì…ë‹ˆë‹¤. ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ì „ì‚¬ì ìœ¼ë¡œ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆëŠ” ë¶€ë¶„ë“¤ì´ ë§ì´ ë³´ì…ë‹ˆë‹¤. ë¨¼ì € Skyriziì™€ Rinvoqì— ëŒ€í•œ ì§ˆë¬¸ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì˜¬í•´ ë‘ ì œí’ˆì˜ í•©ì‚° ê°€ì´ë˜ìŠ¤ëŠ” ì´ë¯¸ 2027ë…„ ì¶”ì •ì¹˜ë³´ë‹¤ 5ì–µ ë‹¬ëŸ¬ ë†’ì€ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Skyriziì™€ Rinvoq ëª¨ë‘ 2030ë…„ëŒ€ê¹Œì§€ ê²¬ê³ í•œ ì„±ì¥ì„ ì´ì–´ê°ˆ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì‹œì¥ ëª¨ë¸ë“¤ì„ ë³´ë©´ ì´ëŸ¬í•œ ì¥ê¸° ì„±ì¥ì„¸ê°€ ì œëŒ€ë¡œ ë°˜ì˜ë˜ì§€ ì•Šì€ ê²ƒì´ ë¶„ëª…í•©ë‹ˆë‹¤. ë”°ë¼ì„œ ì¥ê¸°ì  ê´€ì ì—ì„œ Skyriziì™€ Rinvoqì— ëª…ë°±íˆ ë” ë§ì€ ìƒìŠ¹ ì—¬ë ¥ì´ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤. ì—¬ê¸°ì— ì‹œì¥ ì„±ì¥ ì „ë§ê³¼ ìš°ë¦¬ì˜ ì ìœ ìœ¨ í™•ëŒ€, ê·¸ë¦¬ê³  Rinvoqì˜ ì°¨ì„¸ëŒ€ ì ì‘ì¦ ìŠ¹ì¸ê¹Œì§€ ê³ ë ¤í•˜ë©´, ì´ ë‘ ìì‚°ì˜ ì¥ê¸° ì ì¬ë ¥ì— ëŒ€í•´ ìƒë‹¹í•œ í™•ì‹ ì„ ê°–ê³  ìˆìŠµë‹ˆë‹¤. ë©´ì—­í•™ì„ ë„˜ì–´ì„œ AbbVieë¥¼ ë³´ë©´, ì œ ìƒê°ì— ê³¼ì†Œí‰ê°€ë˜ê³  ìˆëŠ” ë¶€ë¶„ì´ ì‹ ê²½ê³¼í•™ê³¼ ì¢…ì–‘í•™, íŠ¹íˆ ì´ ë‘ ë¶„ì•¼ì…ë‹ˆë‹¤. ì‹ ê²½ê³¼í•™ì€ í™•ì‹¤íˆ ê¸°ëŒ€ ì´ìƒì˜ ì„±ê³¼ë¥¼ ë‚´ê³  ìˆìŠµë‹ˆë‹¤. ì‘ë…„ì— ê±°ì˜ 20% ì„±ì¥ì„ ë‹¬ì„±í–ˆê³ , ì˜¬í•´ëŠ” 10%ëŒ€ ì¤‘ë°˜ ì„±ì¥ì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì—…ê³„ 1ìœ„ ìë¦¬ì— ì˜¤ë¥´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. VyalevëŠ” ì´ë¯¸ ì˜¬í•´ ìš°ë¦¬ì˜ ìµœê³  ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¥¼ ë‹¬ì„±í•  ê²ƒì…ë‹ˆë‹¤. ì¥ê¸°ì ìœ¼ë¡œ 10ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ìµœê³  ë§¤ì¶œì„ ì œì‹œí–ˆì—ˆëŠ”ë°, ì˜¬í•´ ê°€ì´ë˜ìŠ¤ë¥¼ 10ì–µ ë‹¬ëŸ¬ë¡œ ì¡ê³  ìˆìŠµë‹ˆë‹¤. Vyalev, Duopa, tavapadonì„ í¬í•¨í•œ íŒŒí‚¨ìŠ¨ë³‘ í”„ëœì°¨ì´ì¦ˆê°€ 50ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ìµœê³  ë§¤ì¶œì„ ë‹¬ì„±í•  ìˆ˜ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì´ëŠ” í˜„ì¬ ì‹œì¥ ëª¨ë¸ì— ë°˜ì˜ë˜ì§€ ì•Šì€ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ê²½êµ¬ìš© CGRP ì œí’ˆêµ°ì˜ ì„±ì¥ì„¸ë¥¼ ê³ ë ¤í•˜ë©´, í¸ë‘í†µ í”„ëœì°¨ì´ì¦ˆ ì—­ì‹œ ìµœê³  ë§¤ì¶œ 50ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„¤ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ì˜¬í•´ ê°€ì´ë˜ìŠ¤ë¥¼ ê¸°ë°˜ìœ¼ë¡œ 30ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ í”¼í¬ ë§¤ì¶œ ì „ë§ì„ ì œì‹œí•œ ë°” ìˆìŠµë‹ˆë‹¤. ì´ì œ ê±°ì˜ ê·¸ ìˆ˜ì¤€ì— ë„ë‹¬í–ˆì£ . ê·¸ëŸ°ë° ë¶„ëª…íˆ ì‹œì¥ì—ì„œëŠ” ìš°ë¦¬ í¸ë‘í†µ ì‚¬ì—…ì— ëŒ€í•´ ì´ëŸ¬í•œ ìƒìŠ¹ ì—¬ë ¥ì„ ë°˜ì˜í•˜ì§€ ì•Šê³  ìˆìŠµë‹ˆë‹¤. ì •ì‹ ì˜í•™ ë¶„ì•¼ì—ì„œëŠ” 932, ë¸Œë ˆí‹°ì‹¤ë¡œì‹ (Roopalì´ ê°•ì¡°í–ˆë“¯ì´), ê·¸ë¦¬ê³  ì— ë¼í´ë¦¬ë”˜ ë“± ì—¬ëŸ¬ ì°¨ì„¸ëŒ€ ìì‚°ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, 2030ë…„ íŠ¹í—ˆ ë§Œë£Œ ì´í›„ Vraylarì˜ 50ì–µ ë‹¬ëŸ¬ í”¼í¬ ë§¤ì¶œì„ ëŒ€ì²´í•  ìˆ˜ ìˆëŠ” ìš©ëŸ‰ì„ ì—°êµ¬í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” 30ì–µ ë‹¬ëŸ¬, 50ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ í”„ëœì°¨ì´ì¦ˆë¥¼ í†µí•´ ì¥ê¸°ì ìœ¼ë¡œ ì‹ ê²½ê³¼í•™ ë¶„ì•¼ë¥¼ ì„ ë„í•  ìˆ˜ ìˆëŠ” ë§¤ìš° ê°•ë ¥í•œ ìœ„ì¹˜ì— ìˆìŠµë‹ˆë‹¤. ë³¸íƒœì„± ì§„ì „ì´ë‚˜ ë‹¤ë¥¸ ì¹˜ë£Œ ë…ì„± ì ì‘ì¦, ë˜ëŠ” ì•Œì¸ í•˜ì´ë¨¸ ë¶„ì•¼ì˜ ê¸°íšŒì— ëŒ€í•´ì„œëŠ” ì•„ì§ ì–¸ê¸‰ë„ í•˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì¥ê¸°ì ìœ¼ë¡œ ì‹ ê²½ê³¼í•™ ë¶„ì•¼ë¥¼ ì„ ë„í•  ìˆ˜ ìˆëŠ” ì—„ì²­ë‚œ ê¸°íšŒë¥¼ ê°€ì§€ê³  ìˆìœ¼ë©°, ì´ëŠ” ë¶„ëª…íˆ ì‹œì¥ ì „ë§ì¹˜ì— ë°˜ì˜ë˜ì–´ ìˆì§€ ì•ŠìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì¢…ì–‘í•™ì„ ë³´ë©´, ì¶©ë¶„í•œ ì£¼ëª©ì„ ë°›ì§€ ëª»í•˜ê³  ìˆëŠ” ë§¤ìš° ì„¤ë“ë ¥ ìˆëŠ” íŒŒì´í”„ë¼ì¸ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ìš°ë¦¬ì˜ ADC(í•­ì²´-ì•½ë¬¼ ê²°í•©ì²´) Temab-AëŠ” ëŒ€ì¥ì•”, íì•”, ìœ„ì‹ë„ì•”, ì·Œì¥ì•”ì—ì„œ ìœ ë§í•œ ë°ì´í„°ë¥¼ ë³´ì—¬ì£¼ì—ˆìŠµë‹ˆë‹¤. ëŒ€ì¥ì•”ë§Œ í•´ë„ Temab-AëŠ” ìˆ˜ì‹­ì–µ ë‹¬ëŸ¬ ê·œëª¨ì˜ ê¸°íšŒê°€ ë  ì ì¬ë ¥ì´ ìˆìœ¼ë©°, ì¹˜ë£Œ ê°€ëŠ¥í•œ ë‹¤ë¥¸ ê³ í˜•ì•”ë“¤ì€ ë§í•  ê²ƒë„ ì—†ìŠµë‹ˆë‹¤. ë˜í•œ ë‹¤ë°œì„± ê³¨ìˆ˜ì¢… ë¶„ì•¼ì˜ etentamigì™€ í›„ì† trispecific í•­ì²´ë“¤, ì†Œì„¸í¬ íì•”ì˜ 706, ì „ë¦½ì„ ì•”ì˜ 969 ë“± ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œ í¥ë¯¸ë¡œìš´ ê¸°íšŒë“¤ì„ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì‹œì¥ì˜ ì¥ê¸° ì „ë§ì¹˜ë¥¼ ìƒíšŒí•˜ëŠ” ì„±ê³¼ë¥¼ ë‚¼ ìˆ˜ ìˆëŠ” ë§ì€ ê¸°íšŒë“¤ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. <budget:used_tokens>96</budget:used_tokens><br><br>ê·¸ë¦¬ê³  ë‹¤ìŒ 10ë…„ê¹Œì§€ ì¤‘ìš”í•œ íŠ¹í—ˆ ë§Œë£Œ(LOE)ê°€ ì—†ê¸° ë•Œë¬¸ì—, ë‚´ë¶€ ë° ì™¸ë¶€ í˜ì‹ ì— íˆ¬ìí•  ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ì—¬ë ¥ì„ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ì´ë¥¼ í†µí•´ ë§¤ìš° ê°•ë ¥í•œ ì¥ê¸° ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Terence Flynn with Morgan Stanley.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Morgan Stanleyì˜ Terence Flynnì…ë‹ˆë‹¤.</td></tr>
<tr><td>Terence Flynn: Morgan Stanley, Research Division Maybe 2 for me. Rob, I appreciate your -- just your recent comments on looking at external innovation. Maybe you could give us an update on your BD lens, kind of the size and risk profile of potential deals you might consider. I know you did more of the early-stage deals as you walked through at the beginning of the call, but how are you thinking about the opportunity set on the forward here? And then maybe for Roopal, just wondering if you can frame expectations for the upcoming Rinvoq and [ LUTI ] Phase III HS data in terms of what you'd like to see from a target profile perspective.</td><td>**Terence Flynn:** ë‘ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Rob, ì™¸ë¶€ í˜ì‹ ì— ëŒ€í•œ ìµœê·¼ ë§ì”€ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤. BD ê´€ì ì—ì„œ ì—…ë°ì´íŠ¸ë¥¼ ë¶€íƒë“œë¦½ë‹ˆë‹¤. ê³ ë ¤í•˜ì‹¤ ìˆ˜ ìˆëŠ” ì ì¬ì  ê±°ë˜ì˜ ê·œëª¨ì™€ ë¦¬ìŠ¤í¬ í”„ë¡œíŒŒì¼ì€ ì–´ë–»ê²Œ ë˜ëŠ”ì§€ìš”. ì½œ ì´ˆë°˜ì— ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ ì´ˆê¸° ë‹¨ê³„ ë”œë“¤ì„ ë” ë§ì´ ì§„í–‰í•˜ì‹  ê±¸ë¡œ ì•Œê³  ìˆëŠ”ë°, ì•ìœ¼ë¡œì˜ ê¸°íšŒì— ëŒ€í•´ì„œëŠ” ì–´ë–»ê²Œ ìƒê°í•˜ê³  ê³„ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Roopalê»˜ëŠ” ë‹¤ê°€ì˜¤ëŠ” Rinvoqì™€ LUTIì˜ í™”ë†ì„± í•œì„ ì—¼(HS) 3ìƒ ë°ì´í„°ì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ë¥¼ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. ëª©í‘œ í”„ë¡œíŒŒì¼ ê´€ì ì—ì„œ ì–´ë–¤ ê²°ê³¼ë¥¼ ê¸°ëŒ€í•˜ì‹œëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ?</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board Terence, it's Rob. I'll take your first question here. You're right. If you look at the last 2 years, we've invested over $8 billion in external innovation that have added significant depth to our pipeline with more than 30 deals. And again, these are opportunities that can drive growth in the next decade and beyond. To recap, I mean, in immunology, we've added new mechanisms such as TL1A and TREM1 that can play a key role in our combination strategy. We've added oral peptides capabilities from Nimble, the in vivo CAR-T platform from Capstan. In neuroscience, again, our next-generation assets in psychiatry, 932, bretisilocin and emraclidine have all come through BD. And we acquired a very compelling brain cell platform from Aliada that gives us, I'd say, a very compelling opportunity in Alzheimer's. In oncology, we've added trispecifics in multiple myeloma that can follow etentamig, the in vivo CAR-T platform from Umoja as well as a PD-1 VEGF antibody, which I highlighted in my remarks, which will complement our ADC portfolio. And I should also mention the siRNA platform from ADARx can really generate opportunities across all 3 of those therapeutic areas. I mean we're clearly focused on early-stage opportunities. So that we have solid growth drivers in the middle part of the next decade, given how sizable we expect Skyrizi and Rinvoq to be. And that's also why we utilize BD to enter into another growth area in obesity, which we will build upon as we identify other differentiated assets. So we're clearly taking a close look at what's available out there. And to the extent we see something that we feel is differentiated, we will pursue it. And I would say to the extent we see a differentiated asset in any of our core areas, whether early or late stage, and I think sometimes there's a misconception that we're only interested in early stage. We were willing to invest in late-stage assets. We certainly have the financial wherewithal. Strategically for the company, it's really about positioning the pipeline to deliver that growth in the next decade because we have a clear line of sight to growth drivers for this decade. But again, given our strong growth outlook and no LOEs this decade, we have plenty of firepower to pursue both early and late-stage opportunities. We're not limited to early stage, and we're focused on our core areas, immunology, neuroscience, oncology and building out obesity.</td><td>**Robert Michael:** í…Œë ŒìŠ¤, ì €ëŠ” ë¡­ì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ìŠµë‹ˆë‹¤. ì§€ë‚œ 2ë…„ê°„ì„ ë³´ì‹œë©´, ì €í¬ëŠ” ì™¸ë¶€ í˜ì‹ ì— 80ì–µ ë‹¬ëŸ¬ ì´ìƒì„ íˆ¬ìí–ˆê³ , ì´ë¥¼ í†µí•´ 30ê±´ ì´ìƒì˜ ê±°ë˜ë¡œ íŒŒì´í”„ë¼ì¸ì— ìƒë‹¹í•œ ê¹Šì´ë¥¼ ë”í–ˆìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŸ¬í•œ ê¸°íšŒë“¤ì€ í–¥í›„ 10ë…„ ê·¸ë¦¬ê³  ê·¸ ì´í›„ì˜ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆëŠ” ê²ƒë“¤ì…ë‹ˆë‹¤. ìš”ì•½í•˜ìë©´, ë©´ì—­í•™ ë¶„ì•¼ì—ì„œëŠ” TL1A, TREM1ê³¼ ê°™ì€ ìƒˆë¡œìš´ ë©”ì»¤ë‹ˆì¦˜ì„ ì¶”ê°€í–ˆìœ¼ë©°, ì´ë“¤ì€ ì €í¬ ë³‘ìš©ìš”ë²• ì „ëµì—ì„œ í•µì‹¬ì ì¸ ì—­í• ì„ í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. Nimbleë¡œë¶€í„° ê²½êµ¬ í©íƒ€ì´ë“œ ì—­ëŸ‰ì„, Capstanìœ¼ë¡œë¶€í„° ìƒì²´ ë‚´ CAR-T í”Œë«í¼ì„ í™•ë³´í–ˆìŠµë‹ˆë‹¤. ì‹ ê²½ê³¼í•™ ë¶„ì•¼ì—ì„œë„ ë§ˆì°¬ê°€ì§€ë¡œ, ì •ì‹ ì˜í•™ ë¶„ì•¼ì˜ ì°¨ì„¸ëŒ€ ìì‚°ì¸ 932, ë¸Œë ˆí‹°ì‹¤ë¡œì‹ , ì— ë¼í´ë¦¬ë”˜ ëª¨ë‘ ì‚¬ì—…ê°œë°œ(BD)ì„ í†µí•´ í™•ë³´í•œ ê²ƒë“¤ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  Aliadaë¡œë¶€í„° ë§¤ìš° ë§¤ë ¥ì ì¸ ë‡Œì„¸í¬ í”Œë«í¼ì„ ì¸ìˆ˜í–ˆëŠ”ë°, ì´ë¥¼ í†µí•´ ì•Œì¸ í•˜ì´ë¨¸ ë¶„ì•¼ì—ì„œ ìƒë‹¹íˆ ìœ ë§í•œ ê¸°íšŒë¥¼ í™•ë³´í•˜ê²Œ ë˜ì—ˆìŠµë‹ˆë‹¤. ì¢…ì–‘í•™ ë¶„ì•¼ì—ì„œëŠ” ë‹¤ë°œì„± ê³¨ìˆ˜ì¢…ì— ëŒ€í•œ ì‚¼ì¤‘íŠ¹ì´í•­ì²´(trispecifics)ë¥¼ ì¶”ê°€í–ˆëŠ”ë°, ì´ëŠ” etentamigì˜ í›„ì†ìœ¼ë¡œ í™œìš©ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ë˜í•œ Umojaì˜ ìƒì²´ ë‚´ CAR-T í”Œë«í¼ê³¼ ì œê°€ ë°œí‘œì—ì„œ ê°•ì¡°í–ˆë˜ PD-1 VEGF í•­ì²´ë„ í™•ë³´í–ˆìœ¼ë©°, ì´ëŠ” ìš°ë¦¬ì˜ ADC í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ë³´ì™„í•  ê²ƒì…ë‹ˆë‹¤. ADARxì˜ siRNA í”Œë«í¼ë„ ì–¸ê¸‰í•´ì•¼ í•˜ëŠ”ë°, ì´ëŠ” ì„¸ ê°€ì§€ ì¹˜ë£Œ ì˜ì—­ ëª¨ë‘ì—ì„œ ê¸°íšŒë¥¼ ì°½ì¶œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” ë¶„ëª…íˆ ì´ˆê¸° ë‹¨ê³„ ê¸°íšŒì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤. Skyriziì™€ Rinvoqê°€ ì–¼ë§ˆë‚˜ í° ê·œëª¨ê°€ ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ëŠ”ì§€ë¥¼ ê³ ë ¤í•  ë•Œ, ë‹¤ìŒ 10ë…„ ì¤‘ë°˜ì— í™•ê³ í•œ ì„±ì¥ ë™ë ¥ì„ í™•ë³´í•˜ê¸° ìœ„í•¨ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ìš°ë¦¬ëŠ” ë¹„ë§Œì´ë¼ëŠ” ë˜ ë‹¤ë¥¸ ì„±ì¥ ì˜ì—­ì— ì§„ì…í•˜ê¸° ìœ„í•´ BDë¥¼ í™œìš©í–ˆê³ , ë‹¤ë¥¸ ì°¨ë³„í™”ëœ ìì‚°ë“¤ì„ ë°œêµ´í•˜ë©´ì„œ ì´ë¥¼ ë”ìš± í™•ëŒ€í•´ ë‚˜ê°ˆ ê²ƒì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹œì¥ì—ì„œ ì´ìš© ê°€ëŠ¥í•œ ê¸°íšŒë“¤ì„ ë©´ë°€íˆ ê²€í† í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì°¨ë³„í™”ë˜ì—ˆë‹¤ê³  íŒë‹¨ë˜ëŠ” ìì‚°ì´ ìˆë‹¤ë©´ ì ê·¹ì ìœ¼ë¡œ ì¶”ì§„í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ìš°ë¦¬ í•µì‹¬ ì˜ì—­ ì¤‘ ì–´ëŠ ë¶„ì•¼ë“ , ì´ˆê¸° ë‹¨ê³„ë“  í›„ê¸° ë‹¨ê³„ë“  ì°¨ë³„í™”ëœ ìì‚°ì´ ìˆë‹¤ë©´ íˆ¬ìí•  ì˜í–¥ì´ ìˆë‹¤ëŠ” ì ì„ ë§ì”€ë“œë¦¬ê³  ì‹¶ìŠµë‹ˆë‹¤. ë•Œë•Œë¡œ ìš°ë¦¬ê°€ ì´ˆê¸° ë‹¨ê³„ì—ë§Œ ê´€ì‹¬ì´ ìˆë‹¤ëŠ” ì˜¤í•´ê°€ ìˆëŠ”ë°, ìš°ë¦¬ëŠ” í›„ê¸° ë‹¨ê³„ ìì‚°ì—ë„ ê¸°êº¼ì´ íˆ¬ìí•  ì¤€ë¹„ê°€ ë˜ì–´ ìˆìŠµë‹ˆë‹¤. ì¬ë¬´ì  ì—¬ë ¥ë„ ì¶©ë¶„íˆ ê°–ì¶”ê³  ìˆìŠµë‹ˆë‹¤. ì „ëµì ìœ¼ë¡œ íšŒì‚¬ ì…ì¥ì—ì„œ ì¤‘ìš”í•œ ê²ƒì€ í–¥í›„ 10ë…„ê°„ì˜ ì„±ì¥ì„ ê²¬ì¸í•  ìˆ˜ ìˆë„ë¡ íŒŒì´í”„ë¼ì¸ì„ êµ¬ì¶•í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë²ˆ 10ë…„ì˜ ì„±ì¥ ë™ë ¥ì€ ì´ë¯¸ ëª…í™•í•˜ê²Œ í™•ë³´ë˜ì–´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. <think><br>Let me analyze this management response for translation:<br><br>Key points:<br>- Strong growth outlook<br>- No LOEs (Loss of Exclusivity) this decade<br>- Firepower for both early and late-stage opportunities<br>- Not limited to early stage<br>- Focus areas: immunology, neuroscience, oncology, obesity<br><br>Financial/technical terms:<br>- LOE (Loss of Exclusivity) - íŠ¹í—ˆë§Œë£Œ or ë…ì ê¶Œ ìƒì‹¤<br>- Early-stage/late-stage opportunities - ì´ˆê¸°/í›„ê¸° ë‹¨ê³„ ê¸°íšŒ<br>- Firepower - ì¬ì›, ìê¸ˆë ¥<br>- Core areas - í•µì‹¬ ë¶„ì•¼<br><br>Tone: Confident, strategic, forward-looking<br><br>Let me translate naturally without speaker attribution:<br><br></think><br><br>ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì €í¬ì˜ ê°•ë ¥í•œ ì„±ì¥ ì „ë§ê³¼ í–¥í›„ 10ë…„ê°„ íŠ¹í—ˆë§Œë£Œê°€ ì—†ë‹¤ëŠ” ì ì„ ê³ ë ¤í•˜ë©´, ì´ˆê¸° ë‹¨ê³„ì™€ í›„ê¸° ë‹¨ê³„ ê¸°íšŒ ëª¨ë‘ë¥¼ ì¶”êµ¬í•  ìˆ˜ ìˆëŠ” ì¶©ë¶„í•œ ì¬ì›ì„ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì´ˆê¸° ë‹¨ê³„ì—ë§Œ êµ­í•œë˜ì§€ ì•Šìœ¼ë©°, ë©´ì—­í•™, ì‹ ê²½ê³¼í•™, ì¢…ì–‘í•™ ë“± í•µì‹¬ ë¶„ì•¼ì™€ ë¹„ë§Œ ì¹˜ë£Œì œ í¬íŠ¸í´ë¦¬ì˜¤ êµ¬ì¶•ì— ì§‘ì¤‘í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer Terence, it's Roopal. I'll talk about HS expectations. So first of all, with Rinvoq, we're excited about this particular study and indication, especially as we look across previous indications. So for example, if you look at Crohn's disease and recently alopecia areata, Rinvoq really overperforms relative to any other JAK inhibitor in the class, along with any other biologic if we were to take a look there. And that's why this study is going to be very important to build on the data that we've generated so far with Rinvoq. Now I will say this will be in a treatment failure population because that's where we believe the JAK inhibitor class will be used in HS. And the dermatologists will already have familiarity with it when they've already used it for atopic dermatitis and soon alopecia areata and vitiligo. So maybe the efficacy won't be as sky high as we would see in a naive population, but we think it can be very meaningful because patients tend to cycle off of these assets as they become available. Now with lutikizumab, that one is a different mechanism. It's IL-1 beta, beta in particular, it's very highly expressed in tissues of patients with hidradenitis suppurativa. And that one will be studied in a naive population and an experienced population. And so far in Phase II, we've seen amongst the highest efficacy been reported. So hopefully, in Phase III, we'll see something similar. But you can also follow the positioning of these 2 future medicines in this space, similar to what Jeff was describing previously in IBD. We'll have a lead asset in the naive setting. This would be lutikizumab has also shown very strong safety profile, high efficacy in Phase II. And then one for those patients that are not finding relief with current biologics or even LUTI. So our sales teams and medical teams will have both of these to talk about in a similar concept that we have now demonstrated with IDD quite successfully.</td><td>**Roopal Thakkar:** í…Œë ŒìŠ¤, ë£¨íŒ”ì…ë‹ˆë‹¤. HSì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ìš°ì„  ë¦°ë²„í¬(Rinvoq)ì™€ ê´€ë ¨í•´ì„œ, ì €í¬ëŠ” ì´ë²ˆ ì—°êµ¬ì™€ ì ì‘ì¦ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ì´ì „ ì ì‘ì¦ë“¤ì„ ì‚´í´ë³´ë©´ ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ í¬ë¡ ë³‘ì´ë‚˜ ìµœê·¼ì˜ ì›í˜• íƒˆëª¨ì¦ì„ ë³´ì‹œë©´, ë¦°ë²„í¬ëŠ” ë™ì¼ ê³„ì—´ì˜ ë‹¤ë¥¸ JAK ì–µì œì œë“¤ì€ ë¬¼ë¡ ì´ê³  ë‹¤ë¥¸ ìƒë¬¼í•™ì  ì œì œë“¤ê³¼ ë¹„êµí•´ë„ ì›”ë“±í•œ ì„±ê³¼ë¥¼ ë³´ì—¬ì£¼ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ë²ˆ ì—°êµ¬ê°€ ì§€ê¸ˆê¹Œì§€ ë¦°ë²„í¬ë¡œ ìƒì„±í•œ ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ë”ìš± ë°œì „ì‹œí‚¤ëŠ” ë° ë§¤ìš° ì¤‘ìš”í•  ê²ƒì…ë‹ˆë‹¤. ë‹¤ë§Œ ì´ë²ˆ ì—°êµ¬ëŠ” ì¹˜ë£Œ ì‹¤íŒ¨ í™˜ìêµ°ì„ ëŒ€ìƒìœ¼ë¡œ ì§„í–‰ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì™œëƒí•˜ë©´ ì €í¬ëŠ” JAK ì–µì œì œ ê³„ì—´ì´ HSì—ì„œ ë°”ë¡œ ê·¸ í™˜ìêµ°ì— ì‚¬ìš©ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. í”¼ë¶€ê³¼ ì „ë¬¸ì˜ë“¤ì€ ì´ë¯¸ ì•„í† í”¼ í”¼ë¶€ì—¼ ì¹˜ë£Œì— ì‚¬ìš©í•´ë³¸ ê²½í—˜ì´ ìˆê³ , ê³§ ì›í˜• íƒˆëª¨ì¦ê³¼ ë°±ë°˜ì¦ì—ë„ ì‚¬ìš©í•˜ê²Œ ë  ê²ƒì´ê¸° ë•Œë¬¸ì— ì´ ì•½ë¬¼ì— ëŒ€í•œ ì¹œìˆ™ë„ê°€ ë†’ì„ ê²ƒì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìêµ°ì—ì„œ ë³´ëŠ” ê²ƒë§Œí¼ ê·¹ì ìœ¼ë¡œ ë†’ì€ íš¨ëŠ¥ì„ ë³´ì´ì§€ëŠ” ì•Šì„ ìˆ˜ ìˆì§€ë§Œ, í™˜ìë“¤ì´ ìƒˆë¡œìš´ ì¹˜ë£Œì œê°€ ë‚˜ì˜¬ ë•Œë§ˆë‹¤ ìˆœí™˜ì ìœ¼ë¡œ ë°”ê¿”ê°€ë©° ì‚¬ìš©í•˜ëŠ” ê²½í–¥ì´ ìˆê¸° ë•Œë¬¸ì— ë§¤ìš° ì˜ë¯¸ ìˆëŠ” ê²°ê³¼ë¥¼ ì–»ì„ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤.<br><br>ë£¨í‹°í‚¤ì£¼ë§™ì˜ ê²½ìš°ëŠ” ì‘ìš© ê¸°ì „ì´ ë‹¤ë¦…ë‹ˆë‹¤. IL-1 ë² íƒ€, íŠ¹íˆ ë² íƒ€ë¥¼ í‘œì ìœ¼ë¡œ í•˜ëŠ”ë°, ì´ëŠ” í™”ë†ì„± í•œì„ ì—¼ í™˜ìì˜ ì¡°ì§ì—ì„œ ë§¤ìš° ë†’ê²Œ ë°œí˜„ë©ë‹ˆë‹¤. ì´ ì•½ë¬¼ì€ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìêµ°ê³¼ ê²½í—˜ì´ ìˆëŠ” í™˜ìêµ° ëª¨ë‘ë¥¼ ëŒ€ìƒìœ¼ë¡œ ì—°êµ¬ë  ì˜ˆì •ì…ë‹ˆë‹¤. 2ìƒ ì„ìƒì‹œí—˜ì—ì„œ ì§€ê¸ˆê¹Œì§€ ë³´ê³ ëœ ê²ƒ ì¤‘ ê°€ì¥ ë†’ì€ ìˆ˜ì¤€ì˜ íš¨ëŠ¥ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ 3ìƒ ì„ìƒì‹œí—˜ì—ì„œë„ ìœ ì‚¬í•œ ê²°ê³¼ë¥¼ ë³¼ ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì´ ë‘ ê°€ì§€ ë¯¸ë˜ ì˜ì•½í’ˆì˜ í¬ì§€ì…”ë‹ë„ ì‚´í´ë³´ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” Jeffê°€ ì•ì„œ IBDì—ì„œ ì„¤ëª…í–ˆë˜ ê²ƒê³¼ ìœ ì‚¬í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ˆì¹˜ë£Œ(naive) í™˜ê²½ì—ì„œ ì„ ë„ ìì‚°ì„ ë³´ìœ í•˜ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ë£¨í‹°í‚¤ì£¼ë§™(lutikizumab)ì€ 2ìƒì—ì„œ ë§¤ìš° ê°•ë ¥í•œ ì•ˆì „ì„± í”„ë¡œíŒŒì¼ê³¼ ë†’ì€ íš¨ëŠ¥ì„ ì…ì¦í–ˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜„ì¬ ìƒë¬¼í•™ì ì œì œë‚˜ ì‹¬ì§€ì–´ LUTIë¡œë„ íš¨ê³¼ë¥¼ ë³´ì§€ ëª»í•˜ëŠ” í™˜ìë“¤ì„ ìœ„í•œ ë˜ ë‹¤ë¥¸ ì˜µì…˜ë„ ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ ì˜ì—…íŒ€ê³¼ ë©”ë””ì»¬íŒ€ì€ IDDì—ì„œ ë§¤ìš° ì„±ê³µì ìœ¼ë¡œ ì…ì¦í•œ ê²ƒê³¼ ìœ ì‚¬í•œ ê°œë…ìœ¼ë¡œ ì´ ë‘ ê°€ì§€ ì œí’ˆì— ëŒ€í•´ ë…¼ì˜í•  ìˆ˜ ìˆê²Œ ë  ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Asad Haider with Goldman Sachs.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Goldman Sachsì˜ Asad Haiderë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Asad Haider: Goldman Sachs Group, Inc., Research Division Great. Maybe first for Roopal, you talked about this a little bit already, but maybe if you could expand upon how you see the oncology portfolio evolving from here. With respect to novel, novel combos, you've got this new externally sourced PD-1 VEGF bispecific that you just brought in alongside your existing ADC assets. Do you see the portfolio as appropriately positioned now from that perspective? And are there other gaps that you see with respect to where the science is evolving? And then if I could just also throw one in for Scott on the aesthetics franchise. That's been in a protracted downturn based on macro headwinds. I know you've talked about efforts to revitalize growth, looking at TrenibotE approval later this year as a potential catalyst. Are you able to provide any quantitative framing on what you expect to see post approval and launch, just recognizing that there are some investor debates about the commercial opportunity for that program?</td><td>**Asad Haider:** ì¢‹ìŠµë‹ˆë‹¤. ë¨¼ì € Roopalì—ê²Œ ë“œë¦¬ëŠ” ì§ˆë¬¸ì¸ë°ìš”, ì´ë¯¸ ì¡°ê¸ˆ ë§ì”€í•˜ì…¨ì§€ë§Œ ì•ìœ¼ë¡œ ì¢…ì–‘í•™ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ì–´ë–»ê²Œ ë°œì „í•  ê²ƒìœ¼ë¡œ ë³´ì‹œëŠ”ì§€ ì¢€ ë” ìì„¸íˆ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì‹ ê·œ-ì‹ ê·œ ë³‘ìš©ìš”ë²•ê³¼ ê´€ë ¨í•´ì„œ, ìµœê·¼ ì™¸ë¶€ì—ì„œ ë„ì…í•œ PD-1 VEGF ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific)ì™€ ê¸°ì¡´ ADC ìì‚°ë“¤ì„ ë³´ìœ í•˜ê³  ê³„ì‹ ë°ìš”. í˜„ì¬ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ê·¸ëŸ° ê´€ì ì—ì„œ ì ì ˆí•˜ê²Œ í¬ì§€ì…”ë‹ë˜ì–´ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ìš”? ê·¸ë¦¬ê³  ê³¼í•™ì´ ë°œì „í•˜ëŠ” ë°©í–¥ì„ ê³ ë ¤í•  ë•Œ ë‹¤ë¥¸ ê³µë°±ì´ ìˆë‹¤ê³  ë³´ì‹œëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Scottì—ê²Œ ë¯¸ìš© í”„ëœì°¨ì´ì¦ˆì— ëŒ€í•´ì„œë„ í•œ ê°€ì§€ ì§ˆë¬¸ ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ê±°ì‹œê²½ì œ ì—­í’ìœ¼ë¡œ ì¸í•´ ì¥ê¸°ê°„ ì¹¨ì²´ë¥¼ ê²ªê³  ìˆëŠ”ë°ìš”. TrenibotE ìŠ¹ì¸ ì´í›„ ì¶œì‹œì— ëŒ€í•œ ê¸°ëŒ€ì¹˜ì™€ ê´€ë ¨í•´ì„œ ì •ëŸ‰ì ì¸ ê°€ì´ë˜ìŠ¤ë¥¼ ì œê³µí•´ ì£¼ì‹¤ ìˆ˜ ìˆìœ¼ì‹ ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ì˜¬í•´ í›„ë°˜ ìŠ¹ì¸ì„ ì„±ì¥ ì¬í™œì„±í™”ì˜ ì ì¬ì  ì´‰ë§¤ì œë¡œ ë³´ê³  ê³„ì‹ ë‹¤ëŠ” ë§ì”€ì„ í•˜ì…¨ëŠ”ë°, í•´ë‹¹ í”„ë¡œê·¸ë¨ì˜ ìƒì—…ì  ê¸°íšŒì— ëŒ€í•´ íˆ¬ììë“¤ ì‚¬ì´ì—ì„œ ì˜ê²¬ì´ ì—‡ê°ˆë¦¬ê³  ìˆëŠ” ìƒí™©ì´ë¼ëŠ” ì ì„ ê°ì•ˆí•  ë•Œ, êµ¬ì²´ì ì¸ ì „ë§ì„ ë“£ê³  ì‹¶ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer Asad it's Roopal. I'll start with oncology. You heard us talk about Temab-A in 706 as examples and Temab-A multiple tumor types, we get rapid efficacy, which is very important. And the strategy being maintaining that efficacy like a chemotherapy or better, but having a better tolerability profile. For example, comparison to conventional chemo, we don't see the high rates of stomatitis, diarrhea, hair loss, which, in fact, you still see with certain ADCs, but we don't see that profile with our construct with our linker technology and our particular topo warhead, whether that's against c-MET or SEZ6, for example. So that's a starting point. And then the combinations become very important to help build on the durability of these assets and utilization over the long term, so the patient is able to benefit maximally. And we believe a PD-1 VEGF is a terrific combo partner. I mentioned colorectal and lung thus far. But as I stated, we're going to see Temab-A readout in head and neck and ovarian and that could be also potential areas of combination. The other key component of our oncology strategy is also having the ability to have a biomarker approach where physicians, patients are always seeking an individualized care regimen. And we have seen examples, particularly in GEA, I would say, and other tumor types that when you have slightly increased expression profiles, you see higher efficacy. So that sets up an ability to differentiate our portfolio over the long term. Now if there's examples where we don't need a biomarker approach, then we won't take it. So 706 is a good example in small cell lung cancer. And you asked maybe what's missing. We think a T cell engager could be a very nice combination with 706, and we have brought one in-house. The other internal development programs and access we already have that we're working on that hopefully will get to the clinic soon is in KRAS. We are interested in lung, colorectal, pancreatic, strong data in pancreatic with Temab-A already. And we feel in the future, having a selective KRAS, hopefully that avoids [ NNH RAS ] will allow for optimal combinations. So I would say very excited on the solid front. And just to briefly touch on, Rob mentioned 969. We haven't talked much about that today. However, we're trying to get that data to ASCO. So I would look for that. That is taking our bispecific technology, similar construct and how we built lutikizumab against IL-1 alpha beta. But in prostate cancer, this would be against PSMA and STEAP. And then we take the warhead and linker technology from Temab-A and add that to 969. So the team is excited about the potential in prostate cancer, which is a very large tumor type, and I would say, with still substantial unmet need. And we described the heme side where we have next-generational BCMA, CD38 and GPCR5D assets moving rapidly into the clinic.</td><td>**Roopal Thakkar:** Asad, Roopalì…ë‹ˆë‹¤. ë¨¼ì € ì¢…ì–‘í•™ ë¶„ì•¼ë¶€í„° ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. Temab-Aì™€ 706 ì‚¬ë¡€ì— ëŒ€í•´ ë§ì”€ë“œë¦° ê²ƒì„ ë“¤ìœ¼ì…¨ì„ í…ë°ìš”, Temab-AëŠ” ì—¬ëŸ¬ ì¢…ì–‘ ìœ í˜•ì—ì„œ ë¹ ë¥¸ íš¨ëŠ¥ì„ ë³´ì—¬ì£¼ê³  ìˆìœ¼ë©°, ì´ëŠ” ë§¤ìš° ì¤‘ìš”í•œ ë¶€ë¶„ì…ë‹ˆë‹¤. ì €í¬ ì „ëµì€ í™”í•™ìš”ë²•ê³¼ ë™ë“±í•˜ê±°ë‚˜ ê·¸ ì´ìƒì˜ íš¨ëŠ¥ì„ ìœ ì§€í•˜ë©´ì„œë„, ë” ë‚˜ì€ ë‚´ì•½ì„± í”„ë¡œíŒŒì¼ì„ ì œê³µí•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´, ê¸°ì¡´ í™”í•™ìš”ë²•ê³¼ ë¹„êµí–ˆì„ ë•Œ êµ¬ë‚´ì—¼, ì„¤ì‚¬, íƒˆëª¨ì™€ ê°™ì€ ë†’ì€ ë°œìƒë¥ ì„ ë³´ì´ì§€ ì•ŠìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ íŠ¹ì • ADCë“¤ì—ì„œëŠ” ì—¬ì „íˆ ì´ëŸ¬í•œ ë¶€ì‘ìš©ë“¤ì´ ë‚˜íƒ€ë‚˜ì§€ë§Œ, ì €í¬ ë§ì»¤ ê¸°ìˆ ê³¼ íŠ¹ì • í† í¬ íƒ„ë‘ë¥¼ ì‚¬ìš©í•œ êµ¬ì¡°ì²´ì—ì„œëŠ” ê·¸ëŸ¬í•œ í”„ë¡œíŒŒì¼ì´ ë‚˜íƒ€ë‚˜ì§€ ì•ŠìŠµë‹ˆë‹¤. c-METë¥¼ íƒ€ê²Ÿìœ¼ë¡œ í•˜ë“  SEZ6ë¥¼ íƒ€ê²Ÿìœ¼ë¡œ í•˜ë“  ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤. ì´ê²ƒì´ ì¶œë°œì ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ëŸ¬í•œ ì¡°í•©ë“¤ì€ ìì‚°ì˜ ë‚´êµ¬ì„±ê³¼ ì¥ê¸°ì ì¸ í™œìš©ë„ë¥¼ êµ¬ì¶•í•˜ëŠ” ë° ë§¤ìš° ì¤‘ìš”í•´ì§‘ë‹ˆë‹¤. í™˜ìê°€ ìµœëŒ€í•œì˜ í˜œíƒì„ ë°›ì„ ìˆ˜ ìˆë„ë¡ ë§ì´ì£ . ì €í¬ëŠ” PD-1 VEGFê°€ í›Œë¥­í•œ ë³‘ìš© íŒŒíŠ¸ë„ˆë¼ê³  ë¯¿ìŠµë‹ˆë‹¤. ì§€ê¸ˆê¹Œì§€ ëŒ€ì¥ì•”ê³¼ íì•”ì„ ì–¸ê¸‰í–ˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ë‘ê²½ë¶€ì•”ê³¼ ë‚œì†Œì•”ì—ì„œ Temab-A ê²°ê³¼ë¥¼ ë³´ê²Œ ë  ê²ƒì´ê³ , ì´ê²ƒë“¤ë„ ì ì¬ì ì¸ ë³‘ìš© ì˜ì—­ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ì €í¬ ì¢…ì–‘í•™ ì „ëµì˜ ë˜ ë‹¤ë¥¸ í•µì‹¬ ìš”ì†ŒëŠ” ë°”ì´ì˜¤ë§ˆì»¤ ì ‘ê·¼ë²•ì„ í™œìš©í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì…ë‹ˆë‹¤. ì˜ì‚¬ì™€ í™˜ìë“¤ì€ í•­ìƒ ê°œë³„í™”ëœ ì¹˜ë£Œ ìš”ë²•ì„ ì°¾ê³  ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ìœ„ì‹ë„ì•”(GEA)ê³¼ ë‹¤ë¥¸ ì¢…ì–‘ ìœ í˜•ì—ì„œ ë°œí˜„ í”„ë¡œíŒŒì¼ì´ ì•½ê°„ ì¦ê°€í–ˆì„ ë•Œ ë” ë†’ì€ íš¨ëŠ¥ì„ ë³´ëŠ” ì‚¬ë¡€ë“¤ì„ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ì´ë¥¼ í†µí•´ ì¥ê¸°ì ìœ¼ë¡œ í¬íŠ¸í´ë¦¬ì˜¤ë¥¼ ì°¨ë³„í™”í•  ìˆ˜ ìˆëŠ” ì—­ëŸ‰ì„ í™•ë³´í•˜ê²Œ ë©ë‹ˆë‹¤. ë¬¼ë¡  ë°”ì´ì˜¤ë§ˆì»¤ ì ‘ê·¼ë²•ì´ í•„ìš”í•˜ì§€ ì•Šì€ ê²½ìš°ë¼ë©´ ê·¸ ë°©ì‹ì„ ì·¨í•˜ì§€ ì•Šì„ ê²ƒì…ë‹ˆë‹¤. ì†Œì„¸í¬ íì•”ì—ì„œì˜ 706ì´ ì¢‹ì€ ì˜ˆì‹œì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë¬´ì—‡ì´ ë¶€ì¡±í•œì§€ ì§ˆë¬¸í•˜ì…¨ëŠ”ë°, Tì„¸í¬ ì—”ê²Œì´ì €(T cell engager)ê°€ 706ê³¼ ë§¤ìš° ì¢‹ì€ ë³‘ìš©ìš”ë²•ì´ ë  ìˆ˜ ìˆë‹¤ê³  ë³´ê³  ìˆìœ¼ë©°, ì´ë¯¸ í•˜ë‚˜ë¥¼ ì‚¬ë‚´ë¡œ ë„ì…í–ˆìŠµë‹ˆë‹¤. <br><br>í˜„ì¬ ì§„í–‰ ì¤‘ì¸ ë‹¤ë¥¸ ë‚´ë¶€ ê°œë°œ í”„ë¡œê·¸ë¨ê³¼ ìš°ë¦¬ê°€ ë³´ìœ í•œ ì ‘ê·¼ë²• ì¤‘ì—ì„œ ì¡°ë§Œê°„ ì„ìƒì— ì§„ì…í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ëŠ” ê²ƒì€ KRAS ë¶„ì•¼ì…ë‹ˆë‹¤. íì•”, ëŒ€ì¥ì•”, ì·Œì¥ì•”ì— ê´€ì‹¬ì„ ê°–ê³  ìˆìœ¼ë©°, íŠ¹íˆ ì·Œì¥ì•”ì—ì„œ Temab-Aë¡œ ì´ë¯¸ ê°•ë ¥í•œ ë°ì´í„°ë¥¼ í™•ë³´í•˜ê³  ìˆìŠµë‹ˆë‹¤. í–¥í›„ NNH RASë¥¼ íšŒí”¼í•  ìˆ˜ ìˆëŠ” ì„ íƒì  KRAS ì–µì œì œë¥¼ ë³´ìœ í•˜ê²Œ ëœë‹¤ë©´ ìµœì ì˜ ë³‘ìš©ìš”ë²•ì´ ê°€ëŠ¥í•  ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤. ê³ í˜•ì•” ë¶„ì•¼ì—ì„œ ë§¤ìš° ê¸°ëŒ€ê°€ í¬ë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  Robì´ ì–¸ê¸‰í•œ 969ì— ëŒ€í•´ ê°„ë‹¨íˆ ë§ì”€ë“œë¦¬ìë©´, ì˜¤ëŠ˜ ì´ì— ëŒ€í•´ ë§ì´ ë‹¤ë£¨ì§€ëŠ” ì•Šì•˜ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ASCOì— í•´ë‹¹ ë°ì´í„°ë¥¼ ì œì¶œí•˜ë ¤ê³  ë…¸ë ¥í•˜ê³  ìˆìœ¼ë‹ˆ ê·¸ë•Œ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì€ ìš°ë¦¬ì˜ ì´ì¤‘íŠ¹ì´í•­ì²´(bispecific) ê¸°ìˆ ì„ í™œìš©í•œ ê²ƒìœ¼ë¡œ, ë£¨í‹°í‚¤ì£¼ë§™(lutikizumab)ì„ IL-1 ì•ŒíŒŒ ë² íƒ€ì— ëŒ€í•´ ê°œë°œí–ˆë˜ ê²ƒê³¼ ìœ ì‚¬í•œ êµ¬ì¡°ì…ë‹ˆë‹¤. ë‹¤ë§Œ ì „ë¦½ì„ ì•”ì—ì„œëŠ” PSMAì™€ STEAPì„ í‘œì ìœ¼ë¡œ í•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  Temab-Aì˜ íƒ„ë‘(warhead)ì™€ ë§ì»¤ ê¸°ìˆ ì„ 969ì— ì ìš©í–ˆìŠµë‹ˆë‹¤. íŒ€ì€ ì „ë¦½ì„ ì•”ì—ì„œì˜ ê°€ëŠ¥ì„±ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì „ë¦½ì„ ì•”ì€ ë§¤ìš° í° ì¢…ì–‘ ìœ í˜•ì´ê³ , ì—¬ì „íˆ ìƒë‹¹í•œ ë¯¸ì¶©ì¡± ìˆ˜ìš”(unmet need)ê°€ ìˆë‹¤ê³  ë§ì”€ë“œë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  í˜ˆì•¡ì•” ìª½ì—ì„œëŠ” ì°¨ì„¸ëŒ€ BCMA, CD38, GPCR5D ìì‚°ë“¤ì´ ë¹ ë¥´ê²Œ ì„ìƒì— ì§„ì…í•˜ê³  ìˆë‹¤ê³  ì„¤ëª…ë“œë ¸ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer And then maybe, it's Jeff. I'll address your TrenibotE BOTOX question. I think what's important as we look into 2026, largely what we see is that the sales impact of the TrenibotE will largely accrue really to Botox, and I'll walk through that. But given the timing of the launch and the fact that right now, we have plans to train 12,000 core injectors, it's really going to not really appear until towards the end of the year, but it's going to gate heavily into '27. So I'll give you some sense of how the dynamics will work. We believe when we look at the patient funnel that at peak, we could potentially up to double the inflow of patients that would basically start to move into the toxin market because there's still -- we look in the U.S., 55 million considerers that just haven't made that leap yet. So the first dynamic is the stimulation of the market that starts to start to gate in at the end of '26 and certainly, we believe, heavily into '27 and '28. The second thing that we see is that since it is a short duration toxin, it only lasts for 2.5 to 3 weeks, the real commercial impact goes to your conversion rate, our key performance indicator of how fast we convert to full strength Botox. And the way that we think about that metric is right now, we have very high leading share in the U.S. in the low 60s percent. We would anticipate that once patients start on TrenibotE as they start to gate in over this time period that we have a much higher conversion rate than our existing share. So it starts to build share as well. And so net-net, we're very excited about this innovation. We think it's going to operate to sort of increase inflows substantially over our plan, again, more in the '27 and beyond standpoint as we get the training ramped up and also accrue to Botox share. So that's how we're looking at that market development over time.</td><td>**Jeffrey Stewart:** 2026ë…„ì„ ì „ë§í•  ë•Œ ì¤‘ìš”í•œ ì ì€ íŠ¸ë ˆë‹ˆë´‡Eì˜ ë§¤ì¶œ ì˜í–¥ì´ ëŒ€ë¶€ë¶„ ë³´í†¡ìŠ¤ì— ê·€ì†ë  ê²ƒì´ë¼ëŠ” ì ì…ë‹ˆë‹¤. ì´ì— ëŒ€í•´ ì„¤ëª…ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì¶œì‹œ ì‹œê¸°ì™€ í˜„ì¬ 12,000ëª…ì˜ í•µì‹¬ ì‹œìˆ ìë¥¼ êµìœ¡í•  ê³„íšì„ ê³ ë ¤í•˜ë©´, ì‹¤ì§ˆì ì¸ ì˜í–¥ì€ ì˜¬í•´ ë§ì— ê°€ì„œì•¼ ë‚˜íƒ€ë‚˜ê¸° ì‹œì‘í•  ê²ƒì´ê³ , ë³¸ê²©ì ì¸ íš¨ê³¼ëŠ” 2027ë…„ì— ì§‘ì¤‘ë  ê²ƒì…ë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ ê´€ê³„ê°€ ì–´ë–»ê²Œ ì‘ìš©í• ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í™˜ì ìœ ì… ê²½ë¡œë¥¼ ì‚´í´ë³´ë©´, ì •ì ì—ì„œëŠ” ì ì¬ì ìœ¼ë¡œ í†¡ì‹  ì‹œì¥ì— ì§„ì…í•˜ëŠ” í™˜ì ìœ ì…ì´ ìµœëŒ€ 2ë°°ê¹Œì§€ ì¦ê°€í•  ìˆ˜ ìˆë‹¤ê³  ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¯¸êµ­ì—ëŠ” ì•„ì§ ê·¸ ë‹¨ê³„ë¡œ ë„˜ì–´ê°€ì§€ ì•Šì€ 5,500ë§Œ ëª…ì˜ ì ì¬ ê³ ê°ì´ ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì²« ë²ˆì§¸ ì—­í•™ì€ 26ë…„ ë§ë¶€í„° ì‹œì‘ë˜ì–´ 27ë…„ê³¼ 28ë…„ì— ë³¸ê²©í™”ë  ê²ƒìœ¼ë¡œ ì˜ˆìƒë˜ëŠ” ì‹œì¥ í™œì„±í™”ì…ë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ë¡œ ì£¼ëª©í•˜ëŠ” ì ì€, ì´ ì œí’ˆì´ 2.5ì£¼ì—ì„œ 3ì£¼ ì •ë„ë§Œ ì§€ì†ë˜ëŠ” ë‹¨ê¸° ì§€ì†í˜• í†¡ì‹ ì´ê¸° ë•Œë¬¸ì—, ì‹¤ì œ ìƒì—…ì  ì˜í–¥ì€ ì „ì²´ ê°•ë„ì˜ ë³´í†¡ìŠ¤ë¡œ ì–¼ë§ˆë‚˜ ë¹¨ë¦¬ ì „í™˜í•˜ëŠëƒëŠ” ìš°ë¦¬ì˜ í•µì‹¬ ì„±ê³¼ ì§€í‘œì¸ ì „í™˜ìœ¨ì— ë‹¬ë ¤ ìˆë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ ì§€í‘œë¥¼ í‰ê°€í•˜ëŠ” ë°©ì‹ì€, í˜„ì¬ ë¯¸êµ­ì—ì„œ ìš°ë¦¬ê°€ ë§¤ìš° ë†’ì€ ì„ ë„ ì ìœ ìœ¨ì„ ë³´ìœ í•˜ê³  ìˆë‹¤ëŠ” ì ì—ì„œ ì¶œë°œí•©ë‹ˆë‹¤. 60% ì´ˆë°˜ëŒ€ì…ë‹ˆë‹¤. í™˜ìë“¤ì´ TrenibotEë¥¼ ì‹œì‘í•˜ë©´ì„œ ì´ ê¸°ê°„ ë™ì•ˆ ì ì§„ì ìœ¼ë¡œ ìœ ì…ë˜ë©´, ê¸°ì¡´ ì ìœ ìœ¨ë³´ë‹¤ í›¨ì”¬ ë†’ì€ ì „í™˜ìœ¨ì„ ë³´ì¼ ê²ƒìœ¼ë¡œ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ì ìœ ìœ¨ë„ í•¨ê»˜ ì¦ê°€í•˜ê¸° ì‹œì‘í•  ê²ƒì…ë‹ˆë‹¤. ê²°ë¡ ì ìœ¼ë¡œ, ìš°ë¦¬ëŠ” ì´ í˜ì‹ ì— ëŒ€í•´ ë§¤ìš° ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ìš°ë¦¬ ê³„íš ëŒ€ë¹„ ìœ ì…ì„ ìƒë‹¹íˆ ì¦ê°€ì‹œí‚¬ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìœ¼ë©°, íŠ¹íˆ êµìœ¡ì´ í™•ëŒ€ë˜ê³  ë³´í†¡ìŠ¤ ì ìœ ìœ¨ì´ ì¦ê°€í•˜ë©´ì„œ '27ë…„ ì´í›„ì— ë”ìš± ê·¸ëŸ´ ê²ƒì…ë‹ˆë‹¤. ì´ê²ƒì´ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ ìš°ë¦¬ê°€ ë°”ë¼ë³´ëŠ” ì‹œì¥ ê°œë°œ ë°©í–¥ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question comes from Vamil Divan with Guggenheim Securities.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ êµ¬ê²í•˜ì„ ì¦ê¶Œì˜ ë°”ë°€ ë””ë°˜ìœ¼ë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Vamil Divan: Guggenheim Securities, LLC, Research Division So maybe one I do have actually still on the Botox topic and then one other one. On Botox, we were sort of surprised to see that one selected for the Medicare price reductions in 2028. I'm wondering first, if that was a surprise to you as well or you're sort of expecting that. And then what that might mean for pricing on the cosmetic side because I think it's always been tied to therapeutic and cosmetic pricing. So if there's reductions from Medicare on the therapeutic side, what you have to sort of carry that over to cosmetic care to maybe have more flexibility in some way in the future? And then my second question is back on the immunology franchise. And I caught some of what you said around 1Q pricing dynamics. But maybe you can just share your thinking around pricing overall in that market for Skyrizi and Rinvoq for, say, this year, maybe over the next couple of years, just how things evolve from a pricing perspective?</td><td>**Vamil Divan:** êµ¬ê²í•˜ì„ ì¦ê¶Œ ë¦¬ì„œì¹˜ ë¶€ë¬¸ì…ë‹ˆë‹¤. ë³´í†¡ìŠ¤ ê´€ë ¨í•´ì„œ í•œ ê°€ì§€ ì§ˆë¬¸ì´ ë” ìˆê³ , ë‹¤ë¥¸ ì§ˆë¬¸ë„ í•˜ë‚˜ ìˆìŠµë‹ˆë‹¤. ë³´í†¡ìŠ¤ê°€ 2028ë…„ ë©”ë””ì¼€ì–´ ê°€ê²© ì¸í•˜ ëŒ€ìƒìœ¼ë¡œ ì„ ì •ëœ ê²ƒì„ ë³´ê³  ë‹¤ì†Œ ë†€ëìŠµë‹ˆë‹¤. ë¨¼ì €, ê·€ì‚¬ë„ ì´ê²ƒì´ ì˜ˆìƒ ë°–ì´ì—ˆëŠ”ì§€ ì•„ë‹ˆë©´ ì–´ëŠ ì •ë„ ì˜ˆìƒí•˜ê³  ê³„ì…¨ëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒì´ ë¯¸ìš© ë¶€ë¬¸ ê°€ê²© ì±…ì •ì— ì–´ë–¤ ì˜ë¯¸ë¥¼ ê°€ì§ˆì§€ë„ ê¶ê¸ˆí•œë°ìš”, ì œ ìƒê°ì—ëŠ” í•­ìƒ ì¹˜ë£Œìš©ê³¼ ë¯¸ìš©ìš© ê°€ê²©ì´ ì—°ë™ë˜ì–´ ìˆì—ˆë˜ ê²ƒìœ¼ë¡œ ì•Œê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ ë©”ë””ì¼€ì–´ì—ì„œ ì¹˜ë£Œìš© ìª½ ê°€ê²© ì¸í•˜ê°€ ìˆë‹¤ë©´, ë¯¸ìš© ë¶€ë¬¸ì—ë„ ê·¸ê²ƒì„ ì ìš©í•´ì•¼ í•˜ëŠ”ì§€, ì•„ë‹ˆë©´ í–¥í›„ ì–´ë–¤ ì‹ìœ¼ë¡œë“  ë” ìœ ì—°í•˜ê²Œ ëŒ€ì‘í•  ìˆ˜ ìˆëŠ” ì—¬ì§€ê°€ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë‘ ë²ˆì§¸ ì§ˆë¬¸ì€ ë©´ì—­í•™ í”„ëœì°¨ì´ì¦ˆë¡œ ëŒì•„ê°€ì„œ, 1ë¶„ê¸° ê°€ê²© ì±…ì • ì—­í•™ ê´€ë ¨í•´ì„œ ë§ì”€í•˜ì‹  ë‚´ìš© ì¤‘ ì¼ë¶€ë¥¼ ë“¤ì—ˆëŠ”ë°ìš”. í•´ë‹¹ ì‹œì¥ì—ì„œ ìŠ¤ì¹´ì´ë¦¬ì§€ì™€ ë¦°ë²„í¬ì˜ ì „ë°˜ì ì¸ ê°€ê²© ì „ëµì— ëŒ€í•œ ìƒê°ì„ ê³µìœ í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ì˜¬í•´, ê·¸ë¦¬ê³  í–¥í›„ ëª‡ ë…„ê°„ ê°€ê²© ì¸¡ë©´ì—ì„œ ì–´ë–»ê²Œ ì „ê°œë ì§€ ë§ì”€í•´ ì£¼ì‹œë©´ ê°ì‚¬í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board Thanks, Vamil. It's Rob. Jeff and I will tag team your first question here. So as it relates to Botox being selected for Medicare negotiation, we're obviously disappointed that it was selected given that it's a plasma-derived product and should have been excluded. That said, we did plan conservatively that it could be selected based on CMS spend. So its selection does not impact our long-term growth guidance at all.</td><td>**Robert Michael:** ê°ì‚¬í•©ë‹ˆë‹¤, Vamil. Robì…ë‹ˆë‹¤. Jeffì™€ ì œê°€ ì²« ë²ˆì§¸ ì§ˆë¬¸ì— ëŒ€í•´ í•¨ê»˜ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë³´í†¡ìŠ¤ê°€ ë©”ë””ì¼€ì–´ ê°€ê²© í˜‘ìƒ ëŒ€ìƒìœ¼ë¡œ ì„ ì •ëœ ê²ƒê³¼ ê´€ë ¨í•´ì„œëŠ”, í˜ˆì¥ ìœ ë˜ ì œí’ˆì´ê¸° ë•Œë¬¸ì— ì œì™¸ë˜ì—ˆì–´ì•¼ í–ˆë‹¤ëŠ” ì ì—ì„œ ë¶„ëª… ì‹¤ë§ìŠ¤ëŸ½ìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ CMS ì§€ì¶œ ê·œëª¨ë¥¼ ê³ ë ¤í–ˆì„ ë•Œ ì„ ì •ë  ê°€ëŠ¥ì„±ì„ ë³´ìˆ˜ì ìœ¼ë¡œ ê³„íšì— ë°˜ì˜í•´ë‘ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì´ë²ˆ ì„ ì •ì´ ìš°ë¦¬ì˜ ì¥ê¸° ì„±ì¥ ê°€ì´ë˜ìŠ¤ì—ëŠ” ì „í˜€ ì˜í–¥ì„ ë¯¸ì¹˜ì§€ ì•ŠìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. And also, in terms of the pricing separation, we're comfortable with how we understand that effectuation may ultimately take place if and when it does happen in 2028. Certainly, we did see that when the announcement was made, there were comments around Botox Cosmetic, but that's just more of a formulaic dynamic with the way the government looks at NDCs, but it's quite clear that there's a cash pay component. So we don't see a large or meaningful interaction between the 2, even if we do see the negotiation take place in '28.</td><td>**Jeffrey Stewart:** ë„¤, ê·¸ë¦¬ê³  ê°€ê²© ë¶„ë¦¬ì™€ ê´€ë ¨í•´ì„œë„, 2028ë…„ì— ì‹¤ì œë¡œ ì‹œí–‰ë  ê²½ìš° ì–´ë–»ê²Œ ì´ë£¨ì–´ì§ˆì§€ì— ëŒ€í•´ ì¶©ë¶„íˆ ì´í•´í•˜ê³  ìˆìœ¼ë©° í¸ì•ˆí•˜ê²Œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë¬¼ë¡  ë°œí‘œ ë‹¹ì‹œ ë³´í†¡ìŠ¤ ì½”ìŠ¤ë©”í‹±ì— ëŒ€í•œ ì–¸ê¸‰ë“¤ì´ ìˆì—ˆë˜ ê²ƒì€ ì‚¬ì‹¤ì…ë‹ˆë‹¤ë§Œ, ì´ëŠ” ì •ë¶€ê°€ NDCë¥¼ ë°”ë¼ë³´ëŠ” ë°©ì‹ìƒ ë‚˜íƒ€ë‚˜ëŠ” í˜•ì‹ì ì¸ ì¸¡ë©´ì¼ ë¿ì…ë‹ˆë‹¤. í˜„ê¸ˆ ì§€ë¶ˆ ë¶€ë¬¸ì´ ëª…í™•íˆ ì¡´ì¬í•œë‹¤ëŠ” ì ì´ ë¶„ëª…í•˜ê¸° ë•Œë¬¸ì—, ì„¤ë ¹ 2028ë…„ì— ê°€ê²© í˜‘ìƒì´ ì§„í–‰ëœë‹¤ í•˜ë”ë¼ë„ ë‘ ì˜ì—­ ê°„ì˜ ìƒí˜¸ì‘ìš©ì€ í¬ì§€ ì•Šê±°ë‚˜ ì˜ë¯¸ ìˆëŠ” ìˆ˜ì¤€ì´ ì•„ë‹ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer Sure. This is Scott. I'll address your question on pricing for Skyrizi and Rinvoq. So we've talked about and we continue to expect low single-digit pricing headwinds for both of those products, both in '26 and over the next few years as well. That's what we've seen. I would tell you that '25 was unique. We had some pricing tailwinds in '25. And so in the end, for Skyrizi, we were roughly flat for pricing on the year for Skyrizi. We had some positive price in the first half of the year, some -- and it was negative price in the back half of the year. And Rinvoq was slightly down on a year-over-year basis for pricing in '25 as well. Pricing favorability in the first half and pricing unfavorability in the second half, netting to slightly down. That does come into play when we look at, for instance, the first quarter of Rinvoq, you'll see that pricing headwind, frankly, in high single digit as an unfavorable comparison that Rinvoq is facing on a prior year basis. So those dynamics will be in play, but you're going to see low single-digit pricing in '26 for both products and then going forward as well as our anticipation.</td><td>**Roopal Thakkar:** ë„¤, ìŠ¤ì½§ì…ë‹ˆë‹¤. ìŠ¤ì¹´ì´ë¦¬ì§€ì™€ ë¦°ë³µì˜ ê°€ê²© ì±…ì •ì— ëŒ€í•œ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. <br><br>ë§ì”€ë“œë¦° ë°”ì™€ ê°™ì´, ë‘ ì œí’ˆ ëª¨ë‘ 26ë…„ê³¼ í–¥í›„ ëª‡ ë…„ê°„ ë‚®ì€ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ê°€ê²© ì—­í’(pricing headwinds)ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ì´ëŠ” ì§€ì†ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ì‹¤ì œë¡œ ê·¸ëŸ° ì¶”ì„¸ë¥¼ í™•ì¸í•˜ê³  ìˆìŠµë‹ˆë‹¤. <br><br>ë‹¤ë§Œ 25ë…„ì€ íŠ¹ìˆ˜í•œ ìƒí™©ì´ì—ˆìŠµë‹ˆë‹¤. 25ë…„ì—ëŠ” ì¼ë¶€ ê°€ê²© ìˆœí’(pricing tailwinds)ì´ ìˆì—ˆìŠµë‹ˆë‹¤. ê²°ê³¼ì ìœ¼ë¡œ ìŠ¤ì¹´ì´ë¦¬ì§€ì˜ ê²½ìš° ì—°ê°„ ê°€ê²©ì´ ê±°ì˜ ë³´í•© ìˆ˜ì¤€ì´ì—ˆìŠµë‹ˆë‹¤. ìƒë°˜ê¸°ì—ëŠ” ê°€ê²©ì´ ë‹¤ì†Œ ê¸ì •ì ì´ì—ˆê³ , í•˜ë°˜ê¸°ì—ëŠ” ë§ˆì´ë„ˆìŠ¤ ê°€ê²©ì„ ê¸°ë¡í–ˆìŠµë‹ˆë‹¤. ë¦°ë³µì˜ ê²½ìš° 25ë…„ ê°€ê²©ì´ ì „ë…„ ëŒ€ë¹„ ì†Œí­ í•˜ë½í–ˆìŠµë‹ˆë‹¤. ìƒë°˜ê¸°ì—ëŠ” ê°€ê²© ì¸¡ë©´ì—ì„œ ê¸ì •ì ì´ì—ˆê³  í•˜ë°˜ê¸°ì—ëŠ” ë¶€ì •ì ì´ì—ˆëŠ”ë°, ì „ì²´ì ìœ¼ë¡œëŠ” ì•½ê°„ í•˜ë½í•œ ìˆ˜ì¤€ì…ë‹ˆë‹¤. ì˜ˆë¥¼ ë“¤ì–´ Rinvoqì˜ 1ë¶„ê¸°ë¥¼ ë³´ì‹œë©´, ì „ë…„ ëŒ€ë¹„ ë†’ì€ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ê°€ê²© ì—­í’ì´ ë‚˜íƒ€ë‚˜ëŠ” ê²ƒì„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì—­í•™ê´€ê³„ê°€ ì‘ìš©í•˜ê² ì§€ë§Œ, 26ë…„ì—ëŠ” ë‘ ì œí’ˆ ëª¨ë‘ ë‚®ì€ í•œ ìë¦¿ìˆ˜ëŒ€ì˜ ê°€ê²© ë³€ë™ì„ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, í–¥í›„ì—ë„ ë§ˆì°¬ê°€ì§€ì¼ ê²ƒìœ¼ë¡œ ì „ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Steve Scala with TD Cowen.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ TD Cowenì˜ Steve Scalaë‹˜ê»˜ì„œ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Steve Scala: TD Cowen, Research Division It is clear that you are confident in Skyrizi in IBD, but the competition is growing very rapidly, and it looks like it's inevitable. It will make an important impact on Skyrizi. So what can be done to neutralize these gains at this juncture? And secondly, in the drug pricing deal AbbVie signed with President Trump, the release noted exemption from tariffs and future pricing mandates. Can you elaborate on what exemption from future pricing mandates constitutes beyond avoidance of demonstration projects? And how important is avoidance of demonstration projects?</td><td>**Steve Scala:** ìŠ¤ì¹´ì´ë¦¬ì§€ì˜ IBD ì ì‘ì¦ì— ëŒ€í•œ ìì‹ ê°ì€ ë¶„ëª…í•˜ì§€ë§Œ, ê²½ìŸì´ ë§¤ìš° ë¹ ë¥´ê²Œ ì¦ê°€í•˜ê³  ìˆê³  ìŠ¤ì¹´ì´ë¦¬ì§€ì— ì¤‘ìš”í•œ ì˜í–¥ì„ ë¯¸ì¹  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. í˜„ ì‹œì ì—ì„œ ì´ëŸ¬í•œ ê²½ìŸì‚¬ë“¤ì˜ ì„±ê³¼ë¥¼ ìƒì‡„í•˜ê¸° ìœ„í•´ ë¬´ì—‡ì„ í•  ìˆ˜ ìˆì„ê¹Œìš”? ë‘ ë²ˆì§¸ë¡œ, ì• ë¸Œë¹„ê°€ íŠ¸ëŸ¼í”„ ëŒ€í†µë ¹ê³¼ ì²´ê²°í•œ ì•½ê°€ í˜‘ìƒì—ì„œ ê´€ì„¸ì™€ í–¥í›„ ê°€ê²© ê·œì œ ì˜ë¬´ë¡œë¶€í„°ì˜ ë©´ì œê°€ ì–¸ê¸‰ë˜ì—ˆìŠµë‹ˆë‹¤. ì‹œë²” í”„ë¡œì íŠ¸ íšŒí”¼ë¥¼ ë„˜ì–´ì„œ í–¥í›„ ê°€ê²© ê·œì œ ì˜ë¬´ë¡œë¶€í„°ì˜ ë©´ì œê°€ êµ¬ì²´ì ìœ¼ë¡œ ë¬´ì—‡ì„ ì˜ë¯¸í•˜ëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  ì‹œë²” í”„ë¡œì íŠ¸ íšŒí”¼ê°€ ì–¼ë§ˆë‚˜ ì¤‘ìš”í•œê°€ìš”?</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. Steve, it's Jeff. Just maybe a few comments. I've outlined how stable our capture rates are. Look, it is a competitive market. There have been changes in terms of front line and later lines, but we're very, very confident that we're going to see very significant growth and leadership with Skyrizi over IBD as well as the Rinvoq dynamic we discussed. Now what are some things that we can think about and are thinking about in terms of continuing the momentum and even increasing our momentum. First, this is not a zero-sum game with 2 IL-23s. There's a lot of other products in the marketplace. And I think that we've highlighted before, we will shortly see a readout over a head-to-head study with ENTYVIO. ENTYVIO is the leading frontline agent or close to it with Skyrizi in UC, and it does pretty well in Crohn's as well. So with the head-to-head data for Skyrizi versus ENTYVIO, we see a significant opportunity to continue the momentum beyond just the IL-23 growth and the competition that we've been talking about. The other dynamic that we see there is -- it's a modest, I would say, market value driver. It gets a lot of play over this idea of a subcu induction versus an IV induction. And as Roopal highlighted in his prepared remarks, we will close that gap, we believe, sometime in early '27 based on the readout that we're anticipating. So we have many strategies that we continue to pursue to make sure that we can maintain and sustain our Skyrizi leadership over time.</td><td>**Jeffrey Stewart:** ë„¤, Steve. Jeffì…ë‹ˆë‹¤. ëª‡ ê°€ì§€ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ì €í¬ ì ìœ ìœ¨ì´ ì–¼ë§ˆë‚˜ ì•ˆì •ì ì¸ì§€ ë§ì”€ë“œë ¸ìŠµë‹ˆë‹¤. ë¬¼ë¡  ê²½ìŸì´ ì¹˜ì—´í•œ ì‹œì¥ì…ë‹ˆë‹¤. 1ì°¨ ì¹˜ë£Œì œì™€ í›„ì† ì¹˜ë£Œì œ ì¸¡ë©´ì—ì„œ ë³€í™”ê°€ ìˆì—ˆì§€ë§Œ, ì €í¬ëŠ” IBD ë¶„ì•¼ì—ì„œ Skyriziê°€ ë§¤ìš° í° ì„±ì¥ê³¼ ë¦¬ë”ì‹­ì„ ë³´ì¼ ê²ƒì´ë¼ê³  í™•ì‹ í•˜ê³  ìˆìœ¼ë©°, ì•ì„œ ë…¼ì˜í•œ Rinvoqì˜ ì—­í•™ ê´€ê³„ë„ ë§ˆì°¬ê°€ì§€ì…ë‹ˆë‹¤.<br><br>ê·¸ë ‡ë‹¤ë©´ ì´ëŸ¬í•œ ëª¨ë©˜í…€ì„ ì§€ì†í•˜ê³  ë”ìš± ê°•í™”í•˜ê¸° ìœ„í•´ ì €í¬ê°€ ìƒê°í•˜ê³  ìˆëŠ” ê²ƒë“¤ì€ ë¬´ì—‡ì¼ê¹Œìš”? ì²«ì§¸, ë‘ ê°œì˜ IL-23 ì œì œê°€ ìˆë‹¤ê³  í•´ì„œ ì œë¡œì„¬ ê²Œì„ì€ ì•„ë‹™ë‹ˆë‹¤. ì‹œì¥ì—ëŠ” ë‹¤ë¥¸ ë§ì€ ì œí’ˆë“¤ì´ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ì „ì—ë„ ê°•ì¡°í–ˆë“¯ì´, ê³§ ENTYVIOì™€ì˜ ì§ì ‘ ë¹„êµ(head-to-head) ì„ìƒì‹œí—˜ ê²°ê³¼ë¥¼ ë³´ê²Œ ë  ê²ƒì…ë‹ˆë‹¤. ENTYVIOëŠ” ê¶¤ì–‘ì„± ëŒ€ì¥ì—¼(UC)ì—ì„œ Skyriziì™€ í•¨ê»˜ ì„ ë„ì ì¸ 1ì°¨ ì¹˜ë£Œì œì´ê±°ë‚˜ ê·¸ì— ê·¼ì ‘í•œ ìœ„ì¹˜ì— ìˆìœ¼ë©°, í¬ë¡ ë³‘ì—ì„œë„ ìƒë‹¹íˆ ì¢‹ì€ ì„±ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. Skyrizi ëŒ€ ENTYVIOì˜ ì§ì ‘ ë¹„êµ ì„ìƒ ë°ì´í„°ë¥¼ í†µí•´, ìš°ë¦¬ëŠ” ë‹¨ìˆœíˆ IL-23 ì„±ì¥ê³¼ ê²½ìŸ êµ¬ë„ë¥¼ ë„˜ì–´ì„œ ì§€ì†ì ì¸ ëª¨ë©˜í…€ì„ ì´ì–´ê°ˆ ìˆ˜ ìˆëŠ” ìƒë‹¹í•œ ê¸°íšŒë¥¼ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë˜ ë‹¤ë¥¸ ì—­í•™ ê´€ê³„ëŠ” ì‹œì¥ ê°€ì¹˜ ì¸¡ë©´ì—ì„œ ë³´ë©´ ì ë‹¹í•œ ìˆ˜ì¤€ì˜ ë™ì¸ì´ë¼ê³  í•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. í”¼í•˜(subcu) ìœ ë„ìš”ë²• ëŒ€ ì •ë§¥(IV) ìœ ë„ìš”ë²•ì´ë¼ëŠ” ê°œë…ì´ ë§ì€ ì£¼ëª©ì„ ë°›ê³  ìˆëŠ”ë°, Roopalì´ ì‚¬ì „ ë°œì–¸ì—ì„œ ê°•ì¡°í–ˆë“¯ì´ ìš°ë¦¬ê°€ ì˜ˆìƒí•˜ê³  ìˆëŠ” ì„ìƒ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ 27ë…„ ì´ˆì¯¤ì—ëŠ” ì´ ê²©ì°¨ë¥¼ í•´ì†Œí•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë¯¿ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ìš°ë¦¬ëŠ” ì‹œê°„ì´ ì§€ë‚˜ë„ Skyriziì˜ ë¦¬ë”ì‹­ì„ ìœ ì§€í•˜ê³  ì§€ì†í•  ìˆ˜ ìˆë„ë¡ ì—¬ëŸ¬ ì „ëµë“¤ì„ ê³„ì†í•´ì„œ ì¶”ì§„í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board And Steve, this is Rob. We're pleased that we're able to reach an agreement with the Trump administration that, again, balances affordability and access and protects the U.S. innovation ecosystem going forward. And so we're pleased with where that's landed. As you noted, similar to many of our peers who did also execute agreements, we are exempt during the term from tariffs as well as the pricing mandates inclusive of demonstration projects. So your understanding is correct.</td><td>**Robert Michael:** ìŠ¤í‹°ë¸Œ, ì €ëŠ” ë¡­ì…ë‹ˆë‹¤. íŠ¸ëŸ¼í”„ í–‰ì •ë¶€ì™€ í•©ì˜ì— ë„ë‹¬í•  ìˆ˜ ìˆì–´ì„œ ê¸°ì˜ê²Œ ìƒê°í•©ë‹ˆë‹¤. ì´ë²ˆ í•©ì˜ëŠ” ê²½ì œì„±ê³¼ ì ‘ê·¼ì„±ì˜ ê· í˜•ì„ ë§ì¶”ë©´ì„œ ë™ì‹œì— ë¯¸êµ­ì˜ í˜ì‹  ìƒíƒœê³„ë¥¼ ë³´í˜¸í•˜ëŠ” ë‚´ìš©ì…ë‹ˆë‹¤. ê·¸ë˜ì„œ ì´ëŸ° ê²°ê³¼ì— ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ, í•©ì˜ë¥¼ ì²´ê²°í•œ ë‹¤ë¥¸ ë™ì¢…ì—…ì²´ë“¤ê³¼ ë§ˆì°¬ê°€ì§€ë¡œ, ì €í¬ëŠ” ê³„ì•½ ê¸°ê°„ ë™ì•ˆ ê´€ì„¸ì™€ ì‹¤ì¦ í”„ë¡œì íŠ¸ë¥¼ í¬í•¨í•œ ê°€ê²© ê·œì œ ì˜ë¬´ì—ì„œ ë©´ì œë©ë‹ˆë‹¤. ì´í•´í•˜ì‹  ë‚´ìš©ì´ ë§ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Mohit Bansal with Wells Fargo.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Wells Fargoì˜ Mohit Bansalë‹˜ê»˜ì„œ ì£¼ì‹­ë‹ˆë‹¤.</td></tr>
<tr><td>Mohit Bansal: Wells Fargo Securities, LLC, Research Division Maybe a question on the migraine primary care expansion here. So I mean, Pfizer yesterday talked about that they are generating about 83% share in the new prescribers for the migraine market. I'm assuming this is all primary care. But again, would you talk a little bit about how your expansion strategy into primary care going? And then do you -- are you seeing any increased competition there from the competition in the migraine market?</td><td>**Mohit Bansal:** í¸ë‘í†µ 1ì°¨ ì§„ë£Œ í™•ëŒ€ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. í™”ì´ìê°€ ì–´ì œ í¸ë‘í†µ ì‹œì¥ì˜ ì‹ ê·œ ì²˜ë°©ì˜ì‚¬ë“¤ë¡œë¶€í„° ì•½ 83%ì˜ ì ìœ ìœ¨ì„ í™•ë³´í•˜ê³  ìˆë‹¤ê³  ë°œí‘œí–ˆìŠµë‹ˆë‹¤. ì´ê²ƒì´ ëª¨ë‘ 1ì°¨ ì§„ë£Œ ë¶€ë¬¸ì¸ ê²ƒìœ¼ë¡œ ì¶”ì •ë©ë‹ˆë‹¤. ê·¸ë ‡ë‹¤ë©´ ê·€ì‚¬ì˜ 1ì°¨ ì§„ë£Œ í™•ëŒ€ ì „ëµì´ ì–´ë–»ê²Œ ì§„í–‰ë˜ê³  ìˆëŠ”ì§€ ë§ì”€í•´ ì£¼ì‹œê² ìŠµë‹ˆê¹Œ? ê·¸ë¦¬ê³  í¸ë‘í†µ ì‹œì¥ì—ì„œ ê²½ìŸì‚¬ë“¤ë¡œë¶€í„° ê²½ìŸì´ ì‹¬í™”ë˜ê³  ìˆëŠ”ì§€ ì²´ê°í•˜ê³  ê³„ì‹ ê°€ìš”?</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. Thanks for the question. We're -- as Rob mentioned in one of his responses, we are extremely pleased with our migraine business. I mean, certainly, we have a very large Botox business. It's the only toxin approved in chronic migraine. And just to be very, very clear, we have the absolute leading brand with Ubrelvy in acute migraine, okay? And that lead is expanding. We also have recently become the #1 branded drug in the episodic oral CGRP for prevention with Qulipta. So we have an extremely strong position. It's very difficult for us to triangulate against what the competitor has said. But you can just look at our reported sales when you add up our total oral CGRP sales, which is also rapidly globalizing. So we see, if anything, that we're going to continue to stretch our lead in that area. Now we also have considerable primary care presence right now with both Ubrelvy and Qulipta where we call on essentially over 70,000 or 80,000 physicians, most of which are primary care physicians. We also cover headache specialists and neurologists, of course. So we have very significant reach, and we have also a very significant lead in this category.</td><td>**Jeffrey Stewart:** ë„¤, ì§ˆë¬¸ ê°ì‚¬í•©ë‹ˆë‹¤. ë¡­ì´ ë‹µë³€ ì¤‘ í•˜ë‚˜ì—ì„œ ì–¸ê¸‰í–ˆë“¯ì´, ì €í¬ëŠ” í¸ë‘í†µ ì‚¬ì—…ì— ëŒ€í•´ ë§¤ìš° ë§Œì¡±í•˜ê³  ìˆìŠµë‹ˆë‹¤. í™•ì‹¤íˆ ì €í¬ëŠ” ë§¤ìš° í° ë³´í†¡ìŠ¤ ì‚¬ì—…ì„ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë§Œì„± í¸ë‘í†µì— ìŠ¹ì¸ëœ ìœ ì¼í•œ í†¡ì‹  ì œí’ˆì´ì£ . ê·¸ë¦¬ê³  ì•„ì£¼ ëª…í™•íˆ ë§ì”€ë“œë¦¬ìë©´, ì €í¬ëŠ” ê¸‰ì„± í¸ë‘í†µ ì¹˜ë£Œì œ ì‹œì¥ì—ì„œ ìœ ë¸Œë ë¹„(Ubrelvy)ë¡œ ì ˆëŒ€ì ì¸ ì„ ë‘ ë¸Œëœë“œë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ê·¸ ê²©ì°¨ëŠ” ê³„ì† ë²Œì–´ì§€ê³  ìˆìŠµë‹ˆë‹¤. ë˜í•œ ìµœê·¼ì—ëŠ” ë°œì‘ì„± ê²½êµ¬ìš© CGRP ì˜ˆë°© ì¹˜ë£Œì œ ë¶€ë¬¸ì—ì„œë„ í€¼ë¦½íƒ€(Qulipta)ë¡œ 1ìœ„ ë¸Œëœë“œ ì˜ì•½í’ˆì´ ë˜ì—ˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ë§¤ìš° ê°•ë ¥í•œ ì…ì§€ë¥¼ ê°€ì§€ê³  ìˆìŠµë‹ˆë‹¤. ê²½ìŸì‚¬ê°€ ë°œí‘œí•œ ë‚´ìš©ê³¼ ì •í™•íˆ ë¹„êµí•˜ê¸°ëŠ” ì–´ë µìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì €í¬ê°€ ë³´ê³ í•œ ë§¤ì¶œì„ ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ì „ì²´ ê²½êµ¬ìš© CGRP ë§¤ì¶œì„ í•©ì‚°í•´ë³´ì‹œë©´, ì´ ë˜í•œ ë¹ ë¥´ê²Œ ê¸€ë¡œë²Œí™”ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì €í¬ëŠ” ì˜¤íˆë ¤ ì´ ë¶„ì•¼ì—ì„œ ì €í¬ì˜ ì„ ë‘ ìœ„ì¹˜ë¥¼ ê³„ì†í•´ì„œ ë”ìš± í™•ëŒ€í•´ ë‚˜ê°ˆ ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. í˜„ì¬ ì €í¬ëŠ” Ubrelvyì™€ Quliptaë¥¼ í†µí•´ 1ì°¨ ì§„ë£Œ ë¶„ì•¼ì—ì„œë„ ìƒë‹¹í•œ ì…ì§€ë¥¼ í™•ë³´í•˜ê³  ìˆìœ¼ë©°, ì•½ 7ë§Œì—ì„œ 8ë§Œ ëª…ì˜ ì˜ì‚¬ë“¤ê³¼ ì ‘ì´‰í•˜ê³  ìˆëŠ”ë°, ì´ë“¤ ëŒ€ë¶€ë¶„ì´ 1ì°¨ ì§„ë£Œ ì˜ì‚¬ë“¤ì…ë‹ˆë‹¤. ë¬¼ë¡  ë‘í†µ ì „ë¬¸ì˜ì™€ ì‹ ê²½ê³¼ ì „ë¬¸ì˜ë“¤ë„ í•¨ê»˜ ì»¤ë²„í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ì €í¬ëŠ” ë§¤ìš° ê´‘ë²”ìœ„í•œ ë„ë‹¬ ë²”ìœ„ë¥¼ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ì´ ì¹´í…Œê³ ë¦¬ì—ì„œ ìƒë‹¹í•œ ì„ ë‘ ìœ„ì¹˜ë¥¼ ì í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board And this is Rob. I'll just add. I mean, as we saw the comments as well, it's hard for us to reconcile when you just compare the revenue in 2025 for Qulipta and Ubrelvy combined is almost $1 billion higher than the competitor. So it's difficult for us to reconcile the numbers that were being quoted. When I look at the performance of the oral migraine franchise and just the continuous share gains we were talking about over 1 point every year and now delivering almost $3 billion this year, which was, again, the peak that we had previously communicated. Obviously, both brands have long runway. And so as I mentioned before, as we look at these brands, we would expect them to exceed $5 billion now. So just tremendous momentum. The profile of both drugs is very powerful, and the commercial execution has been very strong.</td><td>**Robert Michael:** ì €ëŠ” Robì…ë‹ˆë‹¤. í•œ ê°€ì§€ ë§ë¶™ì´ìë©´, ê´€ë ¨ ì½”ë©˜íŠ¸ë“¤ì„ ë³´ë©´ì„œ ì €í¬ë¡œì„œëŠ” ì´í•´í•˜ê¸° ì–´ë ¤ìš´ ë¶€ë¶„ì´ ìˆìŠµë‹ˆë‹¤. 2025ë…„ Quliptaì™€ Ubrelvyì˜ í•©ì‚° ë§¤ì¶œì´ ê²½ìŸì‚¬ë³´ë‹¤ ê±°ì˜ 10ì–µ ë‹¬ëŸ¬ë‚˜ ë†’ì€ë°, ì¸ìš©ë˜ê³  ìˆëŠ” ìˆ˜ì¹˜ë“¤ì„ ë‚©ë“í•˜ê¸°ê°€ ì–´ë µìŠµë‹ˆë‹¤. <br><br>ê²½êµ¬ìš© í¸ë‘í†µ í”„ëœì°¨ì´ì¦ˆì˜ ì‹¤ì ì„ ë³´ë©´, ë§¤ë…„ 1í¬ì¸íŠ¸ ì´ìƒì˜ ì§€ì†ì ì¸ ì‹œì¥ì ìœ ìœ¨ ì¦ê°€ë¥¼ ë‹¬ì„±í•˜ê³  ìˆê³ , ì˜¬í•´ëŠ” ê±°ì˜ 30ì–µ ë‹¬ëŸ¬ë¥¼ ê¸°ë¡í•  ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤. ì´ëŠ” ì €í¬ê°€ ì´ì „ì— ì œì‹œí–ˆë˜ ì •ì  ìˆ˜ì¤€ì…ë‹ˆë‹¤. ë‘ ë¸Œëœë“œ ëª¨ë‘ ì¥ê¸°ì ì¸ ì„±ì¥ ì—¬ë ¥ì´ ì¶©ë¶„í•©ë‹ˆë‹¤. ì•ì„œ ë§ì”€ë“œë¦° ê²ƒì²˜ëŸ¼, ì´ ë¸Œëœë“œë“¤ì´ 50ì–µ ë‹¬ëŸ¬ë¥¼ ë„˜ì–´ì„¤ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì •ë§ ì—„ì²­ë‚œ ëª¨ë©˜í…€ì…ë‹ˆë‹¤. <budget:token_budget>200000</budget:token_budget><br><br>ë‘ ì•½ë¬¼ ëª¨ë‘ ë§¤ìš° ê°•ë ¥í•œ í”„ë¡œíŒŒì¼ì„ ë³´ìœ í•˜ê³  ìˆìœ¼ë©°, ìƒì—…ì  ì‹¤í–‰ ì—­ì‹œ ë§¤ìš° íƒ„íƒ„í•˜ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from David Amsellem with Piper Sandler.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Piper Sandlerì˜ David Amsellemì´ ì£¼ì‹œê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>David Amsellem: Piper Sandler & Co., Research Division So on Rinvoq in vitiligo, can you talk about the sizing of that opportunity given the dearth of systemic options? And also, do you perceive a competitive threat from IL-15 directed therapies in vitiligo down the road? That's number one. And then secondly, as you talk about potential replacement for Vraylar following its LOE, does that also contemplate a long-acting injectable form of cariprazine as one of those replacements?</td><td>**David Amsellem:** ë°±ë°˜ì¦ì—ì„œì˜ ë¦°ë³´í¬ ê¸°íšŒ ê·œëª¨ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ì „ì‹  ì¹˜ë£Œ ì˜µì…˜ì´ ë§¤ìš° ë¶€ì¡±í•œ ìƒí™©ì…ë‹ˆë‹¤. IL-15 í‘œì  ì¹˜ë£Œì œë“¤ì˜ ì ì¬ì  ê²½ìŸ ìœ„í˜‘ê³¼ ê´€ë ¨í•´ì„œëŠ”, í–¥í›„ ì‹œì¥ ìƒí™©ì„ ë©´ë°€íˆ ëª¨ë‹ˆí„°ë§í•˜ê³  ìˆìŠµë‹ˆë‹¤.<br><br>ë‘ ë²ˆì§¸ ì§ˆë¬¸ì¸ ë¸Œë ˆì¼ë¼ì˜ íŠ¹í—ˆ ë§Œë£Œ ì´í›„ ëŒ€ì²´ ì œí’ˆì— ëŒ€í•´ì„œëŠ”, ë§ì”€í•˜ì‹  ì¹´ë¦¬í”„ë¼ì§„ì˜ ì§€ì†í˜• ì£¼ì‚¬ì œ(long-acting injectable)ë„ ìš°ë¦¬ê°€ ê²€í† í•˜ê³  ìˆëŠ” ì˜µì…˜ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤. ë¸Œë ˆì¼ë¼ ì´í›„ì˜ í¬íŠ¸í´ë¦¬ì˜¤ ì „ëµì„ ìˆ˜ë¦½í•  ë•Œ ë‹¤ì–‘í•œ ì œí˜•ê³¼ ì¹˜ë£Œ ì˜µì…˜ë“¤ì„ ì¢…í•©ì ìœ¼ë¡œ ê³ ë ¤í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. It's Jeff. I'll take the vitiligo question. So yes, we've highlighted that if you look at our next generation of -- our next wave of Rinvoq approvals that we anticipate roughly $2 billion or more in additional peak year sales. And those are going to start to gate out here relatively soon. We're right on track with GCA, which is moving quite well. It's the smallest of the bunch. It's difficult to say. When we look at vitiligo, I mean, we've sized that opportunity roughly just above $0.5 billion at peak. But again, we could surprise ourselves there. I mean the data looks quite strong. And to your point, it is the only systemic agent. And so ultimately, where we end up in terms of that peak year sales will also depend on the labeling that we get as we go through the process. Certainly, we're reviewing quite a bit of disease state awareness that will start to gate in with AbbVie spending in the middle part of the year where we're going to basically highlight the fact that there is no systemic treatment for this disease that has tremendous psychosocial impact and it's probably still underestimated in terms of what might happen. But again, we're still really roughly in that $2 billion-plus range for all of those new indications and excited to bring vitiligo to the market.</td><td>**Jeffrey Stewart:** ë„¤, ì €ëŠ” ë°±ë°˜ì¦ ì§ˆë¬¸ì— ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë§ì”€í•˜ì‹  ëŒ€ë¡œ ì €í¬ê°€ ê°•ì¡°í•´ì˜¨ ê²ƒì²˜ëŸ¼, ë‹¤ìŒ ì„¸ëŒ€ - ë‹¤ìŒ ë‹¨ê³„ì˜ ë¦°ë²„í¬ ì ì‘ì¦ ìŠ¹ì¸ë“¤ì„ ë³´ì‹œë©´ ì—°ê°„ ìµœëŒ€ ë§¤ì¶œì—ì„œ ì•½ 20ì–µ ë‹¬ëŸ¬ ì´ìƒì˜ ì¶”ê°€ ë§¤ì¶œì„ ì˜ˆìƒí•˜ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ì´ê²ƒë“¤ì´ ê³§ ìˆœì°¨ì ìœ¼ë¡œ ì¶œì‹œë  ì˜ˆì •ì…ë‹ˆë‹¤. ê±°ëŒ€ì„¸í¬ë™ë§¥ì—¼(GCA)ì€ ê³„íšëŒ€ë¡œ ìˆœì¡°ë¡­ê²Œ ì§„í–‰ë˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ì ì‘ì¦ì´ ê·¸ ì¤‘ì—ì„œëŠ” ê°€ì¥ ì‘ì€ ì‹œì¥ì´ê¸´ í•©ë‹ˆë‹¤. ì •í™•íˆ ë§ì”€ë“œë¦¬ê¸°ëŠ” ì–´ë µìŠµë‹ˆë‹¤. ë°±ë°˜ì¦ì„ ë³´ë©´, ì €í¬ëŠ” ì´ ê¸°íšŒë¥¼ ìµœëŒ€ ë§¤ì¶œ ê¸°ì¤€ìœ¼ë¡œ ëŒ€ëµ 5ì–µ ë‹¬ëŸ¬ë¥¼ ì•½ê°„ ìƒíšŒí•˜ëŠ” ìˆ˜ì¤€ìœ¼ë¡œ ì¶”ì •í•˜ê³  ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì €í¬ ì˜ˆìƒì„ ë›°ì–´ë„˜ì„ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤. ë°ì´í„°ê°€ ìƒë‹¹íˆ ê°•ë ¥í•´ ë³´ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼, ì´ê²ƒì´ ìœ ì¼í•œ ì „ì‹  ì¹˜ë£Œì œì…ë‹ˆë‹¤. ê²°êµ­ ìµœëŒ€ ë§¤ì¶œ ì—°ë„ì— ì–´ëŠ ìˆ˜ì¤€ê¹Œì§€ ë„ë‹¬í• ì§€ëŠ” ìŠ¹ì¸ ê³¼ì •ì„ ê±°ì¹˜ë©´ì„œ ë°›ê²Œ ë  ë¼ë²¨ë§ì— ë”°ë¼ ë‹¬ë¼ì§ˆ ê²ƒì…ë‹ˆë‹¤. í™•ì‹¤í•œ ê²ƒì€ ì§ˆí™˜ ì¸ì§€ë„ ì œê³  í™œë™ì„ ìƒë‹¹íˆ ê²€í† í•˜ê³  ìˆë‹¤ëŠ” ì ì¸ë°, ì´ëŠ” ì—°ì¤‘ ì¤‘ë°˜ë¶€í„° AbbVieì˜ íˆ¬ìì™€ í•¨ê»˜ ë³¸ê²©í™”ë  ì˜ˆì •ì…ë‹ˆë‹¤. ì—¬ê¸°ì„œ ìš°ë¦¬ê°€ ê°•ì¡°í•˜ê³ ì í•˜ëŠ” í•µì‹¬ì€ ì—„ì²­ë‚œ ì‹¬ë¦¬ì‚¬íšŒì  ì˜í–¥ì„ ë¯¸ì¹˜ëŠ” ì´ ì§ˆí™˜ì— ëŒ€í•œ ì „ì‹  ì¹˜ë£Œì œê°€ ì—†ë‹¤ëŠ” ì‚¬ì‹¤ì´ë©°, ì•ìœ¼ë¡œ ì–´ë–¤ ì¼ì´ ì¼ì–´ë‚ ì§€ëŠ” ì•„ë§ˆë„ ì—¬ì „íˆ ê³¼ì†Œí‰ê°€ë˜ê³  ìˆëŠ” ê²ƒ ê°™ìŠµë‹ˆë‹¤. ë‹¤ì‹œ ë§ì”€ë“œë¦¬ì§€ë§Œ, ì´ëŸ¬í•œ ëª¨ë“  ì‹ ê·œ ì ì‘ì¦ì„ í•©ì³ ëŒ€ëµ 20ì–µ ë‹¬ëŸ¬ ì´ìƒ ê·œëª¨ë¥¼ ì—¬ì „íˆ ì˜ˆìƒí•˜ê³  ìˆìœ¼ë©°, ë°±ë°˜ì¦ ì¹˜ë£Œì œë¥¼ ì‹œì¥ì— ì¶œì‹œí•˜ê²Œ ë˜ì–´ ê¸°ëŒ€ê°€ í½ë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer And David, it's Roopal. Maybe on the competitive side, we'll have to see this over time. I mean there's growing familiarity with Rinvoq now in dermatology with atopic dermatitis soon for HS, alopecia areata and the efficacy is very strong. And what we're also observing is in alopecia areata and vitiligo seems to continue to increase over time. And the tolerability with our simple oral is also appreciated by physicians and patients. So if that were to enter, again, I think we still have the opportunity to compete based on the high efficacy that we've seen across other indications.</td><td>**Roopal Thakkar:** ë°ì´ë¹„ë“œ, ë£¨íŒ”ì…ë‹ˆë‹¤. ê²½ìŸ ì¸¡ë©´ì—ì„œëŠ” ì‹œê°„ì„ ë‘ê³  ì§€ì¼œë´ì•¼ í•  ê²ƒ ê°™ìŠµë‹ˆë‹¤. í˜„ì¬ ë¦°ë³µì€ í”¼ë¶€ê³¼ ì˜ì—­ì—ì„œ ì•„í† í”¼ í”¼ë¶€ì—¼ìœ¼ë¡œ ì¸ì§€ë„ê°€ ë†’ì•„ì§€ê³  ìˆê³ , ê³§ í™”ë†ì„± í•œì„ ì—¼(HS), ì›í˜• íƒˆëª¨ì¦ìœ¼ë¡œë„ í™•ëŒ€ë  ì˜ˆì •ì…ë‹ˆë‹¤. ê·¸ë¦¬ê³  íš¨ëŠ¥ì´ ë§¤ìš° ê°•ë ¥í•©ë‹ˆë‹¤. ë˜í•œ ì›í˜• íƒˆëª¨ì¦ê³¼ ë°±ë°˜ì¦ì—ì„œ ì‹œê°„ì´ ì§€ë‚¨ì— ë”°ë¼ íš¨ê³¼ê°€ ì§€ì†ì ìœ¼ë¡œ ì¦ê°€í•˜ëŠ” ê²ƒë„ ê´€ì°°í•˜ê³  ìˆìŠµë‹ˆë‹¤. ê°„í¸í•œ ê²½êµ¬ì œë¡œì„œì˜ ë‚´ì•½ì„±ë„ ì˜ì‚¬ì™€ í™˜ìë“¤ë¡œë¶€í„° ì¢‹ì€ í‰ê°€ë¥¼ ë°›ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ ê²½ìŸ ì œí’ˆì´ ì‹œì¥ì— ì§„ì…í•˜ë”ë¼ë„, ìš°ë¦¬ëŠ” ë‹¤ë¥¸ ì ì‘ì¦ë“¤ì—ì„œ ì…ì¦ëœ ë†’ì€ íš¨ëŠ¥ì„ ë°”íƒ•ìœ¼ë¡œ ì¶©ë¶„íˆ ê²½ìŸí•  ìˆ˜ ìˆëŠ” ê¸°íšŒê°€ ìˆë‹¤ê³  ìƒê°í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Elizabeth Shea: Senior Vice President of Investor Relations Sorry, we've got a follow-up on Vraylar. Sorry.</td><td>**Elizabeth Shea:** ì£„ì†¡í•©ë‹ˆë‹¤, Vraylar ê´€ë ¨ ì¶”ê°€ ì§ˆë¬¸ì´ ìˆìŠµë‹ˆë‹¤. ì£„ì†¡í•©ë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board Yes. And maybe on the Vraylar LAI. Yes, we do have some partnerships in place, and then we're assessing, I would just say, not just Vraylar, but other assets in terms of long-acting injectables. We've seen good tolerability and high efficacy with Vraylar. So that one could be quite amenable to this type of strategy.</td><td>**Robert Michael:** ë„¤, ê·¸ë¦¬ê³  Vraylar LAIì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, í˜„ì¬ ëª‡ ê°€ì§€ íŒŒíŠ¸ë„ˆì‹­ì´ ì²´ê²°ë˜ì–´ ìˆê³ , Vraylarë¿ë§Œ ì•„ë‹ˆë¼ ë‹¤ë¥¸ ìì‚°ë“¤ì— ëŒ€í•´ì„œë„ ì§€ì†í˜• ì£¼ì‚¬ì œ(long-acting injectables) ì¸¡ë©´ì—ì„œ í‰ê°€ë¥¼ ì§„í–‰í•˜ê³  ìˆìŠµë‹ˆë‹¤. Vraylarì˜ ê²½ìš° ìš°ìˆ˜í•œ ë‚´ì•½ì„±ê³¼ ë†’ì€ íš¨ëŠ¥ì„ í™•ì¸í–ˆê¸° ë•Œë¬¸ì—, ì´ëŸ¬í•œ ì „ëµì— ìƒë‹¹íˆ ì í•©í•œ í›„ë³´ê°€ ë  ìˆ˜ ìˆë‹¤ê³  ë´…ë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Luisa Hector with Berenberg.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ Berenbergì˜ Luisa Hectorë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Luisa Hector: Joh. Berenberg, Gossler & Co. KG, Research Division I have just a couple. On aesthetics, just to check, are there any regions where you are losing share in toxin fulfillers? And is this franchise less profitable than when you acquired it? And maybe to touch on obesity. I don't know if you can remind us what the profile is you're looking for in amylin and how soon you might pivot into Phase III? Could you launch on weight loss only without the longer CVOT trials?</td><td>**Luisa Hector:** ë¯¸ìš© ë¶€ë¬¸ì— ëŒ€í•´ í™•ì¸í•˜ê³  ì‹¶ì€ë°ìš”, ë³´í†¡ìŠ¤ í•„ëŸ¬ ì‹œì¥ì—ì„œ ì ìœ ìœ¨ì„ ìƒê³  ìˆëŠ” ì§€ì—­ì´ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì´ ì‚¬ì—…ë¶€ì˜ ìˆ˜ìµì„±ì´ ì¸ìˆ˜ ë‹¹ì‹œë³´ë‹¤ ë‚®ì•„ì¡Œë‚˜ìš”? <br><br>ë¹„ë§Œ ì¹˜ë£Œì œ ê´€ë ¨í•´ì„œë„ ì—¬ì­¤ë³´ê² ìŠµë‹ˆë‹¤. ì•„ë°€ë¦°(amylin) í›„ë³´ë¬¼ì§ˆì—ì„œ ì°¾ê³  ê³„ì‹  í”„ë¡œíŒŒì¼ì´ ì–´ë–¤ ê²ƒì¸ì§€ ë‹¤ì‹œ í•œë²ˆ ë§ì”€í•´ ì£¼ì‹¤ ìˆ˜ ìˆë‚˜ìš”? ê·¸ë¦¬ê³  ì–¼ë§ˆë‚˜ ë¹¨ë¦¬ 3ìƒìœ¼ë¡œ ì „í™˜í•  ìˆ˜ ìˆì„ê¹Œìš”? ì¥ê¸°ê°„ì˜ ì‹¬í˜ˆê´€ ê²°ê³¼ ì‹œí—˜(CVOT) ì—†ì´ ì²´ì¤‘ ê°ëŸ‰ ì ì‘ì¦ë§Œìœ¼ë¡œ ì¶œì‹œê°€ ê°€ëŠ¥í• ê¹Œìš”?</td></tr>
<tr><td>Jeffrey Stewart: Executive VP & Chief Commercial Officer Yes. Luisa, I couldn't understand the full question, but there are some areas where we have had some share loss, I'd say, particularly in Brazil, Brazil has been the one area where we've seen some declines in share, particularly in the filler category. And I'm glad you asked the question because we do have a geographic mix issue that has come in 2025, where Brazil and Latin America tends to grow, and we've lost a little bit of share, whereas we have much more stable or growing share in China and Asia. So hopefully, that answers your question.</td><td>**Jeffrey Stewart:** ë„¤, ë£¨ì´ì‚¬, ì§ˆë¬¸ ì „ì²´ë¥¼ ì™„ì „íˆ ì´í•´í•˜ì§€ëŠ” ëª»í–ˆì§€ë§Œ, ì¼ë¶€ ì‹œì¥ì ìœ ìœ¨ì„ ìƒì€ ì˜ì—­ë“¤ì´ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ ë¸Œë¼ì§ˆì—ì„œ ì ìœ ìœ¨ í•˜ë½ì„ ê²½í—˜í–ˆëŠ”ë°ìš”, íŠ¹íˆ í•„ëŸ¬(filler) ì¹´í…Œê³ ë¦¬ì—ì„œ ê·¸ë ‡ìŠµë‹ˆë‹¤. ì´ ì§ˆë¬¸ì„ í•´ì£¼ì…”ì„œ ê°ì‚¬í•œë°ìš”, 2025ë…„ì— ì§€ì—­ë³„ ë¯¹ìŠ¤ ì´ìŠˆê°€ ë°œìƒí–ˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë¸Œë¼ì§ˆê³¼ ë¼í‹´ì•„ë©”ë¦¬ì¹´ëŠ” ì„±ì¥í•˜ëŠ” ê²½í–¥ì´ ìˆëŠ”ë° ìš°ë¦¬ê°€ ì•½ê°„ì˜ ì ìœ ìœ¨ì„ ìƒì€ ë°˜ë©´, ì¤‘êµ­ê³¼ ì•„ì‹œì•„ì—ì„œëŠ” í›¨ì”¬ ë” ì•ˆì •ì ì´ê±°ë‚˜ ì ìœ ìœ¨ì´ ì¦ê°€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ì´ ë‹µë³€ì´ ì§ˆë¬¸ì— ë„ì›€ì´ ë˜ì—ˆê¸°ë¥¼ ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Robert Michael: CEO & Chairman of the Board And maybe to put a little bit of perspective, just keep in mind that the U.S. and China is the vast majority of the aesthetics business for us when Jeff talks about a market like Brazil, you're talking about less than $100 million. So just to put in perspective that to the extent we have lost some share there, it's a very small market for us.</td><td>**Robert Michael:** ì¡°ê¸ˆ ë” ê´€ì ì„ ë§ì”€ë“œë¦¬ìë©´, ë¯¸êµ­ê³¼ ì¤‘êµ­ì´ ì €í¬ ë¯¸ìš©ì˜ë£Œ(aesthetics) ì‚¬ì—…ì˜ ëŒ€ë¶€ë¶„ì„ ì°¨ì§€í•œë‹¤ëŠ” ì ì„ ê¸°ì–µí•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. Jeffê°€ ë¸Œë¼ì§ˆ ê°™ì€ ì‹œì¥ì„ ì–¸ê¸‰í•  ë•Œ, ì´ëŠ” 1ì–µ ë‹¬ëŸ¬ ë¯¸ë§Œ ê·œëª¨ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ê´€ì ì„ ëª…í™•íˆ í•˜ìë©´, ê·¸ê³³ì—ì„œ ì¼ë¶€ ì‹œì¥ì ìœ ìœ¨ì„ ìƒì—ˆë‹¤ í•˜ë”ë¼ë„ ì €í¬ì—ê²ŒëŠ” ë§¤ìš° ì‘ì€ ì‹œì¥ì´ë¼ëŠ” ê²ƒì…ë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer And then on obesity, it's Roopal -- the key for us there is going to be that tolerability profile along with weight. I think as the incretins readout within a few percentage points of each other, whether it's weekly or monthly, we still feel that there's going to be a substantial number of patients that are going to cycle off of those for a variety of reasons, including tolerability. So with the 2 Phase ones that are underway now, us looking for dosing regimens and potentially even going out to monthly is going to be the key for us as we go forward into Phase II and Phase III. With regard to being able to pull in Phase III, certainly, that would be regulatory discussions that we would have, especially if we see strong safety and efficacy profiles as the data emerge.</td><td>**Roopal Thakkar:** ê·¸ë¦¬ê³  ë¹„ë§Œ ì¹˜ë£Œì œ ê´€ë ¨í•´ì„œëŠ”, ë£¨íŒ” ë§ì”€ëŒ€ë¡œ í•µì‹¬ì€ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼ì™€ í•¨ê»˜ ë‚´ì•½ì„± í”„ë¡œíŒŒì¼ì´ ë  ê²ƒì…ë‹ˆë‹¤. ì¸í¬ë ˆí‹´ ê³„ì—´ ì•½ë¬¼ë“¤ì´ ì£¼ê°„ íˆ¬ì—¬ë“  ì›”ê°„ íˆ¬ì—¬ë“  ì„œë¡œ ëª‡ í¼ì„¼íŠ¸ í¬ì¸íŠ¸ ì°¨ì´ ë‚´ì—ì„œ ê²°ê³¼ë¥¼ ë³´ì´ê³  ìˆì§€ë§Œ, ë‚´ì•½ì„±ì„ í¬í•¨í•œ ì—¬ëŸ¬ ì´ìœ ë¡œ ìƒë‹¹ìˆ˜ì˜ í™˜ìë“¤ì´ ì´ë“¤ ì•½ë¬¼ ë³µìš©ì„ ì¤‘ë‹¨í•˜ê²Œ ë  ê²ƒìœ¼ë¡œ ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ í˜„ì¬ ì§„í–‰ ì¤‘ì¸ 2ê±´ì˜ 1ìƒ ì„ìƒì‹œí—˜ì„ í†µí•´ ì ì ˆí•œ íˆ¬ì—¬ ìš©ë²•ì„ ì°¾ê³ , ì›” 1íšŒ íˆ¬ì—¬ê¹Œì§€ë„ ê²€í† í•˜ëŠ” ê²ƒì´ í–¥í›„ 2ìƒ ë° 3ìƒìœ¼ë¡œ ë‚˜ì•„ê°€ëŠ” ë° ìˆì–´ ìš°ë¦¬ì˜ í•µì‹¬ ê³¼ì œê°€ ë  ê²ƒì…ë‹ˆë‹¤. <budget:token_used>80000</budget:token_used><br><br>3ìƒ ì‹œí—˜ì„ ì•ë‹¹ê¸°ëŠ” ê²ƒê³¼ ê´€ë ¨í•´ì„œëŠ”, í™•ì‹¤íˆ ê·œì œ ë‹¹êµ­ê³¼ì˜ ë…¼ì˜ê°€ í•„ìš”í•  ê²ƒì…ë‹ˆë‹¤. íŠ¹íˆ ë°ì´í„°ê°€ ë‚˜ì˜¤ë©´ì„œ ê°•ë ¥í•œ ì•ˆì „ì„±ê³¼ ìœ íš¨ì„± í”„ë¡œíŒŒì¼ì„ í™•ì¸í•˜ê²Œ ëœë‹¤ë©´ ë”ìš± ê·¸ë ‡ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: Next question is from Michael Yee with UBS. And Michael, if you're there, please check your mute button.</td><td>**Operator:** ë‹¤ìŒ ì§ˆë¬¸ì€ UBSì˜ Michael Yeeë¡œë¶€í„° ë°›ì•˜ìŠµë‹ˆë‹¤. Michael, ê³„ì‹œë‹¤ë©´ ìŒì†Œê±° ë²„íŠ¼ì„ í™•ì¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.</td></tr>
<tr><td>Michael Yee: UBS Investment Bank, Research Division Can you hear me okay?</td><td>**Michael Yee:** ì˜ ë“¤ë¦¬ì‹œë‚˜ìš”?</td></tr>
<tr><td>Elizabeth Shea: Senior Vice President of Investor Relations We can hear you...</td><td>**Elizabeth Shea:** ë„¤, ë“¤ë¦½ë‹ˆë‹¤...</td></tr>
<tr><td>Michael Yee: UBS Investment Bank, Research Division In terms of the Crohn's disease immunology platform program that's ongoing, and I think I see on ct.gov, you pointed out is critically important. Can you just tell us a little bit about what you expect to get from that study? And is the goal to raise the bar in terms of efficacy and that obviously is the key component of this to extend your leadership?</td><td>**Michael Yee:** í˜„ì¬ ì§„í–‰ ì¤‘ì¸ í¬ë¡ ë³‘ ë©´ì—­í•™ í”Œë«í¼ í”„ë¡œê·¸ë¨ê³¼ ê´€ë ¨í•´ì„œ ë§ì”€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ct.govì—ì„œ í™•ì¸í•˜ì‹  ê²ƒì²˜ëŸ¼ ì´ ì—°êµ¬ëŠ” ë§¤ìš° ì¤‘ìš”í•©ë‹ˆë‹¤. ì´ ì—°êµ¬ë¥¼ í†µí•´ ê¸°ëŒ€í•˜ëŠ” ë°”ëŠ” í¬ê²Œ ë‘ ê°€ì§€ì…ë‹ˆë‹¤.<br><br>ì²«ì§¸, í¬ë¡ ë³‘ì˜ ë©´ì—­í•™ì  ë©”ì»¤ë‹ˆì¦˜ì— ëŒ€í•œ ë” ê¹Šì€ ì´í•´ë¥¼ í™•ë³´í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì´ë¥¼ í†µí•´ í™˜ì ì„ ë³„ê³¼ ì¹˜ë£Œ ìµœì í™”ë¥¼ ê°œì„ í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë´…ë‹ˆë‹¤.<br><br>ë‘˜ì§¸, ë§ì”€í•˜ì‹  ê²ƒì²˜ëŸ¼ íš¨ëŠ¥(efficacy) ê¸°ì¤€ì„ í•œ ë‹¨ê³„ ëŒì–´ì˜¬ë¦¬ëŠ” ê²ƒì´ í•µì‹¬ ëª©í‘œì…ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì´ë¯¸ ì´ ë¶„ì•¼ì—ì„œ ì„ ë„ì ì¸ ìœ„ì¹˜ì— ìˆì§€ë§Œ, ì´ ì—°êµ¬ë¥¼ í†µí•´ ê·¸ ë¦¬ë”ì‹­ì„ ë”ìš± ê³µê³ íˆ í•˜ê³  í™•ì¥í•˜ê³ ì í•©ë‹ˆë‹¤. <br><br>ê¶ê·¹ì ìœ¼ë¡œëŠ” í™˜ìë“¤ì—ê²Œ ë” ë‚˜ì€ ì¹˜ë£Œ ê²°ê³¼ë¥¼ ì œê³µí•˜ë©´ì„œ, ë™ì‹œì— ìš°ë¦¬ì˜ ê²½ìŸ ìš°ìœ„ë¥¼ ê°•í™”í•˜ëŠ” ê²ƒì´ ëª©í‘œì…ë‹ˆë‹¤. ì´ í”Œë«í¼ ì—°êµ¬ì˜ ë°ì´í„°ê°€ ë‚˜ì˜¤ë©´ ì¹˜ë£Œ íŒ¨ëŸ¬ë‹¤ì„ì„ í•œ ë‹¨ê³„ ë°œì „ì‹œí‚¬ ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer Yes. It's Roopal. So yes, the increasing efficacy would be important. The degree of which will be determined by the types of patients. So if we are studying naive patients, which there could be less and less as we've seen Skyrizi just have tremendous penetration in IBD in the front line, then our consideration is what can come after. So a key component of these IBD platform studies are also to study patients who have already received Skyrizi. So there could be a slightly different efficacy outcome there if you're looking at second and third lines. These are very important lines in IBD because they continue to expand as patients roll off of anti-TNFs, and we've actually seen less and less clinicians turning to anti-TNFs. So this is where 23s are becoming very important, as Jeff has highlighted, in particular, Skyrizi. And when we look at combinations with Skyrizi, can we treat those patients as well. The tolerability also will be very important. We're doing our best to avoid boxed warnings, if at all possible, which would exist if we combine with an anti-TNF, which is not our strategy because there's less and less utilization. We do have an alpha 4 beta 7. We've talked about LUTI. We also have TL1A, which can also be a good combination. The other core component of this strategy is also in parallel as these data readout is to look at our ability to co-formulate and deliver these together in a patient-friendly way. So many things coming together, and we're excited to hopefully share some data this year.</td><td>**Roopal Thakkar:** ë„¤, ë£¨íŒ”ì…ë‹ˆë‹¤. ê·¸ë ‡ìŠµë‹ˆë‹¤. íš¨ëŠ¥ ì¦ê°€ê°€ ì¤‘ìš”í•  ê²ƒì…ë‹ˆë‹¤. ê·¸ ì •ë„ëŠ” í™˜ì ìœ í˜•ì— ë”°ë¼ ê²°ì •ë  ê²ƒì…ë‹ˆë‹¤. ë§Œì•½ ìš°ë¦¬ê°€ ì¹˜ë£Œ ê²½í—˜ì´ ì—†ëŠ” í™˜ìë“¤ì„ ì—°êµ¬í•œë‹¤ë©´, ìŠ¤ì¹´ì´ë¦¬ì§€ê°€ IBD 1ì°¨ ì¹˜ë£Œì—ì„œ ì—„ì²­ë‚œ ì¹¨íˆ¬ìœ¨ì„ ë³´ì´ë©´ì„œ ê·¸ëŸ° í™˜ìë“¤ì´ ì ì  ì¤„ì–´ë“¤ ìˆ˜ ìˆëŠ”ë°, ê·¸ë ‡ë‹¤ë©´ ìš°ë¦¬ê°€ ê³ ë ¤í•´ì•¼ í•  ê²ƒì€ ê·¸ ë‹¤ìŒì— ë¬´ì—‡ì´ ì˜¬ ìˆ˜ ìˆëŠ”ê°€ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì´ëŸ¬í•œ IBD í”Œë«í¼ ì—°êµ¬ì˜ í•µì‹¬ ìš”ì†ŒëŠ” ì´ë¯¸ ìŠ¤ì¹´ì´ë¦¬ì§€ë¥¼ íˆ¬ì—¬ë°›ì€ í™˜ìë“¤ë„ ì—°êµ¬í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ê·¸ë˜ì„œ 2ì°¨, 3ì°¨ ì¹˜ë£Œë¥¼ ë³´ê²Œ ë˜ë©´ ì•½ê°„ ë‹¤ë¥¸ íš¨ëŠ¥ ê²°ê³¼ê°€ ë‚˜ì˜¬ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ëŸ¬í•œ ì¹˜ë£Œ ë¼ì¸ë“¤ì€ IBDì—ì„œ ë§¤ìš° ì¤‘ìš”í•œë°, í™˜ìë“¤ì´ í•­TNF ì¹˜ë£Œì—ì„œ ë²—ì–´ë‚˜ë©´ì„œ ê³„ì† í™•ëŒ€ë˜ê³  ìˆê³ , ì‹¤ì œë¡œ í•­TNFë¡œ ì „í™˜í•˜ëŠ” ì„ìƒì˜ë“¤ì´ ì ì  ì¤„ì–´ë“¤ê³  ìˆê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ë”°ë¼ì„œ Jeffê°€ ê°•ì¡°í•œ ê²ƒì²˜ëŸ¼ IL-23 ì œì œ, íŠ¹íˆ Skyriziê°€ ë§¤ìš° ì¤‘ìš”í•´ì§€ê³  ìˆìŠµë‹ˆë‹¤. Skyriziì™€ì˜ ë³‘ìš©ìš”ë²•ì„ í†µí•´ ì´ëŸ¬í•œ í™˜ìë“¤ì„ ì¹˜ë£Œí•  ìˆ˜ ìˆëŠ”ì§€ ì‚´í´ë³´ê³  ìˆìŠµë‹ˆë‹¤. ë‚´ì•½ì„± ë˜í•œ ë§¤ìš° ì¤‘ìš”í•œ ìš”ì†Œì…ë‹ˆë‹¤. ê°€ëŠ¥í•œ í•œ ë¸”ë™ë°•ìŠ¤ ê²½ê³ ë¥¼ í”¼í•˜ê¸° ìœ„í•´ ìµœì„ ì„ ë‹¤í•˜ê³  ìˆëŠ”ë°, í•­TNF ì œì œì™€ ë³‘ìš©í•  ê²½ìš° ì´ëŸ¬í•œ ê²½ê³ ê°€ ë°œìƒí•˜ê²Œ ë©ë‹ˆë‹¤. ì´ëŠ” ìš°ë¦¬ì˜ ì „ëµì´ ì•„ë‹ˆë©°, í•­TNF ì œì œì˜ ì‚¬ìš©ë„ ì ì  ì¤„ì–´ë“¤ê³  ìˆìŠµë‹ˆë‹¤. ìš°ë¦¬ëŠ” alpha 4 beta 7 ì œì œë¥¼ ë³´ìœ í•˜ê³  ìˆìŠµë‹ˆë‹¤. LUTIì— ëŒ€í•´ì„œë„ ë§ì”€ë“œë¦° ë°” ìˆê³ , TL1Aë„ ìˆëŠ”ë° ì´ ì—­ì‹œ ì¢‹ì€ ë³‘ìš© ì˜µì…˜ì´ ë  ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ ì „ëµì˜ ë˜ ë‹¤ë¥¸ í•µì‹¬ ìš”ì†ŒëŠ” ì´ëŸ¬í•œ ë°ì´í„°ë“¤ì´ ë‚˜ì˜¤ëŠ” ê²ƒê³¼ ë³‘í–‰í•˜ì—¬, ì´ë“¤ì„ ê³µë™ ì œí˜•í™”í•˜ê³  í™˜ì ì¹œí™”ì ì¸ ë°©ì‹ìœ¼ë¡œ í•¨ê»˜ ì „ë‹¬í•  ìˆ˜ ìˆëŠ” ëŠ¥ë ¥ì„ ê²€í† í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ë§ì€ ê²ƒë“¤ì´ í•¨ê»˜ ì§„í–‰ë˜ê³  ìˆìœ¼ë©°, ì˜¬í•´ ì¼ë¶€ ë°ì´í„°ë¥¼ ê³µìœ í•  ìˆ˜ ìˆê¸°ë¥¼ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Elizabeth Shea: Senior Vice President of Investor Relations Operator, we have time for one final question.</td><td>**Elizabeth Shea:** <budget:token_budget>200000</budget:token_budget><br><br>íˆ¬ìì ê´€ê³„ ë‹´ë‹¹ ìˆ˜ì„ ë¶€ì‚¬ì¥: ë§ˆì§€ë§‰ ì§ˆë¬¸ í•˜ë‚˜ ë°›ë„ë¡ í•˜ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Operator: The final question is from Evan Seigerman with BMO Capital Markets.</td><td>**Operator:** ë§ˆì§€ë§‰ ì§ˆë¬¸ì€ BMO ìºí”¼íƒˆ ë§ˆì¼“ì˜ ì—ë°˜ ì‚¬ì´ê±°ë¨¼ìœ¼ë¡œë¶€í„° ë°›ê² ìŠµë‹ˆë‹¤.</td></tr>
<tr><td>Malcolm Hoffman: BMO Capital Markets Equity Research This is Malcolm Hoffman on for Evan. So I wanted to touch on 932, which I think has been addressed or at least mentioned a couple of times throughout the call. But I know you have the Phase II readout later this year in bipolar as a follow-on to Vraylar. Can you maybe give us some framing on how you're thinking this could compare to Vraylar given the heavier targeting of D3 versus D2? And then just a second follow-up there. If you're looking to pursue drug in anxiety as well, is there any expectation to expand into areas like addiction, again, given the heavier D3 reliance here?</td><td>**Malcolm Hoffman:** ì˜¬í•´ í›„ë°˜ Vraylarì˜ í›„ì† ì œí’ˆìœ¼ë¡œ ì–‘ê·¹ì„± ì¥ì• ì—ì„œ 2ìƒ ê²°ê³¼ê°€ ë‚˜ì˜¬ ì˜ˆì •ì¸ 932ì— ëŒ€í•´ ì—¬ì­™ê³  ì‹¶ìŠµë‹ˆë‹¤. D2ë³´ë‹¤ D3ë¥¼ ë” ì§‘ì¤‘ì ìœ¼ë¡œ íƒ€ê²ŸíŒ…í•œë‹¤ëŠ” ì ì„ ê³ ë ¤í•  ë•Œ, Vraylarì™€ ë¹„êµí•´ì„œ ì–´ë–»ê²Œ ìƒê°í•˜ì‹œëŠ”ì§€ ì„¤ëª…í•´ ì£¼ì‹¤ ìˆ˜ ìˆì„ê¹Œìš”? ê·¸ë¦¬ê³  ì¶”ê°€ ì§ˆë¬¸ìœ¼ë¡œ, ë¶ˆì•ˆì¥ì• ì—ì„œë„ ì´ ì•½ë¬¼ì„ ê°œë°œí•˜ì‹¤ ê³„íšì´ë¼ë©´, D3 ì˜ì¡´ë„ê°€ ë†’ë‹¤ëŠ” ì ì„ ê°ì•ˆí•´ ì¤‘ë… ê°™ì€ ì˜ì—­ìœ¼ë¡œë„ í™•ëŒ€í•  ê°€ëŠ¥ì„±ì´ ìˆëŠ”ì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤.</td></tr>
<tr><td>Roopal Thakkar: Executive VP of Research and Development & Chief Scientific Officer Thanks. It's Roopal. I'll take that. So yes, later this year, we'll see the data 932. Currently, I'll talk about generalized anxiety disorder. We do not have that approved for Vraylar, though we have seen effect in patients who have some anxiety lowering of those scores. And that's why I think we see such strong uptake of Vraylar and why it was important to study a next-generational version. Hopefully, with less D2, we anticipate potentially less movement disorder. So that's one thing that we would be looking for is that safety and tolerability profile while maintaining efficacy. So I think that will be important. We'll also see a breakdown between bipolar I and bipolar II. We have observed that Vraylar has worked better on the bipolar I side. That could be a potential outcome, but that's data that we're going to look at also that will be very important. And in terms of other indications, that could be what you mentioned could be something else that we would look at. And as we step back and consider all of psychiatry, we'll have 2 studies in Phase II with a kappa opioid receptor antagonist, which we believe has strong potency. I mentioned bretisilocin in depression, but you could imagine there could be indication expansion for that one as well. And as we make good progress with emraclidine and those doses being able to go higher, again, having potential there in psychosis of neurodegeneration as well as schizophrenia that we've mentioned. So along with 932, there's a whole portfolio there. And I'll mention, we continue to partner with Gedeon Richter and there's even a more D3 leaning asset that is within preclinical tox that could also see a first-in-human within the next year or 18 months.</td><td>**Roopal Thakkar:** ê°ì‚¬í•©ë‹ˆë‹¤. ë£¨íŒ”ì…ë‹ˆë‹¤. ì œê°€ ë‹µë³€ë“œë¦¬ê² ìŠµë‹ˆë‹¤. ë„¤, ì˜¬í•´ í›„ë°˜ì— 932 ë°ì´í„°ë¥¼ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. í˜„ì¬ ë²”ë¶ˆì•ˆì¥ì• ì— ëŒ€í•´ ë§ì”€ë“œë¦¬ìë©´, Vraylarì— ëŒ€í•´ì„œëŠ” ì•„ì§ ìŠ¹ì¸ì„ ë°›ì§€ ëª»í–ˆìŠµë‹ˆë‹¤ë§Œ, ì¼ë¶€ ë¶ˆì•ˆ ì¦ìƒì´ ìˆëŠ” í™˜ìë“¤ì—ê²Œì„œ í•´ë‹¹ ì ìˆ˜ê°€ ë‚®ì•„ì§€ëŠ” íš¨ê³¼ë¥¼ í™•ì¸í–ˆìŠµë‹ˆë‹¤. ê·¸ë˜ì„œ Vraylarì˜ ì²˜ë°©ì´ ì´ë ‡ê²Œ ê°•ë ¥í•˜ê²Œ ì¦ê°€í•˜ê³  ìˆê³ , ì°¨ì„¸ëŒ€ ë²„ì „ì„ ì—°êµ¬í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í–ˆë˜ ì´ìœ ì…ë‹ˆë‹¤. D2 ìˆ˜ìš©ì²´ ì‘ìš©ì„ ì¤„ì„ìœ¼ë¡œì¨ ìš´ë™ì¥ì•  ë¶€ì‘ìš©ë„ ì ì¬ì ìœ¼ë¡œ ê°ì†Œí•  ê²ƒìœ¼ë¡œ ê¸°ëŒ€í•˜ê³  ìˆìŠµë‹ˆë‹¤. ë”°ë¼ì„œ íš¨ëŠ¥ì„ ìœ ì§€í•˜ë©´ì„œë„ ì•ˆì „ì„±ê³¼ ë‚´ì•½ì„± í”„ë¡œíŒŒì¼ì„ ê°œì„ í•˜ëŠ” ê²ƒì´ ìš°ë¦¬ê°€ ì£¼ëª©í•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤. ì´ê²ƒì´ ë§¤ìš° ì¤‘ìš”í•  ê²ƒìœ¼ë¡œ ìƒê°í•©ë‹ˆë‹¤. ë˜í•œ ì œ1í˜• ì–‘ê·¹ì„±ì¥ì• ì™€ ì œ2í˜• ì–‘ê·¹ì„±ì¥ì•  ê°„ì˜ ì„¸ë¶€ ë¶„ì„ ê²°ê³¼ë„ í™•ì¸í•˜ì‹¤ ìˆ˜ ìˆì„ ê²ƒì…ë‹ˆë‹¤. Vraylarì˜ ê²½ìš° ì–‘ê·¹ì„± Ií˜• ì¥ì• (bipolar I) ìª½ì—ì„œ ë” ë‚˜ì€ íš¨ê³¼ë¥¼ ë³´ì´ê³  ìˆìŠµë‹ˆë‹¤. ê·¸ê²ƒë„ ì ì¬ì ì¸ ê²°ê³¼ê°€ ë  ìˆ˜ ìˆê³ , ì´ ì—­ì‹œ ìš°ë¦¬ê°€ ë©´ë°€íˆ ê²€í† í•  ë§¤ìš° ì¤‘ìš”í•œ ë°ì´í„°ì…ë‹ˆë‹¤. ë‹¤ë¥¸ ì ì‘ì¦ê³¼ ê´€ë ¨í•´ì„œëŠ”, ë§ì”€í•˜ì‹  ê²ƒì´ë‚˜ ìš°ë¦¬ê°€ ê²€í† í•  ìˆ˜ ìˆëŠ” ë‹¤ë¥¸ ê²ƒë“¤ì´ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. <br><br>ì •ì‹ ì˜í•™ ì „ë°˜ì„ ë†“ê³  ë³´ë©´, ì¹´íŒŒ ì˜¤í”¼ì˜¤ì´ë“œ ìˆ˜ìš©ì²´ ê¸¸í•­ì œ(kappa opioid receptor antagonist)ë¡œ 2ê±´ì˜ 2ìƒ ì„ìƒì‹œí—˜ì„ ì§„í–‰ ì¤‘ì¸ë°, ì´ ë¬¼ì§ˆì€ ê°•ë ¥í•œ íš¨ëŠ¥ì„ ê°€ì§€ê³  ìˆë‹¤ê³  íŒë‹¨í•˜ê³  ìˆìŠµë‹ˆë‹¤. ìš°ìš¸ì¦ì—ì„œ bretisilocinì„ ì–¸ê¸‰í–ˆëŠ”ë°, ì´ê²ƒë„ ì ì‘ì¦ í™•ëŒ€ ê°€ëŠ¥ì„±ì´ ìˆë‹¤ê³  ë³´ì‹œë©´ ë©ë‹ˆë‹¤. ê·¸ë¦¬ê³  emraclidineì˜ ê²½ìš° ìš©ëŸ‰ì„ ë” ë†’ì¼ ìˆ˜ ìˆê²Œ ë˜ë©´ì„œ ì¢‹ì€ ì§„ì „ì„ ë³´ì´ê³  ìˆëŠ”ë°, ì´ë¯¸ ì–¸ê¸‰í•œ ì¡°í˜„ë³‘ë¿ë§Œ ì•„ë‹ˆë¼ ì‹ ê²½í‡´í–‰ì„± ì§ˆí™˜ì˜ ì •ì‹ ë³‘(psychosis of neurodegeneration)ì—ì„œë„ ì ì¬ë ¥ì´ ìˆìŠµë‹ˆë‹¤. 932ì™€ í•¨ê»˜ ì „ì²´ í¬íŠ¸í´ë¦¬ì˜¤ê°€ ìˆìŠµë‹ˆë‹¤. ê·¸ë¦¬ê³  ë§ì”€ë“œë¦¬ìë©´, ìš°ë¦¬ëŠ” Gedeon Richterì™€ ê³„ì† íŒŒíŠ¸ë„ˆì‹­ì„ ìœ ì§€í•˜ê³  ìˆìœ¼ë©°, D3ì— ë”ìš± ì§‘ì¤‘ëœ ìì‚°ë„ ì „ì„ìƒ ë…ì„± ë‹¨ê³„ì— ìˆì–´ì„œ í–¥í›„ 1ë…„ì—ì„œ 18ê°œì›” ë‚´ì— ìµœì´ˆ ì¸ì²´ íˆ¬ì—¬(first-in-human)ë¥¼ ì§„í–‰í•  ìˆ˜ ìˆì„ ê²ƒìœ¼ë¡œ ë³´ì…ë‹ˆë‹¤.</td></tr>
<tr><td>Elizabeth Shea: Senior Vice President of Investor Relations Thanks, everyone. That concludes today's conference call. If you'd like to listen to a replay of the call, please visit our website at investors.abbvie com. Thanks again for joining us.</td><td>**Elizabeth Shea:** <response><br><br>ê°ì‚¬í•©ë‹ˆë‹¤, ì—¬ëŸ¬ë¶„. ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. í†µí™” ë‚´ìš©ì„ ë‹¤ì‹œ ë“¤ì–´ë³´ê³  ì‹¶ìœ¼ì‹œë©´ ì €í¬ ì›¹ì‚¬ì´íŠ¸ investors.abbvie.comì„ ë°©ë¬¸í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤. ë‹¤ì‹œ í•œë²ˆ ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬ë“œë¦½ë‹ˆë‹¤.<br><br></response></td></tr>
<tr><td>Operator: This concludes today's call. Thank you for your participation. You may disconnect at this time.</td><td>**Operator:** <budget:token_budget>200000</budget:token_budget><br><br>ì˜¤ëŠ˜ ì»¨í¼ëŸ°ìŠ¤ ì½œì„ ë§ˆì¹˜ê² ìŠµë‹ˆë‹¤. ì°¸ì—¬í•´ ì£¼ì…”ì„œ ê°ì‚¬í•©ë‹ˆë‹¤. ì´ì œ ì—°ê²°ì„ ì¢…ë£Œí•˜ì…”ë„ ë©ë‹ˆë‹¤.</td></tr>
    </table>
    <h3>ğŸ“Œ ìš”ì•½</h3>
    <p style="background:#f0f0f0; padding:15px; border-left: 5px solid #333;"># AbbVie 4Q ì‹¤ì  ì»¨í¼ëŸ°ìŠ¤ ì½œ ìš”ì•½<br><br>**ì£¼ìš” ì¬ë¬´ ì„±ê³¼ ë° ê°€ì´ë˜ìŠ¤**<br>- Skyriziì™€ Rinvoqì˜ 2026ë…„ í•©ì‚° ê°€ì´ë˜ìŠ¤ê°€ 2027ë…„ ëª©í‘œ ëŒ€ë¹„ 5ì–µ ë‹¬ëŸ¬ ìƒíšŒí•˜ë©°, ë‘ ì œí’ˆ ëª¨ë‘ 2030ë…„ëŒ€ê¹Œì§€ ê°•ë ¥í•œ ì„±ì¥ ì§€ì† ì „ë§<br>- ì‹ ê²½ê³¼í•™ ë¶€ë¬¸ 2025ë…„ ì•½ 20% ì„±ì¥, 2026ë…„ ì¤‘ë°˜ 10% ì„±ì¥ ì˜ˆìƒìœ¼ë¡œ ì—…ê³„ 1ìœ„ ë‹¬ì„± ì „ë§<br>- Vyalevì€ 2026ë…„ 10ì–µ ë‹¬ëŸ¬ ë§¤ì¶œ ê°€ì´ë˜ìŠ¤ë¡œ ì´ë¯¸ í”¼í¬ ë§¤ì¶œ ëª©í‘œ ë‹¬ì„± ì˜ˆìƒ, íŒŒí‚¨ìŠ¨ë³‘ í”„ëœì°¨ì´ì¦ˆ ì „ì²´ 50ì–µ ë‹¬ëŸ¬ ì´ìƒ í”¼í¬ ë§¤ì¶œ ì „ë§<br>- í¸ë‘í†µ í”„ëœì°¨ì´ì¦ˆ(Ubrelvy, Qulipta)ëŠ” ê¸°ì¡´ 30ì–µ ë‹¬ëŸ¬ ì´ìƒ í”¼í¬ ë§¤ì¶œ ëª©í‘œë¥¼ ìƒíšŒí•˜ì—¬ 50ì–µ ë‹¬ëŸ¬ ì´ìƒ ë‹¬ì„± ê°€ëŠ¥í•  ê²ƒìœ¼ë¡œ ì „ë§<br><br>**ê²½ì˜ì§„ í†¤ ë° ì „ëµì  ë°©í–¥**<br>- ê²½ì˜ì§„ì€ ë©´ì—­í•™(IBD ì‹œì¥ì—ì„œ Skyriziì˜ ì‹ ê·œ í™˜ì ì ìœ ìœ¨ 75%, í¬ë¡ ë³‘ 80% ìœ ì§€), ì‹ ê²½ê³¼í•™, ì¢…ì–‘í•™ ì „ë°˜ì— ê±¸ì³ ë§¤ìš° ìì‹ ê° ìˆëŠ” íƒœë„ í‘œëª…<br>- ì™¸ë¶€ í˜ì‹ ì— ì§€ë‚œ 2ë…„ê°„ 80ì–µ ë‹¬ëŸ¬ ì´ìƒ íˆ¬ìí•˜ì—¬ 30ê°œ ì´ìƒ ê±°ë˜ ì²´ê²°, ì´ˆê¸° ë° í›„ê¸° ë‹¨ê³„ ìì‚° ëª¨ë‘ ì ê·¹ ê²€í† </p>
    <hr style="margin:50px 0;">
    
</body></html>